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The endocannabinoid system is composed of endocannabinoids (eCBs), their cognate
receptors, and their biosynthetic and catabolic enzymes. Inhibition of serine hydrolases
(catabolic enzymes), such as carboxylesterases (CES), might result in the accumulation of eCBs.
eCBs, such as 2-arachidonoylglycerol (2-AG), have been shown to increase or reduce
inflammation via engagement with cannabinoid receptors on immune cells. This research
focuses on exploring the ability of eCBs and their metabolizing enzymes to regulate
inflammation. First, a negative feedback mechanism between inflammation and the eCB system
was examined by identifying serine hydrolases inhibited by lipopolysaccharide (LPS) stimulation
in mice. Ces2g activity was inhibited and Il6 levels were induced in the murine spleen,
suggesting a role for this enzyme in an inflammatory response, possibly to limit inflammation.
IL-6 did not influence 2-AG hydrolytic activity in human peripheral blood mononuclear cells
(PBMCs), but monocytic MAGL was shown to be the predominant 2-AG hydrolytic enzyme in
these cells. To investigate a separate mechanism by which serine hydrolases and eCBs may
regulate immune responses, mice were treated with chlorpyrifos (CPF), a pesticide known to
inhibit serine hydrolases, at doses that do not inhibit acetylcholinesterase in the nervous system.

This research is focused on lung tissue since epidemiologic studies have linked pesticide
exposures to respiratory diseases. At low doses, Ces1c (adult and neonatal mice) and Ces1d
(neonatal mice) were markedly inhibited by CPF (2.5 mg/kg, 7 d, PO). Stimulation with LPS
(1.25 mg/kg, IP) following the final CPF dose produced minimal differences in lung immune
responses to LPS. In follow up experiments utilizing wild-type and Ces1d-/- mice, a
downregulation of Ces1c mRNA in adult Ces1d-/- mice corresponded to an upregulation of Tnfa
mRNA in response to LPS in CPF-treated mice. Additionally, Ces1d was found to be expressed
in murine alveolar macrophages, suggesting these cells could be used to study the role of CES1
in immunity. Overall, Ces enzymes appear to play a role in immune homeostasis either through
a protective mechanism or a negative feedback mechanism to control inflammation.
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CHAPTER I
INTRODUCTION
Immune homeostasis describes the ability of the immune system to remain in “steady
state” and can be compared to that of a balance (Figure 1.1). Tipping the balance towards a proinflammatory response is necessary to fight off infections, but it can be a double-edged sword if
the response starts to attack its own cells and tissues (Musa 2013). On the other hand, tipping the
balance towards an anti-inflammatory response is necessary in the resolution phase of
inflammation (Headland and Norling 2015); however, immunosuppression can interfere with the
body’s ability to respond to an infection (Orlicka, Barnes et al. 2013). This dissertation will
focus on the role of the endocannabinoid system (eCB) in immune homeostasis.
Endocannabinoids and their Role as Immune Modulators
The eCB system is composed of arachidonoyl-containing eCB ligands, their cognate
receptors, and their biosynthetic and catabolic enzymes. The two well-known eCB ligands are 2arachidonoylglycerol (2-AG) and anandamide (AEA), both of which are lipid-based
neuromodulators and biosynthesized on demand in cells. AEA is produced by the metabolism of
N-arachidonoyl phosphatidylethanolamine in the phospholipid membrane by the enzyme N-acylphosphatidylethanolamine-specific phospholipase D, which is dependent on elevations of
intracellular Ca2+. AEA is metabolized into ethanolamine and arachidonic acid by the hydrolytic
enzyme fatty acid amide hydrolase (FAAH). In humans, FAAH is expressed at high levels in the
brain and low levels in liver (Ueda, Puffenbarger et al. 2000). 2-AG synthesis is also reliant on
1

increased intracellular Ca2+ levels, but it is synthesized from arachidonic acid-containing
phospholipids by the sequential actions of phospholipase C and diacylglycerol lipase (Di Marzo,
Melck et al. 1998, RodrÍGuez de Fonseca, Del Arco et al. 2005, Nomura, Morrison et al. 2011,
Di Marzo and De Petrocellis 2012, Rom and Persidsky 2013). 2-AG can be degraded by the
following serine hydrolases: monoacylglycerol lipase (MAGL), carboxylesterase (CES), α/βhydrolase domain containing 6 (ABHD6), and ABHD12, which generate arachidonic acid and
glycerol (Savinainen, Saario et al. 2012, Szafran, Borazjani et al. 2015). MAGL is also
expressed at high levels in the brain and it is responsible for about 85% of the brain 2-AG
hydrolytic activity (Grabner, Zimmermann et al. 2017). In addition, MAGL is also abundant in
liver and adipose tissue (Cao, Mulvihill et al. 2013, Grabner, Zimmermann et al. 2017), while
CESs are present in monocytes and macrophages, as well as liver, small intestine, lung, and
spleen (Ghosh 2000, Xie, Borazjani et al. 2010, Ross, Borazjani et al. 2012, Szafran, Borazjani et
al. 2015). Thus, there are a number of components in the eCB system that could be altered by
toxicants or pharmaceutical agents in a tissue-dependent manner.
eCBs have been shown to have a plethora of effects on appetite, behavior, motility, pain,
and immune responses (Di Marzo, Melck et al. 1998, Cabral 2001, Pacher, Bátkai et al. 2006).
In the context of the immune system, there are some conflicting reports but eCBs generally elicit
anti-inflammatory effects, except for those caused by some of the prostaglandin products that are
produced following the hydrolysis of eCBs to arachidonic acid (the precursor of prostaglandins).
However, pro-inflammatory effects of eCBs have been observed in models of allergies and
atherosclerosis (Mach and Steffens 2008, Mimura, Oka et al. 2012). For example, 2-AG
increased ear thickness in an inflamed mouse ear (Mimura, Oka et al. 2012) and it increased cell
infiltrates in the bronchoalveolar lavage (BAL) of a model of allergic bronchitis (Mimura, Oka et
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al. 2012). In the same study, DNA microarray analysis indicated that 2-AG increased proinflammatory cytokine levels in human HL-60 cells. Following AEA injections during the last
trimester of pregnancy, the offspring of treated dams at 4 weeks of age exhibited enhanced ear
thickness following arachidonic acid-induced stimulation of the ears and enhanced hypothermia
following lipopolysaccharide (LPS) exposure at 3 months (Fride and Mechoulam 1996). 2-AG
and AEA have also been shown to activate platelets, a response known to increase the risk of
atherosclerotic plaques and thrombosis. On the other hand, eCBs can exert beneficial effects
such as by decreasing hypertension, thereby reducing the risk of atherosclerotic plaque
development (Mach and Steffens 2008).
The anti-inflammatory benefits of raising eCB levels have been demonstrated in several
disease processes in humans and rodent models of human diseases, including experimental
autoimmune encephalomyelitis (EAE) and colitis (Alhouayek, Lambert et al. 2011,
Lourbopoulos, Grigoriadis et al. 2011). Treatment with exogenous 2-AG in the mouse EAE
model, an animal model of multiple sclerosis, delayed the onset of clinical disease and reduced
its severity (Lourbopoulos, Grigoriadis et al. 2011). Similarly, exogenous 2-AG administered in
a mouse closed-head injury model inhibited cytokine mRNA expression of Il6, Tnfa, and Il1b
(Panikashvili, Shein et al. 2006). In a rat model of periodontal disease, exogenous AEA
decreased the levels of TNF-α and IL-1β measured by ELISA (Rettori, De Laurentiis et al.
2012). In vivo and in vitro studies using mice and mouse macrophages demonstrated a decrease
in TNF-α levels after simultaneous administration of LPS and 2-AG when compared to treatment
of mice and macrophages with LPS alone (Gallily, Breuer et al. 2000). TNF-α levels in mouse
macrophages were inversely correlated with increasing concentrations of 2-AG (Gallily, Breuer
et al. 2000). Another study reported the same effect in cultured rat microglial cells treated with 23

AG and AEA (Facchinetti, Del Giudice et al. 2003). Thus, evidence in the literature suggests an
important role for 2-AG and AEA in many anti-inflammatory and some pro-inflammatory
processes.
Further evidence for anti-inflammatory effects caused by activation of the
endocannabinoid system is suggested by research with phytocannabinoids. For example, the use
of marijuana, which contains a plethora of phytocannabinoids, correlated with an increased risk
of mortality in HIV-positive men (Sidney, Beck et al. 1997). Several studies have shown that
cannabinoids decrease host resistance to both viral and bacterial infections such as herpes
simplex virus (HSV), Listeria, and Staphylococcus (Morahan, Klykken et al. 1979, Mishkin and
Cabral 1985, Friedman, Newton et al. 2003). Because younger (neonates and, to a lesser extent,
juveniles) and older populations are already more susceptible to infection, alterations in the
body’s ability to fight infections can be highly detrimental, as highlighted during the current
COVID-19 pandemic.
Cannabinoid Receptors and their Role in Immunity
The mechanism by which eCBs exert their anti-inflammatory (and sometimes proinflammatory) effects is primarily due to their engagement with cannabinoid receptors. The two
well-known cannabinoid receptors are cannabinoid receptor 1 (CB1) and cannabinoid receptor 2
(CB2), both of which are seven-transmembrane G-protein coupled receptors. 2-AG is a full
agonist of both receptors, whereas AEA is a partial agonist for both. Binding of eCBs with each
receptor activates Gi/o proteins leading to reduced adenylate cyclase activity and diminished
cAMP levels. This reduction prevents the activation of protein kinase A and the subsequent
phosphorylation and activation of transcription factors, such as signal transducer and activator of
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transcription 5 (STAT5) and STAT6, thereby altering cytokine release (Rieder, Chauhan et al.
2010, Kaplan 2013, Rom and Persidsky 2013, Oláh, Szekanecz et al. 2017). The amino acid
sequence of the two cannabinoid receptors are highly conserved among species with humans and
mice sharing approximately 82% sequence identity for CB2 and 90% identity for CB1 (Abood,
Ditto et al. 1997, Rom and Persidsky 2013). Regarding the ontology of CB receptors, they are
detected in rat neonates shortly after birth (Belue, Howlett et al. 1995, Fride and Mechoulam
1996). In rodent brain, CB1 mRNA expression and ligand-binding capacity increase
progressively from birth until early adulthood (PND 21), at which point the expression and
binding capacity plateaus (Belue, Howlett et al. 1995, Fride and Mechoulam 1996). CB1 is
considered to be the main cannabinoid receptor of the central nervous system and it is
responsible for the psychoactive effects of cannabinoids. On the other hand, CB2 is considered
the main peripheral cannabinoid receptor due to its presence in immune cells; however, CB1 has
also been found to play a role in peripheral tissues and CB2 is present in the central nervous
system (Kaplan 2013, Rom and Persidsky 2013).
It is now well established that both types of CB receptor are expressed to varying degrees
in immune cells (Kaplan 2013). While CB1 is found in most immune cells, CB2 is overall more
highly expressed in these cells (Galiègue, Mary et al. 1995). Of the various immune cells, the
highest levels of expression of CB1 and CB2 are found in B cells (Kaplan 2013, Rom and
Persidsky 2013). Two studies indicate that these receptors play a direct role on B-cell IgM
production (Springs, Karmaus et al. 2008, Feng, Milcarek et al. 2014). Δ9-THC, the
psychoactive cannabinoid in marijuana, inhibited IgM production in wild-type (WT) mouse
splenocyte-derived B cells, which was not apparent in Cnr1-/-Cnr2-/- B cells (Springs, Karmaus et
al. 2008). In contrast, work in a human B cell line demonstrated that a CB2 receptor inverse
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agonist inhibited IgM secretion caused by IL-6 exposure, whereas a CB1 receptor antagonist had
no effect (Feng, Milcarek et al. 2014). The immune cell with the second highest expression of
CB1 and CB2 is natural killer (NK) cells. The administration of Δ9-THC to mice caused a
significant inhibition of NK cell activity that was partially reversed using antagonists to both
CB1 and CB2 (Massi, Fuzio et al. 2000). Interestingly, the CB1 antagonist was more effective
than the CB2 antagonist. After NK cells, monocytes and macrophages express the next highest
levels of CB1 and CB2. A study aimed at identifying the mechanisms by which CB1 and CB2
affected macrophage activity discovered opposing roles for each receptor (Han, Lim et al. 2009).
For example, CB1 activation was found to elicit pro-inflammatory effects through the increased
release of reactive oxygen species, TNF-α, and monocyte chemoattractant protein-1. On the
other hand, stimulation of CB2 reversed these effects, indicating an anti-inflammatory role for
this receptor in macrophages. Neutrophils express less CB1 and CB2 than macrophages. In one
study involving neutrophils, stimulation of the CB2 receptor in human neutrophil-like HL60
cells decreased RhoA activation, which is responsible for neutrophil migration (Kurihara,
Tohyama et al. 2006).
The immune cells with the lowest expression of CB1 and CB2 are T cells, of which CD8
cytotoxic T cells expresses more than CD4 T helper cells (Kaplan 2013, Rom and Persidsky
2013). Although they have the lowest expression of both receptors, research indicates that these
receptors play an important role in modulating T-cell functions particularly through CB2,
although CB1 has also been shown to play a role (Eisenstein and Meissler 2015). The most
widely reported effector function caused by CB2 activation in T cells is apoptosis. For example,
a synthetic CB2 agonist was found to inhibit proliferative responses of T cells in response to
mitogens due to the induction of apoptosis (Lombard, Nagarkatti et al. 2007). T regulatory cells
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may also be regulated by the eCB system. In a study involving concanavalin A-induced hepatitis
in mice, a mixed CB1/CB2 synthetic agonist and Δ9-THC each attenuated Con-A-induced
hepatitis in a comparable manner, a process that involved significant increases in T regulatory
cells (Hegde, Hegde et al. 2008). Overall, the expression of cannabinoid receptors in immune
cells is B cells > NK cells > monocytes and macrophages > neutrophils > cytotoxic T cells > T
helper cells.
The immunosuppressive effects caused by CB receptor activation in immune cells is
thought to be due to one or more of the following four effector mechanisms: apoptosis induction,
attenuation of cell proliferation, cytokine inhibition, and promotion of regulatory T cells (Rieder,
Chauhan et al. 2010, Rom and Persidsky 2013). Overall, the role of CB1 and CB2 in immune
cell function is complex, and it is important to note that not all anti-inflammatory effects of eCBs
are caused by their binding to CB1 and CB2. For instance, in the study mentioned earlier
involving eCB treatment of rat microglial cells (Facchinetti, Del Giudice et al. 2003), the effects
were independent of CB1 and CB2. However, the vast majority of research indicates that CB1
and CB2 are responsible for the majority of anti-inflammatory effects attributed to eCBs.
Endocannabinoid Metabolizing Enzymes, Metabolites, and their Roles in Immunity
Blocking the hydrolytic metabolism of eCBs is one proposed mechanism to increase
levels of eCBs and produce anti-inflammatory effects. In fact, inhibition of these enzymes has
been proposed as a treatment for some diseases and inflammatory states. For example, JZL184,
a small-molecule inhibitor of MAGL activity, successfully blocked LPS-induced increases in
cytokines in rat plasma and frontal cortex (Kerr, Harhen et al. 2013). In an LPS-induced model
of acute lung injury, JZL184 decreased lung cellular infiltration and reduced BAL pro7

inflammatory cytokine levels (Costola-de-Souza, Ribeiro et al. 2013). Interestingly, blocking
CB1 and CB2 with receptor antagonists blocked these anti-inflammatory effects. Although
reducing inflammation is helpful in some disease processes, it can be quite the opposite in
instances when a robust immune response is necessary. For example, in a rat skeletal muscle
contusion model, JZL184 treatment decreased the infiltration of macrophages and neutrophils
and the production of pro-inflammatory cytokines while simultaneously interfering with normal
healing processes (Jiang, Zhang et al. 2015).
Arachidonic acid is a shared metabolic product of the hydrolysis of 2-AG and AEA.
Arachidonic acid produced by the hydrolysis of eCBs is further metabolized by cyclooxygenases
(COX) into prostaglandin H2 (PGH2), the precursor for several other prostaglandins including
PGE2, PGD2, PGF2α, and thromboxane A2 (Hammad, Jan de Heer et al. 2003, Park, Pillinger et
al. 2006, Nomura, Morrison et al. 2011, Ricciotti and FitzGerald 2011, Oishi, Yoshida et al.
2015). These prostaglandins are generally known to exert pro-inflammatory effects. Thus, a
working hypothesis that underlies this dissertation is that inhibition of eCB metabolism should
increase anti-inflammatory eCBs while simultaneously decreasing pro-inflammatory metabolites,
altering immune homeostasis. However, research has suggested that PGD2 can also exhibit antiinflammatory properties. For instance, PGD2 inhibited the migration of murine lung dendritic
cells into draining lymph nodes, leading to a subsequent reduction in pro-inflammatory cytokines
(Hammad, Jan de Heer et al. 2003). In the context of allergies, however, PGD2 appears to be
pro-inflammatory. It plays a major role in the development of antigen-dependent responses,
such as bronchoconstriction and eosinophil infiltration, in response to allergen triggers (Ricciotti
and FitzGerald 2011). Regarding PGE2, although it may have a minor anti-inflammatory role in
some contexts, it is primarily a pro-inflammatory molecule, facilitating immune cell influx at the
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site of an insult and promoting pain responses (Nakanishi and Rosenberg 2013). 12(S)Hydroxyeicosatetraenoic acid (12-HETE) is a lipoxygenase-derived metabolite of arachidonic
acid and, similar to PGE2 and PGD2, it has pro- and anti-inflammatory effects (Elmarakby,
Ibrahim et al. 2019). In the ischemic brain, 12-HETE is a neuroprotective molecule through its
activation of the lipid-sensing receptor PPARγ and the subsequent inhibition of NF-κB (Sun, Xu
et al. 2015). In the context of atherosclerosis, 12-HETE can impair macrophage effector
functions such as pro-inflammatory foam cell development (Manega, Fiorelli et al. 2019). Thus,
similar to the eCBs, the roles of eCB-derived metabolites in immunity are complex and varies
depending on the specific context. However, in general, they are typically skewed toward
promoting pro-inflammatory effects.
Introduction to Carboxylesterases
Carboxylesterases (annotations are Ces and CES for mouse and human genes,
respectively) are members of the serine hydrolase superfamily with roles in the hydrolytic
metabolism of pesticides and lipids (Ross, Streit et al. 2010). They are highly expressed in
multiple tissues and are an important binding site of chlorpyrifos oxon (CPO) that aids its
detoxication (Timchalk, Nolan et al. 2002). In other words, Ces/CES enzymes react in a 1:1
stoichiometric ratio with oxons, which for CPO yields a diethylphosphorylated adduct on its
catalytic serine residue resulting in an inactivated enzyme (Ross and Edelmann 2012). In contrast
to humans, which have only one protein-encoding CES1 gene and one protein-encoding CES2
gene, the murine genome contains eight Ces1 and eight Ces2 genes that exhibit a high degree of
sequence homology within each gene family (Holmes, Wright et al. 2010). Although
Magl/MAGL (Magl in rodents, MAGL in humans) is the primary 2-AG hydrolytic enzyme in
mammalian brain (Blankman and Cravatt 2013), human CES1 and CES2 isoforms were also
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shown to hydrolyze 2-AG (Xie, Borazjani et al. 2010, Wang, Borazjani et al. 2013). Indeed,
recombinant human CES1 and MAGL enzymes hydrolyzed 2-AG with similar catalytic
efficiencies (kcat/Km) (Xie, Borazjani et al. 2010, Grabner, Zimmermann et al. 2017). Thus,
Ces/CES enzymes may serve important backup roles as 2-AG hydrolytic enzymes in tissues
where Magl/MAGL is not expressed or expressed at low levels.
Within cells the Ces enzymes are primarily found in the microsomal fraction, particularly
the endoplasmic reticulum, although some are located within other organelles (Lian, Nelson et al.
2018). Ces isoforms differ in their tissue distribution. For example, CES1 is abundant in the
liver and lung while CES2 is most abundant in the small intestine (Holmes, Wright et al. 2010,
Lian, Nelson et al. 2018). The Ces2c isoform is considered to be the murine orthologue of
human CES2 and it is responsible for triglyceride metabolism in the liver and small intestine
(Maresch, Benedikt et al. 2019). The Ces1d isoform is the murine orthologue of human CES1 in
terms of both sequence homology and function (Lian, Nelson et al. 2018). CES1 and Ces1d are
similarly expressed in human and mouse tissues with one exception: macrophages (Lian, Nelson
et al. 2018). Although human macrophages express CES1, mouse resident peritoneal
macrophages do not express Ces1d to any significant extent (Jones, Taylor et al. 2013). Due to
the presence of CES1 in human monocytes/macrophages and its ability to metabolize
immunomodulatory lipids such as endocannabinoids and prostaglandin glyceryl esters (Ghosh
2000, Xie, Borazjani et al. 2010, Wang, Borazjani et al. 2013), it is feasible that CES enzymes
have underappreciated roles in lipid mediator metabolism and immune responses.
Introduction to Chlorpyrifos
Chlorpyrifos (CPF) is an organophosphate (OP) pesticide currently used in agriculture to
protect feed crops from insect damage. It was banned for residential use in 2000 after the EPA
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revised their health risk assessment, particularly due to the risk of harm in children (EPA 2002).
At the time, it was one of the most widely used pesticides for both residential and agricultural
use (Centner 2018). In 2015, the EPA re-evaluated its tolerances for CPF and proposed to
revoke tolerances for the insecticide even for agricultural use; however, in 2017, the agency
denied such a petition (EPA 2015, Centner 2018). In 2018, the EPA was ordered to ban CPF
within 60 days by the U.S. Ninth Circuit Court of Appeals, but a hearing in early 2019
effectively nullified this order (EPA). As of 2020, CPF has not been banned for agricultural use
and the EPA is currently evaluating CPF through a registration review which is expected to be
completed by the end of 2022 (EPA). Because it is still used for agricultural purposes today,
humans are at risk for exposures through consumption of pesticide-residue containing foods,
water supply contamination, and occupational exposure (EPA 2015, Centner 2018).
Although most CPF absorbed into the body is excreted as water-soluble metabolites in
urine, some of it can accumulate in fatty tissues over time. For example, a previous study found
that a 5 mg/kg oral dose in adult rats for 21 days caused significant accumulation of CPF in the
following tissues: adipose > liver > brain > kidney > ovary > blood (Tanvir, Afroz et al. 2015).
CPF levels in muscle and lung were below detectable limits. CPF is bioactivated into its active
metabolite -- termed chlorpyrifos oxon (CPO) -- by cytochrome P450s, specifically CYP2B6.
Conversely, CPF is detoxified by a dearylation reaction catalyzed by CYP2C19, which liberates
3,5,6-trichloro-2-pyridinol as a detoxification product (Crane, Klein et al. 2012). These reactions
are demonstrated in Figure 1.2. CPO is inactivated by its hydrolysis by paraoxonase-1, or by its
stoichiometric binding to carboxylesterases (Li, Furlong et al. 1995, Karanth and Pope 2000,
Kacham, Karanth et al. 2006, Albers, Garabrant et al. 2010, Buratti, De Angelis et al. 2011,
Crane, Klein et al. 2012, Dzul-Caamal, Dominguez-Lopez et al. 2014). Interestingly, CPO has
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been shown to inhibit CB1 agonist binding, but CB1 is a much less sensitive target than most
esterases (Quistad, Nomura et al. 2002). CPO exerts its primary mechanism of toxic action by
inhibiting acetylcholinesterase activity (AChE) (Pope, Karanth et al. 2005), but it has also been
shown to possess harmful health effects at doses too low to inhibit AChE. One such mechanism
involves acting as an endocrine disrupter and, as such, it has been shown to alter thyroid
hormone levels in pregnant mice and their offspring at doses of CPF that do not inhibit AChE
(De Angelis, Tassinari et al. 2009, Bellanger, Demeneix et al. 2015). Another potential
mechanism of action, and a major focus of this dissertation, is its ability to inactivate eCB
metabolizing enzymes (Pope, Karanth et al. 2005).
Chlorpyrifos Effects on the Immune System
Previous work from Carr and co-workers demonstrated that developmental oral exposure
to CPF in rats inhibits eCB metabolizing enzymes and increases the levels of eCBs in brain,
spleen, serum, and liver of rat neonates at doses too low to inhibit brain AChE activity (Carr,
Borazjani et al. 2011, Carr, Adams et al. 2013, Carr, Adams et al. 2013, Carr, Graves et al. 2014,
Robert, Navatha et al. 2017). At the lowest doses of CPF (down to 0.5 mg/kg), only FAAH
activity was inhibited in the brain, but MAGL activity was also inhibited when doses reached 1
mg/kg (Carr, Borazjani et al. 2011, Carr, Adams et al. 2013). The greatest degree of MAGL
inhibition occurred 4-hr post-exposure (Carr, Adams et al. 2013). In a more recent study
(Robert, Navatha et al. 2017), only the highest dosage of CPF inhibited brain AChE activity (1
mg/kg), whereas lower doses inhibited FAAH activity (down to 0.5 mg/mL) and liver 2-AG
hydrolytic activity. The 2-AG hydrolytic activity in liver could not be completely attributed to
MAGL because treatment with a MAGL inhibitor inhibited only ~33% of 2-AG hydrolytic
activity (Robert, Navatha et al. 2017). Furthermore, behavioral studies performed on these rats
12

suggested that they exhibited decreased anxiety in juveniles (Carr, Armstrong et al. 2017).
These studies suggested a potential role for eCB metabolism-dependent alterations in immune
function by CPF. Further work in vitro demonstrated the ability of CPO, the active metabolite of
CPF, to inhibit CES1 and CES2 activity, specifically in human THP1 monocytes & macrophages
(Xie, Borazjani et al. 2010, Crow, Bittles et al. 2012). These studies suggested that CESs could
be inhibited following CPF exposure and are an eCB metabolizing enzyme family worth
investigating, particularly because it is present in immune cells.
Although studies are limited in the human population, the studies performed to date have
also demonstrated that CPF can alter immune function. For example, through questionnaires
sent to farm families, in utero pesticide exposures in farm couples correlated with increased
allergies in their children (Weselak, Arbuckle et al. 2007). In individuals previously exposed to
CPF and reporting chronic health complaints, it was found that CD4+ T cells in naïve peripheral
blood mononuclear cells (PBMCs) were decreased and mitogenic responses to ex vivo
stimulation with phytohemagglutinin and Con A were inhibited (Thrasher, Madison et al. 1993,
Thrasher, Heuser et al. 2002). In human cell lines, CPF and its active metabolite, CPO, were
shown to upregulate pro-inflammatory cytokine mRNA, stimulating cytokine release in human
THP1 cells (Proskocil, Grodzki et al. 2019). Further exploration into the effects of CPF on
immune function are warranted.
Other studies have demonstrated alterations in immune function caused by CPF. For
example, at dosages of 5 mg/kg of CPF in rats, Concanavalin A (Con A)-induced T-lymphocyte
blastogenesis was inhibited compared to non-CPF controls (Blakley, Yole et al. 1999). Two
other studies have shown that early post-natal exposure to CPF can lead to subsequent immune
effects in adult rats or mice (Navarro, Basta et al. 2001, Singh, Parashar et al. 2013). Neonates
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do not have the same CPF detoxification capacities as adults and, therefore, have been shown to
be more sensitive to CPF-induced acute lethality (Karanth and Pope 2000, Kacham, Karanth et
al. 2006, Buratti, De Angelis et al. 2011). In a study that investigated CPF-mediated immune
effects in neonates, treatment with 1 mg/kg of CPF in rats during either PND 1-4 or PND 11-14
led to inhibited T-cell mitogenic responses to Con A in adulthood (Navarro, Basta et al. 2001).
In another study, mouse pups exposed to CPF from GD12 to PND7 by oral administration to the
dam (3 mg/kg) and subsequently to the offspring by oral gavage until PND42 exhibited increased
levels of splenic suppressive T cells in female mice at PND49 (Singh, Parashar et al. 2013).
Further, LPS-stimulated splenocytes from these mice demonstrated a decrease in
lymphoproliferative cell responses and decreased cytokine responses. Thus, there is evidence
that low-dose CPF is immunotoxic and alters how the body responds to an immune insult.
Chlorpyrifos and Respiratory Diseases
There are a host of epidemiologic studies that have linked pesticide exposure to the
development of respiratory diseases such as chronic obstructive pulmonary disease (COPD),
asthma, bronchitis, and airway hypersensitivity (Hernandez, Parron et al. 2011, Mostafalou and
Abdollahi 2013). Most studies focus on agricultural workers because they are on the frontline
working with these chemicals, and generally the workers are provided a survey containing
questions on pesticide use and respiratory symptoms (Faria, Facchini et al. 2005, Fareed, Pathak
et al. 2013). One study reported a higher incidence of respiratory symptoms in female
interviewees (Faria, Facchini et al. 2005), which is in agreement with many others that find a
higher incidence of asthma and airway hypersensitivity in females (Melgert, Postma et al. 2005,
Pignataro, Bonini et al. 2017). Another study paired the questionnaires with measurements of
lung function and esterase activity among pesticide sprayers in North India (Fareed, Pathak et al.
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2013). Exposure duration was found to influence respiratory signs and lung function, and
pesticide sprayers had significantly depleted AChE and butyrylcholinesterase activities
compared to baseline levels, indicating exposure to organophosphorus pesticides. Other studies
have focused on children living in agricultural communities and even those found positive
associations between pesticide exposure and the development of chronic respiratory symptoms
(Salameh, Baldi et al. 2003, Arcury, Grzywacz et al. 2007, Raherison, Baldi et al. 2019). These
effects are, however, not limited to those in agricultural communities. For example, one study
identified a link between OP pesticides, decreased lung functional parameters, and asthma in the
general population (Ye, Beach et al. 2017). The mechanisms behind the development of asthma
caused by pesticide exposure are not known; however, it has been suggested that neuronal M2
muscarinic receptor dysfunction might be involved (Fryer, Lein et al. 2004). At least one
epidemiological study has found a positive correlation between CPF and acute respiratory
infections (Burns, Cartmill et al. 1998), suggesting that the association between OP pesticides
and respiratory disease goes beyond asthma and airway hypersensitivity.
Laboratory animal studies have explored the effects of CPF on lung function and
inflammation. In a rat model, the offspring of dams exposed to CPF from gestation onset
through weaning had higher expiratory times (a dynamic measurement of respiratory mechanics)
and tidal volumes relative to those of untreated controls upon reaching adulthood (Darwiche,
Gay-Quéheillard et al. 2018). Two studies in guinea pigs and rats demonstrated that CPF caused
airway hypersensitivity at doses that do not inhibit AChE activity (Fryer, Lein et al. 2004,
Shaffo, Grodzki et al. 2018). In a study of another organophosphorus insecticide, the treatment of
mice with ethion (2 or 4 mg/kg, PO, 90 days) did not alter LPS-induced lung inflammation
(Verma, Mukhopadhyay et al. 2019); however, a single dose of ethion (8 mg/kg) did augment the
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expression of LPS-induced Tnfa mRNA (Verma and Sethi 2020). In addition, mice exposed to
methamidophos, another OP insecticide, in drinking water from gestation day 10 to postnatal day
21 had lower levels of IL-6 compared to untreated controls following subsequent infection with
respiratory syncytial virus (Watanabe, Yoshida et al. 2013). Parathion (1 mg/kg, SQ) was shown
to induce mRNA expression of Il1b and Tnfa in alveolar macrophages from guinea pigs
(Proskocil, Bruun et al. 2013). Further, pretreatment of guinea pigs with a TNF-α receptor
inhibitor prior to parathion administration prevented parathion-induced airway hypersensitivity.
Overall, these reports provide a strong premise to hypothesize that CPF may alter lung
homeostasis, and these alterations might be caused by the stimulation of alveolar macrophages.
Age-Related Differences in Immunity and Lung Immunity
It is well known that neonates have an underdeveloped immune system, including little
immunological memory (Ygberg and Nilsson 2012, Basha, Surendran et al. 2014). Although the
numbers of various immune cells in neonates is comparable to or even exceeds that of adult
immune cells, their overall function is immature compared to adults (Ygberg and Nilsson 2012).
For example, neonatal monocytes are less polyfunctional, produce far fewer cytokines, and rely
more heavily on the production of superoxide (Ygberg and Nilsson 2012). In response to LPS
stimulation, pro-inflammatory TNF-α release is significantly lower in monocytes from human
neonates than those from adults (Levy, Coughlin et al. 2006). Human neonates do not produce
the same levels of many classical pro-inflammatory cytokines as adults until at least 3 years of
age, and yet some other cytokines only reach adult levels in the teenage years (Ygberg and
Nilsson 2012). Due to their more limited immune system, neonates are more susceptible to
infections such as respiratory infections. It is estimated that approximately 95% of infants under
the age of 2 have experienced an infection with respiratory syncytial virus (Drajac, Laubreton et
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al. 2017). In fact, approximately 20% of deaths in children under the age of 5 are due to
respiratory infections, and, interestingly, some bacterial respiratory infections in this population
are due to bacteria in the normal lung microbiome (Unger and Bogaert 2017). While some
respiratory infections are important for the normal maturation of the lung immune system, there
is concern that severe respiratory infections in infants could disrupt pulmonary development, and
epidemiological studies have linked severe respiratory infections early in life with the
development of asthma-like symptoms later in life (Drajac, Laubreton et al. 2017). However,
early severe respiratory infections are not exclusive in their ability to affect the development of
respiratory disorders because the environment, including pesticide exposures, may play an
important role (Björkstén , Mamane, Raherison et al. 2015).
The basic function of the lung is to enable gas exchange, which occurs at the alveolarcapillary membrane. However, due to the large surface area required for gas exchange to occur
and the close proximity to the bloodstream, the lung serves as an effective portal of entry for
bacteria, viruses, and toxins (Lambrecht 2006). Fortunately, the lung is equipped to handle such
insults. As the first line of defense, the pulmonary epithelium forms a barrier that can neutralize
problems before any type of inflammatory response needs to be activated (Chaudhuri and Sabroe
2008). In addition to the mucociliary action that can trap and assist the clearance of inhaled
particles, epithelial mucous is also important for lung immune homeostasis due to its array of
antimicrobial substances (Lloyd and Marsland 2017, Riches and Martin 2018). For instance,
surfactant proteins are vital components of mucous that bind to pathogens and aids their
phagocytic clearance (Goto, Mitsuhashi et al. 2014, Dy, Tanyaratsrisakul et al. 2018).
Interestingly, individuals with asthma have both lower levels and impaired function of surfactant
proteins (Mackay, Grainge et al. 2016, Dy, Tanyaratsrisakul et al. 2018). In the airway,
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epithelial cells can produce cytokines that activate the NF-κΒ transcription factor pathway in
airway epithelial cells following infectious and non-infectious insults; however, in the alveolar
epithelium, it is the alveolar macrophages that are first to respond to pathogens and other noxious
inhaled agents (Riches and Martin 2018).
Although some tissue-resident macrophages are derived from circulating monocytes,
pulmonary alveolar macrophages are long-lived cells that are derived from embryonic
progenitors (Guilliams, De Kleer et al. 2013). These cells are not detected in neonatal lungs
prior to birth, but they quickly colonize the lungs during the first week of life (Guilliams, De
Kleer et al. 2013). Alveolar macrophages serve 3 purposes in the lung: (i) to neutralize
pathogens and activate an immune response, (ii) regulate pulmonary surfactant, and (iii) suppress
inappropriate innate and adaptive immune responses (Riches and Martin 2018). Most of the time
they are in a quiescent state, but once activated they are estimated to be able to phagocytize up to
109 intratracheally injected bacteria before an adaptive immune response is activated by dendritic
cells due to “spillover” of bacteria (Lambrecht 2006). In addition to these primary functions, a
study by Imamura et. al. suggested that alveolar macrophages play an important role in the
detoxification of toxicants. This study showed that rat lung microsomes and pulmonary alveolar
macrophages contain a Ces enzymatic activity capable of hydrolyzing the organophosphorus
insecticides malathion and phenthoate (Imamura, Schiller et al. 1983). Furthermore, intranasal
inoculation with Pseudomonas aeruginosa induced the Ces activity in alveolar macrophages (the
specific Ces isoform was impossible to know at the time) without affecting the same activity in
lung microsomes (Imamura, Schiller et al. 1983). Although the specific Ces isoforms responsible
for malathion and phenthoate metabolism were not identified, it is known that Ces/CES enzymes
are abundant in rodent and human lung tissue. In fact, the expression level of the three highest
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Ces mRNA species in adult C57BL/6 murine lung follows the rank order: Ces1d >> Ces2g >
Ces1c (Jones, Taylor et al. 2013). Further, in the neonate, Ces expression increases as the lung
matures, thus neonates may have differences in the relative expression of lung Ces isoforms
depending on the stage of maturation (Karanth and Pope 2000). Taken together, these findings
suggest that Ces in alveolar macrophages and lung parenchymal tissue might have dual roles in
xenobiotic detoxification and immunity and that these roles may significantly differ between
neonates and adults.
Research Overview
The overall hypothesis of this dissertation is that alterations to the endocannabinoid
system caused by exposure to chlorpyrifos (CPF) can disrupt immune homeostasis, leading
to changes in the normal lung immune response. A visual representation of this hypothesis
can be seen in Figure 1.3.
Aims 1 and 2 (Chapters 2 and 3) provides the preliminary data that link eCB
metabolizing enzymes and immune homeostasis. Next, I focused to a significant extent on the
inhibition of eCB metabolizing enzymes in the murine lung, particularly carboxylesterases,
caused by CPF exposure, and the immune consequences of this inhibition. First, in Aim 3
(Chapter 4), the ability of CPF to alter eCB levels and their metabolism was determined in
neonatal and adult mice. In addition, the role of the CB1 receptor in mediating any CPF-induced
effects was explored by using a Cnr1-/- mouse model. Second, in Aim 4 (Chapter 5), the ability
of CPF to alter the lung immune response to an immune stimulant, i.e. lipopolysaccharide (LPS),
was determined in mice of both age groups. Additionally, I explored the role of the
carboxylesterases, enzymes capable of metabolizing both eCBs and xenobiotics, in protecting
against adverse CPF-mediated effects using a Ces1d-/- mouse model. Finally, Aim 5 (Chapter 6)
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focuses on an additional topic of interest (e-cigarette toxicity) while also further exploring the
role of endocannabinoids in lung immune homeostasis. Chapter 7 provides a synthesis of the
information that was obtained, overall conclusions, and future directions to be taken.
Specific Aim 1: Role of eCBs in regulating inflammation (Mouse)
The objective of S.A. 1 was to understand the regulatory mechanisms of eCBs in the
context of inflammation in the murine spleen, liver, and brain.
The working hypothesis of S.A. 1 was that the activities of eCB metabolizing enzymes
would decrease with a subsequent increase in eCBs in a model of inflammation.
To evaluate this hypothesis, mice were injected with LPS or saline and then sacrificed
after 6 and 24 hours. To confirm the presence of an immune response, pro-inflammatory
cytokines were measured by RT-qPCR. Endocannabinoid metabolism activity was determined
in spleen, liver, and brain samples. Activity-Based Protein Profiling (ABPP) and ABPP -mass
spectrometry (MS) was utilized to identify the specific serine hydrolases affected by LPS
stimulation (Chapter 2).
Specific Aim 2: Role of eCBs in regulating inflammation (Human PBMCs)
The objective of S.A. 2 was to explore the role of eCB metabolizing enzymes as part of a
negative feedback system to control inflammation in human peripheral blood mononuclear cells
(PBMCs) from individuals diagnosed with Huntington’s Disease (HD) and non-HD individuals.
The working hypothesis for S.A. 2 was that 1) HD individuals would have increased
baseline levels of IL-6 and decreased eCB metabolizing activity, and 2) stimulation of PBMCs
with CpG (unmethylated bacterial DNA) or LPS would modulate the activity of the eCB
metabolizing enzymes, CES and MAGL.
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To evaluate this hypothesis, blood was obtained from HD and non-HD individuals.
PBMCs were isolated and treated with CpG and/or LPS. IL-6 was measured by ELISA from the
plasma and culture supernatants, and the cells were used to measure 2-AG hydrolytic activity.
To identify the primary 2-AG hydrolytic enzyme in human PBMCs, a combination of flow
cytometry, Western blotting, and 2-AG hydrolysis (utilizing specific inhibitors of CES and
MAGL) was performed (Chapter 3).
Specific Aim 3: Compare the effect of CPF exposure on the eCB system, particularly in the
lung, in adult versus neonatal wild type and Cnr1-/- mice
The objective of S.A. 3 was to compare the effects of CPF and the role of CB1 in CPFmediated effects on neonatal and adult endocannabinoids, their metabolizing enzymes, and naïve
immunity of various tissues with and without the addition of an immune stimulant,
lipopolysaccharide (LPS).
The working hypothesis for S.A. 3 was that neonates would be more sensitive to CPFmediated effects on the eCB system as compared to adults due to the greater inhibition of eCB
metabolizing enzymes and that CB1 would play a role in these effects.
To evaluate this hypothesis, wild type and Cnr1-/- adult and neonatal mice (post-natal day
10) were treated with a corn oil (CO) vehicle or 2.5 mg/kg dose of CPF orally for 7 days.
Following treatment, mice were sacrificed, and eCB levels, eCB metabolism, and the
immunophenotype of various tissues, focusing mainly on the lung, were determined (Chapter 4).
ABPP-MS was utilized to identify the specific eCB metabolizing enzymes inhibited by CPF in
the murine lung. Only the role of CB1 (and not CB2) in CPF-mediated effects could be explored
as only Cnr1-/- animals were available. Due to negative results and animal limitations, the role of
CB1 was not further explored utilizing an immune stimulant in S.A. 4.
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Specific Aim 4: Explore the significance of lung carboxylesterase inhibition by CPF in
neonatal and adult mice
The objective of S.A 4 was to explore the role of Ces1d (neonates) and Ces1c (neonates
and adults) in CPF-mediated lung immune alterations in response to stimulation by LPS.
The working hypothesis for S.A. 4 was that inhibition of ces1d and ces1c by CPF would
alter the lung’s immune response to stimulation by LPS in neonatal and adult mouse lungs.
Following the 7-day CPF dosing regimen from S.A. 3, neonatal and adult mice were
injected intraperitoneally with LPS (1.25 mg/kg) or saline (control). 6-hours post injection,
differences in the lung immune responses were evaluated by measuring pro-inflammatory
cytokines (qPCR and ELISA), lipid mediators (LC-MS/MS), and the lung immunophenotype
(flow cytometry) (Chapter 5). Due to the generation of negative data, this study was repeated in
Ces1d-/- mice to determine if masking Ces1d would elicit alterations in how the lungs responded
to an immune insult following CPF exposure. Although these were Ces1d-/- animals and CPF
did not inhibit Ces1d in adult WT mice, measuring ces1c mRNA expression by qPCR allowed
for limited exploration into a protective role for the enzyme from CPF-mediated effects on
immune responses.
Specific Aim 5: The safety of E-cigarette vehicle
Finally, the objective of S.A. 5 was to explore the safety of the e-cigarette vehicles,
vegetable glycerin and propylene glycol, with or without French vanilla flavoring.
The working hypothesis for S.A. 5 was that mice exposed sub-acutely to VG/PG e-cig
aerosols, with or without an additional flavoring, would exhibit lung inflammation and altered
lung function.
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To evaluate the hypothesis, adult female mice were exposed to HEPA-filtered air,
70%/30% VG/PG, or 70%/30% VG/PG with a French vanilla flavoring for 2 hours a day for 6
weeks. Prior to sacrifice, lung function was assessed; broncho-alveolar lavage and lung tissue
were collected for lipid mediator analysis, flow cytometry, histopathology, and gene expression
analyses.
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Figure 1.1

Immune homeostasis as a balance

A healthy immune system relies on a balance between pro- and anti- inflammatory processes.

Figure 1.2

Chemical Overview of CPF and CPO

Chemical schematic describing the bioactivation of CPF to CPO, the bioactive metabolite of the
parent insecticide, and the detoxication pathways of CPF and CPO that yield 3,5,6-trichloro-2pyridinol (TCP). CYPs, cytochrome P450s; PON1, paraoxonase-1; CES, carboxylesterase; [S],
elemental sulfur.
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Figure 1.3

Visual hypothesis for the overall dissertation

Schematic describing the overall hypothesis for the dissertation: Alterations to the
endocannabinoid system caused by exposure to chlorpyrifos (CPF) can disrupt immune
homeostasis, leading to changes in the normal lung immune response.
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CHAPTER II
LIPOPOLYSACCHARIDE SUPPRESSES CARBOXYLESTERASE-2G ACTIVITY AND 2ARACHIDONOYLGLYCEROL HYDROLYSIS: A POSSIBLE MECHANISM TO
REGULATE INFLAMMATION
Introduction
Immune cells are recruited to tissues during acute inflammation to remove the
inflammatory stimuli, clear cellular debris, and initiate healing. On the other hand, chronic
inflammation is implicated as a contributor to several diseases, including autoimmune diseases,
atherosclerosis, heart disease, metabolic disease, and cancer. Thus, regulatory mechanisms exist
to control and/or resolve inflammation to prevent further tissue damage from pro-inflammatory
mediators, such as cytokines, chemokines, reactive oxygen or nitrogen species, and proteolytic
enzymes.
Cannabinoids are plant-derived compounds from Cannabis sativa that possess antiinflammatory effects, in part via engagement of CB2 receptors on innate cells (Rom and
Persidsky 2013). Endocannabinoids, such as anandamide (AEA) and 2-arachidonlyglycerol (2AG), also exhibit anti-inflammatory effects (Gallily, Breuer et al. 2000, Facchinetti, Del Giudice
et al. 2003, Panikashvili, Shein et al. 2006, Lourbopoulos, Grigoriadis et al. 2011, Krishnan and
Chatterjee 2012, Lu, Peng et al. 2014). This suggests that increasing endocannabinoid levels
might be one mechanism by which inflammation is regulated in vivo. In fact, many studies have
demonstrated that inhibition of endocannabinoid degradative enzymes, such as monoacylglycerol
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lipase (MAGL) or fatty acid amide hydrolase (FAAH), resulted in attenuated inflammatory
responses (Alhouayek, Lambert et al. 2011, Costola-de-Souza, Ribeiro et al. 2013, Ghosh, Wise
et al. 2013). For instance, the MAGL inhibitor JZL184 attenuated acute lung injury in response
to intranasal LPS (Costola-de-Souza, Ribeiro et al. 2013), reduced carrageenan-induced
inflammatory pain (Ghosh, Wise et al. 2013), and inhibited trinitrobenzene sulfonic acid-induced
colitis (Alhouayek, Lambert et al. 2011).
Carboxylesterases are promiscuous hydrolytic enzymes of the serine hydrolase family
that have been shown to hydrolyze the endocannabinoid 2-AG (Xie, Borazjani et al. 2010, Wang,
Borazjani et al. 2013). In fact, recombinant human CES1 has the same catalytic efficiency as
human MAGL when it comes to the hydrolysis of 2-AG (Xie, Borazjani et al. 2010). On the
basis of amino acid homology, the CES family of enzymes is classified into five groups in
mammals (CES 1–5), with the majority of isoforms in the CES1 and CES2 groups (Satoh and
Hosokawa 1998, Holmes, Wright et al. 2010). There are eight Ces1 genes and eight Ces2 genes
encoded in the murine genome compared to just one human CES1 gene and one human CES2
gene. Further, the individual murine Ces1 and Ces2 genes within their group are highly
redundant in terms of sequence homology, due to multiple gene duplication events that have
occurred throughout the evolutionary history of the mouse (Holmes, Wright et al. 2010).
The goal of the current work was to determine whether the activities of endocannabinoid
catabolic enzymes are attenuated in response to an inflammatory stimulus as one mechanism by
which inflammation is limited and/or resolved. Specifically, we hypothesized that LPS would
simultaneously induce pro-inflammatory mediators and suppress activity of endocannabinoid
degradative enzymes in brain, liver, and spleen following a single intraperitoneal injection. Upon
verification that pro-inflammatory cytokines were induced in spleen and liver, gel-based activity38

based protein profiling (ABPP) of serine hydrolases was performed on all tissues at 6 and 24 hr
post LPS injection. In addition, mass spectrometry-based ABPP of spleen serine hydrolases
indicated that Ces2g activity was selectively down regulated and 2-AG hydrolytic activity in
spleen was concomitantly decreased early following LPS injection. We then verified that Ces2g
is a bona fide 2-AG hydrolase by overexpressing recombinant murine Ces2g in COS7 cells and
assessing its ability to metabolize 2-AG. Together, these results demonstrate that LPS, in
addition to inducing pro-inflammatory mediators, also inhibits endocannabinoid metabolizing
enzyme activity, suggesting a possible negative feedback mechanism to control inflammation.
Materials and Methods
Chemicals and Reagents
The activity-based serine hydrolase probe, fluorophosphonate-biotin (FP-biotin), was
from Toronto Research Chemicals (North York, ON). β-mercaptoethanol, penicillin,
streptomycin, p-Nitrophenyl valerate (pNPV), streptavidin–agarose beads, avidin–horseradish
peroxidase and all buffer components were from Sigma (St. Louis, MO). Authentic standards of
2-AG, AEA, arachidonic acid (AA), and AA-d8 were from Cayman Chemical (Ann Arbor, MI).
O,O′-Diethyl p-nitrophenyl phosphate (paraoxon, PO) was a gift from H. Chambers (Mississippi
State University). High-performance liquid chromatography (HPLC) grade solvents were from
Thermo-Fisher. Reagents for ABPP-MS were purchased from sources described in Wang, et,
al,(Wang, Borazjani et al. 2013).
Mice
C57BL/6 female mice were obtained from Harlan Laboratories (Indianapolis, IN). Mice
were randomly assigned to cages and housed at 5/cage. Mice were acclimated for two weeks
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prior to use in experiments. Animal rooms were kept at 20–25°C and 40–60% humidity with a
12-hr light cycle. All protocols were conducted in accordance with the Mississippi State
University Institutional Animal Care and Use Committee in an AAALAC-approved facility.
Treatment
Mice (N = 5/group) received either saline or LPS (25 μg/mouse delivered in 0.5 ml saline
i.p.). Mice were euthanized at 6 or 24 hr post saline or LPS injection and spleen, liver, and brain
were harvested. The spleen was divided: half was flash frozen, and the other half was used for
immune function and/or mRNA analysis. Liver was also divided: the left cranial liver lobe was
isolated for mRNA analysis and the remaining lobes were flash-frozen. The brain was removed
and dissected on a stainless steel metal plate placed on dry ice. The brain was dissected into left
and right hemispheres (excluding the optic chiasm, cerebellum, and olfactory bulb), and each
portion was flash-frozen in liquid nitrogen. All frozen tissue and mRNA samples were stored at
−80°C until sample preparation.
Splenocyte Culture
Splenocytes were prepared in a single cell suspension by mechanical disruption. Cells
were seeded at 2 × 107 cells/well in complete media (1X RPMI containing 1% v/v bovine calf
serum, 1% w/v penicillin-streptomycin and 50 μM 2-mercaptoethanol). Splenocytes were either
not treated or treated with LPS (1 μg/ml) for 3.5 hr after which cells were lysed in ice-cold 50
mM Tris-HCl (pH 7.4) buffer by sonication. The lysates were assayed for 2-AG hydrolytic
activity, as described below.
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RNA Isolation
Spleen and liver samples were stored in TRI reagent (Sigma Aldrich, St. Louis, MO).
Samples were thawed at room temperature (RT) and then vigorously mixed with 0.2 ml
bromochloropropane (BCP). After a 15-min incubation at RT, liquid phases were separated by
centrifugation at 12000g for 15 min at 4°C. The aqueous phase was transferred to a fresh tube
and RNA was precipitated with 0.5 ml isopropanol. Samples containing precipitated RNA were
mixed and incubated for 10 min before centrifugation at 12000g for 10 min at 4°C. The RNA
pellet was then subjected to further purification and DNase treatment using the SV Total RNA
Isolation System (Promega, Madison, WI) according to manufacturer’s instructions.
Real-Time PCR
cDNA was prepared from total RNA using a High Capacity cDNA Archive Kit (Applied
Biosystems/Life Technologies, Foster City, CA). cDNA was then used in a Taqman PCR
Reaction with Universal 2X Master Mix and il6 or il17 primer/probes (Applied Biosystems/Life
Technologies). Fold change was calculated using the ΔΔCt method (Livak and Schmittgen 2001)
using the 6-hr saline control as the group to which the other groups were compared. Water
controls were included during cDNA synthesis and Taqman PCR reaction.
Preparation of Native Tissue Proteomes
For liver, ~100 mg tissue was homogenized (20% w/v) in sucrose buffer (50 mM TrisHCl, 0.32 M sucrose, pH 7.4) using a dounce homogenizer on ice. Homogenized samples were
transferred to a 1.5-ml centrifuge tube and centrifuged at full speed (16,100g) for 30 min at 4°C.
The supernatant was retained and stored at −80°C until utilized further. Brain was processed the
same way as liver using the entire right hemisphere. Spleen halves were homogenized in 250 μl
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sucrose buffer using a micro tissue homogenizer. Each sample was centrifuged at 1,000g for 30
min at 4°C to remove debris, and the supernatant was retained and stored at −80°C.
Protein Concentration Determination
Samples from the supernatants were diluted 1:30 v/v in deionized water and incubated
with BCA reagent (ThermoPierce) for 30 min at 37°C. Absorbance of solutions at 560 nm was
measured using a plate reader. The absorbance values were compared against a bovine serum
albumin standard to determine protein concentrations.

ABPP
The native tissue proteomes for liver and brain were diluted with sucrose buffer (50 mM
Tris-HCl, 0.32 M sucrose, pH 7.4) to a final protein concentration of 2 mg/ml in a 100 μl
reaction volume (spleen was diluted to 0.5 mg/ml due to limited sample). FP-biotin was added to
each sample (final concentration, 8 μM; 1.9% v/v DMSO) and allowed to react at room
temperature for 60 min. The reaction was stopped using 20 μl of 6X SDS-PAGE loading buffer
(reducing) and samples heated at 90°C for 5 min. Samples were cooled and resolved on 10%
SDS-PAGE gels. Electrophoresis proceeded at 100 V for 15 min and 120 V for approximately 75
min. Following gel electrophoresis, proteins were transferred to a polyvinylidene fluoride
(PVDF) membrane. Each membrane was blocked in 5% (w/v) non-fat milk for 60 min then
washed with tween buffer. The membranes were incubated with avidin-peroxidase (1:2000 v/v)
in 1% (w/v) non-fat milk for at least 120 min before washing the membrane with tween buffer (3
× 10 min). The membranes were then incubated with chemiluminescent substrate for 5 min and
images were obtained using X–ray film for various exposure times. Negative controls included
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proteomes that were heat denatured at 90°C for 5 min before adding FP-biotin. In some
experiments, proteomes were pre-incubated with PO (1 and 10 μM), a broad-spectrum serine
hydrolase inhibitor, for 15 min at 37°C before adding FP-biotin.
Ces Western Blots
Proteomes from naïve mouse spleen were resolved by 10% SDS-PAGE. Mouse Ces1 and
Ces2 proteins were detected by incubation with rabbit monoclonal anti-human CES1 (1:25,000
v/v; Abcam) and goat polyclonal anti-mouse Ces2 (1:5,000 v/v; R&D Systems), respectively,
followed by incubation with HRP-conjugated goat anti-rabbit or donkey anti-goat secondary
antibody. The anti-human CES1 antibody can recognize mouse Ces1 protein. Equal protein
loading of the gel was verified by detecting β-actin with anti-β-actin antibody.
2-AG and AEA Hydrolysis Activity in Spleen Proteomes
Spleen proteomes were adjusted with 50 mM Tris-HCl (pH 7.4) buffer to a final
concentration of 0.5 mg/ml in a 100 μl reaction volume and preincubated for 5 min at 37°C. 2AG or AEA was added (50 μM final concentration, 1.9% v/v ethanol) and the samples were
incubated for 10 min at 37°C (a preliminary experiment showed that production of AA after 10
min was in the linear range of a reaction-time course). The reactions were terminated with 200 μl
of cold acetonitrile (doped with AA-d8) and placed on ice for 15 min. The samples were
centrifuged at full speed (16,100g) for 10 min at 4°C and supernatants transferred to HPLC vials
with reducing inserts. The samples were stored at −20°C until LC-MS/MS analysis. To account
for the level of endogenous AA in homogenates, “blank” spleen samples were prepared without
either exogenous 2-AG or AEA. Non-tissue proteome controls (i.e., non-enzymatic controls)
were also prepared in 50 mM Tris-HCl (pH 7.4) buffer with 50 μM 2-AG or AEA. In some
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experiments, either PO (1 μM final concentration) or ethanol was added to spleen proteomes and
incubated for 30 min at 37°C prior to the addition of 2-AG. Analysis of AA by LC-MS/MS was
done as described previously (Wang, Borazjani et al. 2013).
ABPP-MS Serine Hydrolase Profiling
Spleen proteomes were adjusted to 1 mg/ml protein concentration in 50 mM Tris-HCl
(pH 7.4) buffer in a total volume of 1 ml. The samples were treated with FP-biotin (8 μM) for 60
min. Reactions were terminated by adding SDS (0.5% w/v final concentration) and heating at
90°C for 10 min. The samples were allowed to cool on ice. Meanwhile, a 3-kDa MWCO Amicon
Ultra centrifugal filter in cartridge (Millipore, Billerica, MA) was set-up in 2-ml centrifuge tubes
for each sample to remove excess unreacted FP-biotin. The samples were transferred to the 3kDa MWCO filter and centrifuged at 14,000 x g for 20 min, and the filtrate was discarded. The
samples were washed three times with 500 μl of 50 mM Tris-HCl (pH 7.4) buffer and
centrifuged each time. After the final wash, the filter was reversed into a new tube and
centrifuged at 100 x g for 2 min. The filter was rinsed three times with 100 μl of 50 mM Tris
buffer and each rinse transferred to sample tube. The samples were stored at 4°C. Streptavidinagarose beads (200 μl; Thermo) were washed in PBS and proteome samples added to the washed
beads and incubated at room temperature for 3.5 h on a rotator. This is done to attach the serine
hydrolases that had reacted with the activity probe FP-biotin on the streptavidin beads. After
attachment, the beads are pelleted by centrifugation at 1,400 x g for 3 min and the supernatant
was discarded. The beads were then washed with 0.2% SDS in PBS (1 ml) once for 10 min
before being centrifuged at 1,400 x g for 3 min. The supernatant was discarded. This wash
process was repeated 3 times using PBS and 3 times using water. After washing the beads, the
samples were reduced in 500 μl of 6 M urea in 50 mM Tris-HCl (pH 7.4) and 10 μl of 500 mM
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TCEP [Tris (2-carboxyethyl) phosphine hydrochloride; final concentration of 10 mM]. Samples
were incubated at 65°C for 15 min then cooled to 37°C. Fresh 500 mM IAA (iodoacetamide; 20
μl) was added to alkylate free cysteines and the samples incubated at 37°C for 30 min in the
dark. Following the alkylation reaction, 950 μl of 50 mM Tris-HCl (pH 7.4) was added. Samples
were centrifuged at 1,400 x g for 2 min to pellet the beads, and the supernatant was discarded.
Two-hundred μl of 2 M urea in 50 mM Tris-HCl (pH 7.4) and 4 μl of trypsin (Pierce) (0.5
mg/ml) were added to the beads. Trypsin was activated with 2 μl of 100 mM CaCl2 (1 mM final
concentration) and the samples were incubated overnight at 37°C with gentle mixing. The
samples were transferred to a spin-desalting column (Zeba 7-kDa MWCO, Thermo) to remove
the beads and collect the filtrate containing the peptides. The beads in the column were washed
two times with water and the filtrates were pooled together (total volume 300 μl). Three μl of
10% v/v formic acid in water was added to the filtrates containing peptides and the filtrates were
desalted with a Sep-Pak C18 cartridge (Waters Associates, Milford, MA) following the
manufacturer’s instructions. The peptides were eluted in 65% aqueous acetonitrile and the
solvent was evaporated completely in a Speedvac concentrator. The residues were re-suspended
in 20 μl of 0.1% v/v formic acid in water for proteomic LC-MS/MS analysis as described
previously (Wang, Borazjani et al. 2013). In brief, tryptic peptides were injected on a 75 μm
(inside diameter) × 15 cm reverse phase C18 column (Thermo) controlled by an Ultimate 3000
nanoflow HPLC system (Dionex) and eluted using a water/acetonitrile (containing 0.1% formic
acid) gradient at a flow rate of 0.3 μl/min. The separated peptides were introduced into an LTQ
OrbiTrap Velos mass spectrometer (ThermoFisher). Normalized spectral counts for each
identified serine hydrolase were determined using the commercially available Scaffold version
4.0.7 (Wang, Borazjani et al. 2013).
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Overexpression of Ces2g and Assessment of 2-AG Hydrolytic Activity
Recombinant murine Ces2g was overexpressed in COS-7 cells transfected with an
expression vector containing Ces2g cDNA (Origene), as described previously (Xie, Borazjani et
al. 2010, Wang, Borazjani et al. 2013). Control transfections of COS-7 cells included an
expression vector without the Ces2g cDNA insert (mock transfection). Cells were harvested 24–
48 hr after transfection and lysed in 50 mM Tris-HCl (pH 7.4) buffer by sonication. The esterase
activity of the lysates was assessed using pNPV, as described previously (Xie, Borazjani et al.
2010). 2-AG hydrolytic activity of the lysates was determined by adding exogenous 2-AG (10
μM final concentration) and incubating for 10 min at 37°C. Reactions were quenched by addition
of an equal volume of cold acetonitrile doped with internal standard (AA-d8). The amount of AA
produced in the reaction was determined by LC-MS/MS as previously described (Wang,
Borazjani et al. 2013).
Statistical Analysis
The mean ± SE (or SD) was determined for each treatment group. Differences between
means were determined with a two-way analysis of variance. When significant differences were
detected, treatment groups within time points were compared to the 6 hr saline using
Bonferroni’s test. For RT-PCR data, Grubb’s outlier test was performed for each treatment group
using Delta Ct (Ct target gene − Ct18S). In addition, fold change values were transformed using
natural log (fold change +1) prior to statistical analysis. Statistical analyses were performed
using GraphPad Prism version 4.0a for Macintosh OSX, GraphPad software (San Diego, CA).
Comparison of spectral count data from saline and LPS-treated samples following ABPP-MS
were assessed by Student’s t-test. Enzymatic activities of mock and Ces2g-overexpressed
homogenates were assessed by Student’s t-test.
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Results
LPS-induced inflammatory response
To verify that LPS induced inflammation in the mice, the levels of two representative
classical pro-inflammatory cytokines, Il6 and Il17a, were assessed in spleen and liver (Figure
2.1). Both Il6 and Il17a mRNA levels increased significantly in spleen and liver by 6 hr post
LPS injection. By 24 hr, the mRNA levels of Il6 and Il17a had returned to baseline levels.
LPS-induced modulation of serine hydrolase activity
ABPP enables the activities of enzymes with conserved catalytic mechanisms, such as the
serine hydrolases, to be evaluated in their native environments within tissues and cells (Niphakis
and Cravatt 2014). Serine hydrolase activities were assessed in brain, liver, and spleen
proteomes in response to LPS using the activity probe FP-biotin and gel-based ABPP (Figure
2.2). This probe reacts with most, but not all, active serine hydrolases. In brain, the serine
hydrolases FAAH, NCEH1, ABHD12 and MAGL were detected, as we and others have
previously shown (Long, Nomura et al. 2009, Carr, Borazjani et al. 2011); however, none were
altered by LPS treatment (Figure 2.2 A). In liver, Ces and AADAC activities were detected, but
again, were not changed by LPS (Figure 2.2 B). In spleen, there was a modest decrease in Ces
activity in response to LPS at the 6 hr timepoint (Figure 2.2 C), although it did not reach
statistical significance. This Ces band at 60 kDa in the gel-based ABPP is a composite of all Ces
isoforms in the homogenate. No altered serine hydrolase activities were detected in any tissue at
24 hr post LPS (data not shown). Non-specific bands indicate those proteins in tissues that are
known to be detected by avidin-peroxidase blotting in the absence of FP-biotin (Carr, Borazjani
et al. 2011).
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Characterization of Ces activity in spleen
In order to verify that Ces and MAGL were active in the spleen, saline-treated spleen
homogenates were incubated in the presence of PO, the bioactive metabolite of the insecticide
parathion, which selectively inhibits Ces (at 1 μM) and at higher concentrations (≥ 10 μM) can
also inhibit MAGL (PO is a more selective inhibitor of Ces relative to MAGL) (Xie, Borazjani et
al. 2010, Crow, Bittles et al. 2012). As seen in (Figure 2.3 A), pre-treatment of spleen proteomes
with PO at a concentration of 1 μM resulted in the complete abrogation of Ces activity, as
demonstrated by the lack of a visible band, indicating that the FP-biotin probe was unable to
modify the PO-inactivated Ces proteins. On the other hand, the intensity of the band annotated as
MAGL was unchanged relative to vehicle control; however, pre-treatment with a higher
concentration of PO (10 μM) caused a decrease in its activity. Two serine hydrolases ~31 kDa
were also inhibited by PO, particularly at 10 μM, although their identities are unknown.
Moreover, using PO (1 μM) to inhibit all Ces activity, the hydrolysis of exogenous 2-AG in
spleen homogenates was completely abolished (Figure 2.3 B), suggesting that Ces can hydrolyze
2-AG in the spleen. In response to LPS, there was a significant inhibition of 2-AG hydrolysis
activity at 6 hr post LPS, with no effect on 2-AG hydrolysis at the 24 hr timepoint. It was also
notable that the AEA hydrolytic activity in spleen was markedly lower than the 2-AG hydrolytic
activity (Figure 2.3 B). In addition, there was no difference in AEA hydrolysis activity detected
in the spleen at 6 h post LPS compared to saline control. The LPS-induced suppression of 2-AG
hydrolytic activity was confirmed in vitro using splenocytes treated with LPS (Figure 2.4 A).
Identification of Ces isoforms in the spleen
We next assessed the serine hydrolase activities in the 6 hr saline- and LPS-treated spleen
samples using ABPP-MS to specifically identify which serine hydrolase isoforms were
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modulated by LPS, because the gel-based ABPP results indicated that LPS-induced suppression
of a Ces isoform was involved in the reduction in 2-AG hydrolysis by LPS (Figure 2.2 C).
Indeed, Ces1c, Ces2g, and Ces1d were all identified in spleen with Ces1c being most abundant
(Figure 2.5 A). Interestingly, of the three Ces isoforms, only the activity of Ces2g was
suppressed by LPS (Figure 2.5 A), suggesting that the reduced 2-AG hydrolysis in spleen at 6 hr
(Figure 2.4 A) was due to LPS-induced suppression of Ces2g activity specifically. It was notable
that FAAH was not detected in the spleen by ABPP-MS (Figure 2.5 A), which is consistent with
the minimal AEA hydrolysis activity detected (Figure 2.4 A). Moreover, MAGL (Mgll) activity
was not significantly altered by LPS when assessed by ABPP-MS, again supporting Ces2g as the
primary target of suppression by LPS contributing to reduced 2-AG hydrolysis. Immunoblots of
control spleen homogenates verified that Ces1 and Ces2 isoforms were expressed (Figure 2.5 B),
although specific subclasses of Ces isoforms, such as Ces1c and Ces1d, cannot be distinguished
by immunoblotting due to the lack of specific antibodies.
Ces2g is a 2-AG hydrolytic enzyme
To verify that murine Ces2g is a 2-AG hydrolytic enzyme, we overexpressed it in COS7
cells following transient transfection (Figure 2.6 A) and showed that it could hydrolyze 2-AG to
AA (Figure 2.6 B). Thus, Ces2g appears to be a bona fide 2-AG hydrolytic enzyme. Finally, we
also verified that Ces2g is highly sensitive to the inhibitory effects of PO (Figure 2.6 C), as was
expected for a Ces isoform (Crow, Bittles et al. 2012).
Discussion
The mechanisms involved in inflammation initiation are well-studied as compared to
those involved in resolution. The inflammatory response we observed, as measured by Il6 and
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Il17a gene expression, in the spleen and liver in response to LPS demonstrates the classical,
transient response with high expression early followed by almost complete resolution within 24
hr. The resolution of inflammation must involve more than simply clearance of LPS because in
one study in which cecal ligation and puncture was utilized as a model of systemic endotoxemia,
plasma IL-6 levels returned toward baseline even when plasma endotoxin levels remained high
(Deng, Scott et al. 2013).
In this work, we examined the possibility that LPS not only induced inflammation but
also inhibited endocannabinoid metabolizing enzymes as one mechanism to raise
endocannabinoid levels as a potential negative feedback system to limit inflammation.
Specifically in the spleen, Ces2g activity was suppressed by LPS. Because we also demonstrated
that Ces2g was a 2-AG hydrolytic enzyme, these results show that LPS suppresses 2-AG
hydrolysis in part through inhibition of Ces2g. This result is similar to reports in which FAAH
activity was inhibited by LPS (Maccarrone, De Petrocellis et al. 2001, Liu, Batkai et al. 2003,
Wolfson, Aisemberg et al. 2013). Interestingly, FAAH activity was not detected in the spleen
proteome by ABPP-MS, nor was there any AEA hydrolysis activity detected in spleen
homogenates. Thus, 2-AG is the predominant endocannabinoid in the spleen, consistent with
other reports in which 2-AG was found in nmol/g range, whereas AEA was detected in pmol/g
range in the spleen (Pasquarelli, Porazik et al. 2015). Ces1c was the most abundant serine
hydrolase detected by ABPP-MS; however, Ces1c mRNA was not detected in mouse spleen
(unpublished observation and (Jones, Taylor et al. 2013)). On the other hand, Ces2g mRNA was
detected in spleen (Jones, Taylor et al. 2013), which is consistent with our ABPP-MS result. The
high levels of active Ces1c detected in spleen by ABPP-MS likely stems from contaminating
Ces1c, which is present in abundance in mouse blood (Li, Sedlacek et al. 2005). Spleen is a
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richly perfused tissue and spleen proteomes would be prone to Ces1c contamination via the
blood. Ces2g, however, is not found in mouse blood.
The results demonstrate that 2-AG hydrolysis in the spleen is inhibited early following
LPS administration. The LPS-induced suppression of 2-AG hydrolysis was also shown in vitro in
splenocytes, suggesting that the mediator induced by LPS to suppress CES2g activity in the
spleen could be found in the cells. One such mediator for inhibition of CES2g activity is IL-6. It
was demonstrated in a human HepG2 liver cell line that IL-6 directly inhibited the CES2
promoter region (Yang, Shi et al. 2007). Studies are currently ongoing to determine if IL-6 is
part of the mechanism by which LPS suppressed CES2g in splenocytes leading to inhibition of
2-AG hydrolysis.
The mechanism by which elevated 2-AG exhibits anti-inflammatory actions could be
engagement of CB1 or CB2 on innate cells (Lourbopoulos, Grigoriadis et al. 2011, Lu, Peng et
al. 2014, Dong, Lu et al. 2015). However, it is also possible that Ces2g inhibition leading to
suppression of 2-AG hydrolysis causes the elevated 2-AG to be shunted to an alternative
metabolism pathway. For example, 2-AG can be metabolized by cyclooxygenase-2 (COX-2) to
prostaglandin J2 glycerol esters, which are also anti-inflammatory through their interaction with
PPAR-γ (Rockwell, Snider et al. 2006, Rockwell, Raman et al. 2008, Raman, Kaplan et al. 2011,
Raman, Kaplan et al. 2012). Other anti-inflammatory eicosanoids can be produced following
metabolism of 2-AG by COX-2, and 2-AG can also be metabolized by lipoxygenase and
cytochrome P450 enzymes, which could also yield anti-inflammatory molecules (Rouzer and
Marnett 2011, Alhouayek, Masquelier et al. 2013, Turcotte, Chouinard et al. 2015, Urquhart,
Nicolaou et al. 2015).
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The present studies demonstrate that inflammagens such as LPS possess proinflammatory actions and activate mechanisms to temper inflammatory responses
simultaneously. Identification of the mediator(s) that participate in a negative feedback system to
control inflammation would help guide therapy development; for instance, if IL-6 is an effective
suppressor of endocannabinoid metabolizing enzymes, perhaps it is not a beneficial target of
suppression for inflammatory diseases.
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Figure 2.1

LPS induces inflammatory cytokine mRNA in liver and spleen

Real time RT-PCR was performed on total RNA isolated from liver or spleen at various times
following saline or LPS injection. Taqman RT-PCR was performed for Il6 and Il17. Fold change
was calculated as compared with 6 or 24 hr saline. *p < 0.05 as compared to 6 hr saline in each
tissue.
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Figure 2.2

Profile of serine hydrolases in brain, liver, and spleen following treatment with
saline or LPS

Tissue homogenates were prepared from brain (A), liver (B) or spleen (C). Active serine
hydrolases in the homogenates were detected following treatment with FP-biotin and subsequent
resolution by SDS-PAGE. Probe-modified proteins were detected using streptavidin-conjugated
horseradish peroxidase. Enzymes are identified based on molecular weight and previous
publications (Long, Nomura et al. 2009, Carr, Borazjani et al. 2011, Ross, Borazjani et al. 2012).
Saline- or LPS-treated tissues at the 6 hr timepoint are shown. Non-specific labels refer to
proteins that are endogenously biotinylated and are detected in tissue homogenates that are not
treated with FP-biotin (data not shown). Densitometry of CES bands in spleen samples are
shown next to the blot (p = 0.17).
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Figure 2.3

Ces hydrolyzes 2-AG in the spleen

Saline-treated spleen homogenates (6 hr) were preincubated with ethanol (EtOH) or PO (1–
10 μM) for 15 min at 37°C, followed by treatment with FP-biotin for 1 h (A). Ces and
MAGL activity was then detected using gel-based ABPP. (B) 2-AG hydrolytic activity was
measured by quantifying AA production. Saline-treated spleen homogenates (6 hr) were
preincubated with ethanol (EtOH) or PO (1–10 μM) for 15 min at 37°C, followed by the
addition of 2-AG (50 μM). The amount of AA produced in 10 min was measured by LCMS/MS.

Figure 2.4

LPS suppresses 2-AG hydrolysis in the spleen

(A) Saline- or LPS-treated spleen homogenates were incubated with 2-AG or AEA as substrates
(50 μM) for 10 min. * p < 0.05 as compared to 6 hr saline-treated spleen. (B) Splenocytes (n=6)
were treated in vitro with LPS (1 μg/ml) for 3.5 hr. 2-AG hydrolytic activity (50 μM, 10 min) of
cell lysate was measured by quantifying AA production by LC-MS/MS. ** p < 0.01 as compared
to control.

55

Figure 2.5

LPS suppresses Ces2g activity in the spleen

(A) Saline or LPS-treated spleen homogenates were subjected to ABPP-MS proteomic analysis.
The activity of the identified serine hydrolases was quantified at 6 hr following saline or LPS
treatments. Ces isoforms are designated with red boxes. * p < 0.05 when compared to 6 hr salinetreated spleen. (B) Immunoblots of Ces1 and Ces2 in naïve spleens verified the expression of
these Ces family members.
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Figure 2.6

Ces2g is a 2-AG hydrolytic enzyme

COS-7 cells were transiently transfected with mouse Ces2g cDNA. The ability of the Ces2gexpressing COS-7 homogenates to hydrolyze p-NPV (A) and 2-AG (B) was assessed.
Endocannabinoid hydrolytic activity was measured by quantifying AA production by LCMS/MS. * p < 0.05 when compared to mock-transfected cell lysate. (C) Inhibition of Ces2g
activity by PO. The enzyme was pre-incubated with the indicated concentrations of PO for 10
min (37°C) before assaying the activity of the enzyme using the substrate p-NPV. The estimated
IC50 for PO is 5.2 nM. Error bars are depicted but fall within the symbol.

57

References
Alhouayek, M., D. M. Lambert, N. M. Delzenne, P. D. Cani and G. G. Muccioli (2011).
"Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic
inflammation." FASEB J 25(8): 2711-2721.
Alhouayek, M., J. Masquelier, P. D. Cani, D. M. Lambert and G. G. Muccioli (2013).
"Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the
control of macrophage activation and inflammation by ABHD6." Proc Natl Acad Sci U S A
110(43): 17558-17563.
Carr, R. L., A. Borazjani and M. K. Ross (2011). "Effect of developmental chlorpyrifos
exposure, on endocannabinoid metabolizing enzymes, in the brain of juvenile rats." Toxicol Sci
122(1): 112-120.
Costola-de-Souza, C., A. Ribeiro, V. Ferraz-de-Paula, A. S. Calefi, T. P. Aloia, J. A. GimenesJúnior, V. I. de Almeida, M. L. Pinheiro and J. Palermo-Neto (2013). "Monoacylglycerol lipase
(MAGL) inhibition attenuates acute lung injury in mice." PLoS One 8(10): e77706.
Crow, J. A., V. Bittles, K. L. Herring, A. Borazjani, P. M. Potter and M. K. Ross (2012).
"Inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by
chlorpyrifos oxon, paraoxon and methyl paraoxon." Toxicol Appl Pharmacol 258(1): 145-150.
Deng, M., M. J. Scott, P. Loughran, G. Gibson, C. Sodhi, S. Watkins, D. Hackam and T. R.
Billiar (2013). "Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory
responses are regulated by cell type-specific functions of TLR4 during sepsis." J Immunol
190(10): 5152-5160.
Dong, M., Y. Lu, Y. Zha and H. Yang (2015). "Endocannabinoid 2-arachidonylglycerol protects
primary cultured neurons against homocysteine-induced impairments in rat caudate nucleus
through CB1 receptor." J Mol Neurosci 55(2): 500-508.
Facchinetti, F., E. Del Giudice, S. Furegato, M. Passarotto and A. Leon (2003). "Cannabinoids
ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide." Glia
41(2): 161-168.
Gallily, R., A. Breuer and R. Mechoulam (2000). "2-Arachidonylglycerol, an endogenous
cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in
mice." Eur J Pharmacol 406(1): R5-7.
Ghosh, S., L. E. Wise, Y. Chen, R. Gujjar, A. Mahadevan, B. F. Cravatt and A. H. Lichtman
(2013). "The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the
mouse carrageenan model." Life Sci 92(8-9): 498-505.

58

Holmes, R. S., M. W. Wright, S. J. Laulederkind, L. A. Cox, M. Hosokawa, T. Imai, S. Ishibashi,
R. Lehner, M. Miyazaki, E. J. Perkins, P. M. Potter, M. R. Redinbo, J. Robert, T. Satoh, T.
Yamashita, B. Yan, T. Yokoi, R. Zechner and L. J. Maltais (2010). "Recommended
nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes
and proteins." Mamm Genome 21(9-10): 427-441.
Jones, R. D., A. M. Taylor, E. Y. Tong and J. J. Repa (2013). "Carboxylesterases are uniquely
expressed among tissues and regulated by nuclear hormone receptors in the mouse." Drug Metab
Dispos 41(1): 40-49.
Krishnan, G. and N. Chatterjee (2012). "Endocannabinoids alleviate proinflammatory conditions
by modulating innate immune response in muller glia during inflammation." Glia 60(11): 16291645.
Li, B., M. Sedlacek, I. Manoharan, R. Boopathy, E. G. Duysen, P. Masson and O. Lockridge
(2005). "Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are
present in human plasma." Biochemical Pharmacology 70(11): 1673-1684.
Liu, J., S. Batkai, P. Pacher, J. Harvey-White, J. A. Wagner, B. F. Cravatt, B. Gao and G. Kunos
(2003). "Lipopolysaccharide induces anandamide synthesis in macrophages via
CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor."
J Biol Chem 278(45): 45034-45039.
Livak, K. J. and T. D. Schmittgen (2001). "Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method." Methods 25(4): 402-408.
Long, J. Z., D. K. Nomura and B. F. Cravatt (2009). "Characterization of monoacylglycerol
lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism."
Chem Biol 16(7): 744-753.
Lourbopoulos, A., N. Grigoriadis, R. Lagoudaki, O. Touloumi, E. Polyzoidou, I. Mavromatis, N.
Tascos, A. Breuer, H. Ovadia, D. Karussis, E. Shohami, R. Mechoulam and C. Simeonidou
(2011). "Administration of 2-arachidonoylglycerol ameliorates both acute and chronic
experimental autoimmune encephalomyelitis." Brain Res 1390: 126-141.
Lu, Y., F. Peng, M. Dong and H. Yang (2014). "Endocannabinoid 2-arachidonylglycerol protects
primary cultured neurons against LPS-induced impairments in rat caudate nucleus." J Mol
Neurosci 54(1): 49-58.
Maccarrone, M., L. De Petrocellis, M. Bari, F. Fezza, S. Salvati, V. Di Marzo and A. FinazziAgrò (2001). "Lipopolysaccharide downregulates fatty acid amide hydrolase expression and
increases anandamide levels in human peripheral lymphocytes." Arch Biochem Biophys 393(2):
321-328.
Niphakis, M. J. and B. F. Cravatt (2014). "Enzyme inhibitor discovery by activity-based protein
profiling." Annu Rev Biochem 83: 341-377.
59

Panikashvili, D., N. A. Shein, R. Mechoulam, V. Trembovler, R. Kohen, A. Alexandrovich and
E. Shohami (2006). "The endocannabinoid 2-AG protects the blood-brain barrier after closed
head injury and inhibits mRNA expression of proinflammatory cytokines." Neurobiol Dis 22(2):
257-264.
Pasquarelli, N., C. Porazik, J. Hanselmann, P. Weydt, B. Ferger and A. Witting (2015).
"Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in
brain, spinal cord, liver, spleen, fat and muscle tissue." Neuropharmacology 91: 148-156.
Raman, P., B. L. Kaplan and N. E. Kaminski (2012). "15-Deoxy-Δ¹²,¹⁴-prostaglandin J₂-glycerol,
a putative metabolite of 2-arachidonyl glycerol and a peroxisome proliferator-activated receptor
γ ligand, modulates nuclear factor of activated T cells." J Pharmacol Exp Ther 342(3): 816-826.
Raman, P., B. L. Kaplan, J. T. Thompson, J. P. Vanden Heuvel and N. E. Kaminski (2011). "15Deoxy-delta12,14-prostaglandin J2-glycerol ester, a putative metabolite of 2-arachidonyl
glycerol, activates peroxisome proliferator activated receptor gamma." Mol Pharmacol 80(1):
201-209.
Rockwell, C. E., P. Raman, B. L. Kaplan and N. E. Kaminski (2008). "A COX-2 metabolite of
the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in
activated Jurkat T cells." Biochem Pharmacol 76(3): 353-361.
Rockwell, C. E., N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel and N. E. Kaminski (2006).
"Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome
proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2." Mol
Pharmacol 70(1): 101-111.
Rom, S. and Y. Persidsky (2013). "Cannabinoid receptor 2: potential role in immunomodulation
and neuroinflammation." J Neuroimmune Pharmacol 8(3): 608-620.
Ross, M. K., A. Borazjani, R. Wang, J. A. Crow and S. Xie (2012). "Examination of the
carboxylesterase phenotype in human liver." Arch Biochem Biophys 522(1): 44-56.
Rouzer, C. A. and L. J. Marnett (2011). "Endocannabinoid oxygenation by cyclooxygenases,
lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid
signaling pathways." Chem Rev 111(10): 5899-5921.
Satoh, T. and M. Hosokawa (1998). "The mammalian carboxylesterases: from molecules to
functions." Annu Rev Pharmacol Toxicol 38: 257-288.
Turcotte, C., F. Chouinard, J. S. Lefebvre and N. Flamand (2015). "Regulation of inflammation
by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide,
and their metabolites." J Leukoc Biol 97(6): 1049-1070.
Urquhart, P., A. Nicolaou and D. F. Woodward (2015). "Endocannabinoids and their
oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases." Biochim Biophys Acta
1851(4): 366-376.
60

Wang, R., A. Borazjani, A. T. Matthews, L. C. Mangum, M. J. Edelmann and M. K. Ross
(2013). "Identification of palmitoyl protein thioesterase 1 in human THP1 monocytes and
macrophages and characterization of unique biochemical activities for this enzyme."
Biochemistry 52(43): 7559-7574.
Wolfson, M. L., J. Aisemberg, A. I. Salazar, A. P. Domínguez Rubio, C. A. Vercelli and A. M.
Franchi (2013). "Progesterone reverts LPS-reduced FAAH activity in murine peripheral blood
mononuclear cells by a receptor-mediated fashion." Mol Cell Endocrinol 381(1-2): 97-105.
Xie, S., A. Borazjani, M. J. Hatfield, C. C. Edwards, P. M. Potter and M. K. Ross (2010).
"Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by
activated organophosphorus insecticides: role of carboxylesterases 1 and 2." Chem Res Toxicol
23(12): 1890-1904.
Yang, J., D. Shi, D. Yang, X. Song and B. Yan (2007). "Interleukin-6 alters the cellular
responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of
carboxylesterases HCE1 and HCE2." Mol Pharmacol 72(3): 686-694.

61

CHAPTER III
CHARACTERIZATION OF ENDOCANNABINOID-METABOLIZING ENZYMES IN
HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS UNDER
INFLAMMATORY CONDITIONS
Introduction
The endocannabinoid system comprises arachidonoyl-containing endocannabinoids, their
cognate G-protein coupled receptors, and biosynthetic and catabolic enzymes that regulate the
levels of these lipid signaling molecules. Engagement of the cannabinoid 1 or 2 receptors by
plant-derived cannabinoids or endogenous cannabinoids is known to produce anti-inflammatory
effects (Kaplan 2013, Rom and Persidsky 2013). 2-Arachidonoylglycerol (2-AG) and
anandamide (AEA) are the best characterized endocannabinoids and are hydrolytically
catabolized by monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH),
respectively, yielding pro-inflammatory arachidonic acid (AA) (Carr, Adams et al. 2013, Kerr,
Harhen et al. 2013). Other enzymes known to hydrolyze and inactivate 2-AG include
carboxylesterases (CES1 and CES2 in human, Ces2g in mice; human and mouse gene symbols
for carboxylesterases are CES and Ces, respectively), α,β-hydrolase domain (ABHD) 6, and
ABHD12 (Xie, Borazjani et al. 2010, Savinainen, Saario et al. 2012, Wang, Borazjani et al.
2013). It should be noted that FAAH is also capable of hydrolyzing 2-AG (Lu and Mackie
2016). Inactivation of one or more of these enzymes can increase steady-state endocannabinoid
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levels and is one proposed mechanism to limit or reduce inflammation (Gallily, Breuer et al.
2000, Lourbopoulos, Grigoriadis et al. 2011, Szafran, Borazjani et al. 2015).
Previous work from our lab demonstrated that lipopolysaccharide (LPS) treatment of
mice induced pro-inflammatory mediators such as interleukin (IL)-6 and reduced the metabolism
of endocannabinoids in the spleen by Ces2g (Szafran, Borazjani et al. 2015). Several studies
using in vivo and ex vivo approaches have shown that 2-AG can suppress pro-inflammatory
cytokine levels such as tumor necrosis factor-α (TNF-α), IL-6, and IL-1β by decreasing their
production or release (Lourbopoulos, Grigoriadis et al. 2011, Carr, Adams et al. 2013). For
example, mouse macrophages and rat microglial cells treated with exogenous 2-AG exhibited
decreased production or release of these cytokines in response to LPS treatment (Gallily, Breuer
et al. 2000, Facchinetti, Del Giudice et al. 2003). 2-AG was also shown to have a protective role
in several disease processes in humans and rodents, such as experimental autoimmune
encephalomyelitis (mouse model of multiple sclerosis), colitis, and autoimmune disease
(Alhouayek, Lambert et al. 2011, Lourbopoulos, Grigoriadis et al. 2011, Sido, Nagarkatti et al.
2015). Treatment of animal models with small-molecule inhibitors that block endocannabinoidmetabolizing enzymes was shown to reduce disease-associated inflammation (Ghosh, Wise et al.
2013, Kerr, Harhen et al. 2013, Alhouayek, Masquelier et al. 2014, Pihlaja, Takkinen et al.
2015). For example, inhibition of MAGL by the inhibitor JZL184 following a muscle contusion
injury in rats decreased TNF-α, IL-6, and IL-1β levels three days post-injury (Jiang, Zhang et al.
2015). Within the context of neuroinflammation, JZL184 decreased inflammatory responses of
microglia in the APdE9 mouse model of Alzheimer’s disease when exposed to LPS, IFN-γ, and
Aβ42 (Ghosh, Wise et al. 2013). Interestingly, another study found that IL-6 suppressed CES1
and CES2 mRNA and enzyme activity in primary human hepatocytes (Yang, Shi et al. 2007),
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providing evidence to support the hypothesis we proposed in our earlier publication (Szafran,
Borazjani et al. 2015) that this may be a negative feedback mechanism to regulate 2-AG
catabolism and inflammation resolution.
Huntington’s disease (HD) is a progressive neurodegenerative disease caused by a
polyglutamine expansion in the human HTT gene, which is located on chromosome 4. This
mutation results in the aggregation of mutated huntingtin protein in many neuronal cell types,
including medium spiny neurons of the striatum (Vonsattel, Myers et al. 1985). Mutant protein
aggregation leads to progressive cell loss and development of motor, cognitive, and psychiatric
manifestations of HD over time (McColgan and Tabrizi 2018). Chronic inflammation is
observed in both the central and peripheral nervous system in HD, and IL-6 levels have been
reported to be elevated in the plasma and cerebrospinal fluid of HD individuals and a mouse
model of HD (Dalrymple, Wild et al. 2007, Bjorkqvist, Wild et al. 2008, Bouchard, Truong et al.
2012, Chang, Wu et al. 2015, Crotti and Glass 2015). It was also reported that FAAH activity
was reduced in blood lymphocytes from HD individuals compared to those from non-HD
individuals (Battista, Bari et al. 2007). Another study in the R6/2 mouse model of HD found a
decreased level of FAAH activity in the striatum and increased 2-AG levels in whole brain as
compared to control mice. However, no differences in peripheral lymphocyte FAAH activity
were observed between R6/2 and control mice (Bari, Battista et al. 2013). These studies suggest
that inflammatory diseases might be associated with decreased activities of endocannabinoidmetabolizing enzymes and that HD disease could be a potential model to determine whether IL-6
can suppress endocannabinoid-metabolizing enzyme activity. Therefore, the goals of this study
were to (i) examine the role of inflammation, specifically IL-6, on endocannabinoidmetabolizing enzyme activity in peripheral blood mononuclear cells (PBMCs) obtained from
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non-HD and HD individuals; (ii) identify the primary 2-AG hydrolytic enzymes in human
PBMCs; and (iii) determine the cell specificity of MAGL and CES1 expression in human
PBMCs. We hypothesized that HD individuals would have elevated plasma IL-6 levels and
decreased PBMC endocannabinoid-metabolizing activity as compared to non-HD individuals.
We examined IL-6 levels in plasma obtained from HD and non-HD individuals, assessed IL-6
levels and endocannabinoid-metabolizing enzyme activity in PBMCs isolated from HD and nonHD individuals that were stimulated with inflammogens, and characterized the expression of
MAGL and CES1 in PBMCs using immunoblot and flow cytometry.
Materials and Methods
Chemicals and Reagents
Histopaque, p-nitrophenyl valerate (pNPVa), and LPS (E. coli 055:B5) were purchased
from Sigma (St. Louis, MO, USA). AIM V® Serum Free Medium was purchased from ThermoFisher (Waltham, MA, USA). RIPA lysis buffer and protease inhibitors (phenylmethylsulfonyl
fluoride, PMSF; 4-(2-aminoethyl)benzenesulfonyl fluoride, AEBSF; bestatin; pepstatin A;
leupeptin hemisulfate; and aprotinin) were from Santa Cruz Biotechnology (Dallas, TX, USA).
Antibodies used for Western blots (anti-CES1, anti-MAGL, β-actin, goat anti-rabbit, and goat
anti-mouse) were purchased from Abcam (Cambridge, MA, USA). Authentic 2-AG,
anandamide, AA, and its deuterated analog AA-d8 were purchased from Cayman Chemical
Company (Ann Arbor, MI, USA). Small molecules JZL184 and WWL113 were purchased from
Sigma. CpG was purchased from InvivoGen (San Diego, CA, USA). Primary CES1 and MAGL
antibodies for flow cytometry were purchased from Abcam. Fluorescence secondary antibodies
for flow cytometry and antibodies against IL-6 used to neutralize IL-6 or perform ELISA were
purchased from Biolegend (San Diego, CA, USA). For some of the experiments, monocyte65

depleted (n = 1) and whole PBMCs (n = 5) were purchased from Astarte Biologics (Bothell,
WA, USA).
Blood Collection
Human venous blood was collected in EDTA Vacutainer tubes from 8 non-HD
individuals and 8 symptomatic HD individuals at the University of Rochester (Rochester, NY,
USA). Blood was shipped at room temperature (RT) overnight to Mississippi State University
for analysis. All analysis performed at Mississippi State University prior to the statistical analysis
was performed blinded to individual HD status. All study-specific procedures were approved by
the University of Rochester Research Subject Review Board and the Mississippi State University
Institutional Review Board.
PBMC Isolation and Culture
PBMCs were isolated from whole blood utilizing Histopaque density gradient
centrifugation. PBMCs (average yield was 90 million cells per subject) were resuspended in
AIM V® Serum Free Medium and divided equally into 10–12 wells at a volume of 4 mL each.
Cells were either left untreated (naïve) or treated for 3.5 h at 37 °C with an isotype control (IgG;
0.5 mg/mL), anti-IL-6 to neutralize levels of extracellular IL-6 (0.5 mg/mL), LPS (1 µg/mL),
LPS plus anti-IL-6, LPS plus IgG, CpG (1 µM), or CpG plus anti-IL-6. After the culture period
was over, supernatants were collected for ELISA; cells were separated from the medium by
centrifugation and washed with 1 mL of PBS. The cells and supernatants were stored at −80 °C.
Determination of IL-6 Levels by ELISA in Supernatants and Plasma
Before isolating PBMCs, 500 µL of whole blood was transferred to a BD microtainer
separator tube and centrifuged at 3000× g for 15 min. The resulting plasma was stored at −80 °C.
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An ELISA plate containing 100 µL of a 1:500 dilution of anti-human IL-6 antibody (Biolegend)
in ELISA wells was incubated overnight at 4 °C. The plate was then rinsed three times each in
3% BSA in PBS and distilled water, and the plate was blocked for 1 h at RT in 3% BSA in PBS.
The plate was rinsed again and 50 µL or 100 µL of IL-6 standards, 50 µL of plasma, or 100 µL
of PBMC culture supernatant was added to each well for a 1 h incubation. After rinsing, 100 µL
of a 1:500 biotinylated anti-human IL6 antibody (Biolegend) was added for a 1 h incubation. The
plate was rinsed again, and 100 µL of 1:1000 horse radish peroxidase (HRP)-Avidin (Biolegend)
was added to each well and incubated for 30 min. In the next step, 100 µL of a 1:1
tetramethylbenzidine (TMB) solution (Thermo-Fisher) was added to each well after a rinse. The
reaction was allowed to incubate for 15 min at RT and was stopped with 100 µL of 2 N H2SO4
before reading on a plate reader at an absorbance of 450 nm.
Cell Lysate Preparation and Protein Determination
PBMCs were resuspended in 100 µL of 50 mM Tris-HCl (pH 7.4) and lysed by
sonication (3 × 10 sec intervals) on ice. Lysed samples were centrifuged at 1000× g at 4 °C for
10 min to remove cellular debris, and the supernatants were stored at −80 °C until utilized
further. The lysates were diluted 1:5 v/v (25 µL total volume) in deionized water and incubated
with bicinchoninic acid (BCA) working reagent (200 µL) for 30 min at 37 °C. Absorbance was
measured at 560 nm on a plate reader and compared to a bovine serum albumin standard to
determine the protein concentrations of the samples.
Preparation of Commercially Obtained PBMCs
After receiving the commercial PBMCs, they were stored at −150 °C until processing.
Each sample was thawed quickly at 37 °C and the cells washed with 9 mL of 1× PBS. The
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samples were centrifuged at 500× g for 5 min before removing the supernatant. The washed cells
were resuspended in 2 mL of PBS and divided equally into two microcentrifuge tubes. The
samples were then centrifuged at 16,100 × g (full speed) for 5 min and washed again in 1 mL of
PBS. One aliquot of the cells used for Western blots was lysed in 250 µL of RIPA lysis buffer
containing protease inhibitors. After a 30 min incubation on ice, the lysed cells were further
sonicated on ice (3 × 10 sec intervals) and then divided into 80 µL aliquots for storage at −80 °C.
The second aliquot of cells used for enzyme activity assays was resuspended in 250 µL of 50
mM Tris-HCl (pH 7.4) and sonicated on ice (3 × 10 sec intervals) and then divided into 80 µL
aliquots for storage at −80 °C.
2-AG Hydrolysis Activity of PBMC Lysates
A quantity of 10 µL of PBMC lysate (prepared in Tris buffer) was diluted to a final
volume of 50 µL with 50 mM Tris-HCl (pH 7.4) and pre-incubated for 5 min at 37 °C. Authentic
2-AG was then added (final concentration of 50 µM), and the sample was incubated for 10 min
at 37 °C before quenching the reaction with 100 µL of cold acetonitrile (containing 2.5 µM of
AA-d8). The samples were stored on ice for at least 10 min before centrifugation at 16,100× g
(full speed) for 10 min at 4 °C. A quantity of 100 µL of supernatant was transferred to HPLC
vials with glass reducing inserts and the vials stored at −20 °C until analysis. Non-lysate controls
containing 50 µL of 50 mM Tris-HCl (pH 7.4) were also prepared in an identical manner. To
ensure that levels of endogenous AA in cell lysates did not affect results, samples were prepared
without the addition of authentic 2-AG. In some experiments, cell lysates were pre-incubated for
15 min at 37 °C with 0.1% DMSO (vehicle control), JZL184 (1 µM), or WWL113 (1 µM) prior
to adding 2-AG. Analysis of AA levels was performed by LC/MS-MS as described; peak areas
of AA were normalized on the AA-d8 internal standard peak area and protein amount (Lee, Hou
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et al. 2017). 2-AG hydrolysis rates are reported as nmol or pmol AA formed/mg protein/10 min.
At least two technical replicates for each PBMC sample were performed.
Determination of Carboxylesterase Activity by pNPVa Hydrolysis Assay
PBMC lysates were diluted in 50 mM Tris-HCl (pH 7.4) and pre-incubated for 5 min at
37 °C. pNPVa in ethanol stock was added to the mixture to give a final concentration of 500 μM.
The production of para-nitrophenol was evaluated continuously for 5 min at 405 nm, and the
calculated enzyme activity was corrected by the protein concentration of the sample. In some
experiments, lysates were pre-incubated for 5 min at 37 °C with 0.1% DMSO (vehicle control),
JZL184 (1 µM), or WWL113 (1 µM) prior to adding pNPVa. Experiments were performed in
technical triplicates.
Western Blot Analysis
PBMC lysates (25 μg per sample) were resolved on 10% SDS-PAGE gels and transferred
to a PDVF membrane. CES1 and MAGL proteins were detected by incubation with rabbit
monoclonal anti-human CES1 (1:25,000 v/v) or mouse monoclonal anti-human MAGL
(1:10,000 v/v), followed by incubation with goat anti-rabbit or goat anti-mouse secondary
(1:8000 v/v). β-Actin was detected with an anti-β-actin antibody to ensure equal loading of
protein. Blots were visualized on film using enhanced chemiluminescence using
ThermoSupersignal West Pico ECL reagent. The resulting films were scanned, and densitometry
analysis was performed using ImageJ v1.49a (NIH, Bethesda, MD, USA).
Flow Cytometry
PBMCs (1 million per well) were stained with Near-IR fixed viability dye (Biolegend)
before the Fc receptors were blocked with TruX stain. Cells were then stained with extracellular
69

antibodies for CD4 (FITC), CD8 (PECy7), CD11b (PECy5), CD14 (APC), CD19 (BV650), and
CD3 (PacBlue). Following extracellular staining, cells were fixed, permeabilized, and incubated
with a primary antibody for CES1 or MAGL for 30 min at RT. Cells were then incubated with a
secondary antibody conjugated to PE for 30 min and analyzed on an ACEA Novocyte Flow
Cytometer. Antibody capture beads (eBioscience) were used to set compensation, and
fluorescence minus one controls were used to set gates. A secondary-only control was used to
verify specific staining for CES1 and MAGL. However, because the same secondary antibody
was used to detect CES1 and MAGL, each sample had to be analyzed separately and the results
are presented as mean fluorescence intensity as compared to the secondary-only control for each
protein.
Statistical Analysis
The mean and standard deviation (or standard error) were calculated for each
experimental group. Student’s t-test and one-way or two-way analysis of variance were used to
assess differences between groups or treatments with GraphPad Prism Software (Version 7, San
Diego, CA, USA) when appropriate. Spearman regression correlations between 2-AG hydrolytic
data and Western blot results were determined using SigmaPlot Software (Version 11.0, San
Jose, CA, USA). A p-value of <0.05 was considered significant.
Results
IL-6 Quantification in Human Plasma and PBMCs
IL-6 levels were determined in plasma obtained from non-HD and HD individuals
(Figure 3.1 A); the mean plasma IL-6 level was higher in HD individuals compared to non-HD
controls, although it was not statistically significant (p = 0.266). IL-6 production by PBMCs
70

from the two groups was also assessed following ex vivo activation with inflammatory mediators
(Figure 3.1 B). CpG was found to induce only low levels of IL-6, whereas LPS gave a much
more robust response. Therefore, LPS was used instead of CpG to stimulate PBMCs in
additional experiments. LPS-induced production of IL-6 from PBMCs did not differ statistically
between HD and non-HD individuals (Figure 3.1 C). Importantly, the IL-6 antibody effectively
neutralized LPS-evoked IL-6 from the PBMCs (Figure 3.1 C), allowing us to examine the effect
of IL-6 on 2-AG hydrolytic activity in subsequent studies.
2-AG Hydrolytic Activity in Human PBMCs
2-AG hydrolysis activity in PBMC lysates was determined by quantifying the amount of
AA liberated from exogenously added 2-AG by LC/MS-MS (Figure 3.2 A, B). No differences
were noted between HD and non-HD individuals, regardless of whether PBMCs had been
stimulated with CpG (Figure 3.2 A) or LPS (Figure 3.2 B). In addition, initial experimentation
indicated that the AEA (i.e., FAAH) activity of PBMC lysates (~2 nmol AA produced/mg
protein/10 min) was markedly lower than the 2-AG hydrolytic activity (>60 nmol AA
produced/mg protein/10 min), so it was not further evaluated in this study.
To characterize the enzymes responsible for the 2-AG hydrolytic activity in PBMCs from
non-HD and HD individuals, lysates from untreated (i.e., naïve) cells were pre-incubated with
either JZL184—an inhibitor of both MAGL and CES1 (Crow, Bittles et al. 2012) —or
WWL113—a selective inhibitor of CES1 (Dominguez, Galmozzi et al. 2014) —prior to adding
exogenous 2-AG substrate (Figure 3.2 C). There was no significant change in 2-AG hydrolysis
activity in cell lysates pretreated with WWL113 compared to vehicle control, whereas
pretreatment with JZL184 significantly reduced 2-AG hydrolysis activity by 81.1 ± 3.9%. No
differences in response to the inhibitors were noted between non-HD and HD individuals. The
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marked inhibition by JZL184 of 2-AG hydrolytic activity without an effect by WWL113
strongly indicates that MAGL is the primary 2-AG hydrolytic enzyme in human PBMCs.
Because many of the assessed endpoints were not different in non-HD and HD individuals, we
conducted subsequent analyses with commercially obtained human PBMCs. For instance, results
using inhibitors of 2-AG hydrolytic activity were similar, with JZL184 significantly reducing 2AG hydrolysis activity by >6-fold and WWL113 having no effect (Figure 3.2 D). We also
verified that WWL113 and JZL184 were functionally active using a colorimetric pan-CES
substrate, p-nitrophenyl valerate (pNPVa; Figure 3.2 E). JZL184 and WWL113 were both
equally effective at inhibiting CES activity in the PBMC lysates. That WWL113 was unable to
inhibit 2-AG hydrolysis whereas JZL184 provides evidence that MAGL is the primary 2-AG
hydrolytic enzyme in PMBCs.
CES1 and MAGL Protein Expression in Human PBMCs
Whereas CES1 is the primary CES isoform expressed in human PBMCs (Munger, Shi et
al. 1991) and monocytes in particular (Ghosh 2000, Crow, Middleton et al. 2008), MAGL
activity in human PBMCs has not to our knowledge been clearly documented, although it is
expressed in human T cells (Coopman, Smith et al. 2007). To evaluate the expression levels of
CES1 and MAGL in human PBMCs, commercially obtained PBMC whole lysates were
separated by SDS-PAGE and probed with antibodies that recognize these serine hydrolases
(Figure 3.3 A). CES1 and MAGL were expressed in all PBMC samples, and considerable intersubject variability was noted in their expression levels. CES1 and MAGL were also expressed in
monocyte-depleted PBMCs as well as whole PBMCs (Figure 3.3 A), suggesting that
lymphocytes could also express these enzymes. Human THP-1 monocytic cell lines (control and
CES1 knockdown) were used as controls for CES1 detection (Crow, Middleton et al. 2008).
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Equal loading of proteins was confirmed by the consistent band density of the β-actin protein
between samples.
Next, we performed a correlation analysis between CES1 and MAGL protein amounts in
individual PBMCs and their associated 2-AG hydrolytic activities. On the basis of Western blots
and enzymatic assays obtained for the PBMCs, a strong positive correlation was observed
between MAGL protein abundance and 2-AG hydrolytic activity (r2 = 0.9853; Figure 3.3 B),
whereas the correlation was weaker between CES1 protein abundance and 2-AG hydrolytic
activity (r2 = 0.2575; Figure 3.3 C). This correlation analysis provides further evidence that
MAGL is the major 2-AG hydrolytic enzyme expressed in human PBMCs.
Monocytes and Lymphocytes Express MAGL and CES1
Although we determined that MAGL is the primary 2-AG hydrolytic enzyme expressed
in human PBMCs, we also showed that CES1 is present and active in these cells. Thus, we
developed a flow-cytometry-based assay to identify the specific cell types in PBMCs that
express MAGL and CES1. We assessed the expression of MAGL and CES1 in monocytes
(CD14 or CD11b), T cells (CD4 or CD8), and B cells (CD19). MAGL and CES1 expression was
relatively higher in monocytes than in lymphocytes (Figure 3.4 A-D). Incubation of cells with
the secondary antibody only resulted in a minimal fluorescence signal, demonstrating that the
fluorescence from the secondary antibody following CES1 or MAGL staining was specific.
Although the absolute fluorescence associated with CES1 expression was higher than that
associated with MAGL expression in each cell type, this difference in fluorescence signal does
not reflect differences in CES1 and MAGL protein levels because the binding affinity of the
secondary antibody for primary antibodies that recognize CES1 and MAGL is most likely
different. Thus, we cannot determine whether MAGL or CES1 is the more abundant enzyme in a
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specific cell type by this analysis; however, it does enable the relative expression of each enzyme
across individual cell types to be determined. The major cell types (monocytes and lymphocytes)
that comprise PBMCs appear to express both MAGL and CES1, with monocytes expressing
more of each enzyme than B and T cells.
Discussion
Inflammation is a complex process and the roles of endocannabinoids and their
biosynthetic and catabolic enzymes in this process are not fully understood. For instance, it is
well established that endocannabinoids and inhibitors of endocannabinoid catabolism exert antiinflammatory effects in some disease processes such as autoimmune disorders, LPS-induced
inflammation, and colitis (Gallily, Breuer et al. 2000, Facchinetti, Del Giudice et al. 2003,
Alhouayek, Lambert et al. 2011, Lourbopoulos, Grigoriadis et al. 2011, Kerr, Harhen et al. 2013,
Rom and Persidsky 2013, Alhouayek, Masquelier et al. 2014, Sido, Nagarkatti et al. 2015). On
the other hand, endocannabinoids might be more pro-inflammatory in some disease processes
such as atherosclerosis (Mach and Steffens 2008). The role that the endocannabinoid system
plays in inflammation resolution is even less understood. Previous work in our laboratory
showed that during inflammation which was induced in mice by LPS, there was simultaneous
induction of IL-6 levels and inhibition of the activity of the endocannabinoid hydrolytic enzyme
Ces2g (Szafran, Borazjani et al. 2015). These findings suggested the possibility of increased
endocannabinoid levels as a negative feedback mechanism to limit inflammation. In this work,
we further investigated this possibility using human PBMCs obtained from non-HD and HD
individuals by testing the hypothesis that high IL-6 levels observed in individuals with HD could
inhibit MAGL and CES activity, thereby increasing or stabilizing 2-AG levels as a potential
mechanism to limit inflammation.
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It was reported previously that IL-6 levels are increased in the plasma of individuals with
HD, and this cytokine has been proposed as a potential biomarker for the onset and progression
of the disease (Bjorkqvist, Wild et al. 2008, Chang, Wu et al. 2015). In our study, an increased
(but nonsignificant) trend in plasma IL-6 levels in HD individuals as compared to non-HD
individuals was noted. There are several possible explanations for why our results were not
statistically significant. First, only five subjects in each group were evaluated for plasma IL-6
levels. Second, it has been reported in the literature that there is a possibility of alterations in
cytokine levels during processing and storage of blood (Niwa, Akamatsu et al. 2000, Zhou,
Fragala et al. 2010, Henno, Storjord et al. 2017). Additionally, the sample collection procedure,
patient behavior before a blood draw, patient health, and physical activity can all influence
cytokine levels (Zhou, Fragala et al. 2010).
We initially utilized CpG, a form of bacterial DNA that binds to TLR9, to stimulate the
human PBMCs to produce IL-6. However, LPS was found to be much more effective than CpG
at stimulating IL-6 production. Although there was no significant difference between the IL-6
levels in PBMC supernatants derived from HD and non-HD individuals, there was an increased
trend of IL-6 in HD individuals versus non-HD individuals. This trend is consistent with the
literature in which IFN-γ-stimulated monocytes from HD individuals and an HD mouse model
displayed a more robust immune response than did those from controls (Bjorkqvist, Wild et al.
2008). However, we must acknowledge that our studies were limited to assessing IL-6 after one
time point (3.5 h), so future studies evaluating additional time points and cytokines would be
needed to further explore this.
Regardless of individual type (non-HD or HD), there was no significant difference in 2AG hydrolytic activity between non-stimulated and stimulated PBMCs. The lack of difference in
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2-AG hydrolytic activities in PBMCs from HD and non-HD individuals was in contrast to
previous reports that reported that the activity of FAAH, which hydrolyzes AEA, was markedly
reduced (by less than 10% of healthy controls) in the lymphocytes of individuals with HD
(Battista, Bari et al. 2007). Together these results suggest that the catabolic enzymes for 2-AG
and AEA in HD individuals could be differentially regulated.
Although we did not identify a role for IL-6 in decreasing endocannabinoid metabolism
in this study, increasing 2-AG levels by inactivating enzymes that catabolize it has been shown
to induce a protective effect in several disease processes (Gallily, Breuer et al. 2000, Alhouayek,
Lambert et al. 2011, Ghosh, Wise et al. 2013, Kerr, Harhen et al. 2013, Alhouayek, Masquelier
et al. 2014, Jiang, Zhang et al. 2015, Patsenker, Sachse et al. 2015, Pihlaja, Takkinen et al. 2015,
Sido, Nagarkatti et al. 2015), so it is important to further characterize the 2-AG hydrolytic
enzymes in humans. In the present study, we used specific inhibitors of MAGL and CES1 to
determine that MAGL is the primary 2-AG hydrolytic enzyme in human PBMCs. Further
support for this finding was obtained by correlation analysis of MAGL and CES expression
levels with the 2-AG hydrolytic activity in each PBMC sample. Thus, MAGL, and not CES,
would be the best therapeutic target in human PBMCs to increase 2-AG levels in circulating
immune cells.
In our previous study, Ces2g activity was attenuated in mouse spleen after in vivo LPS
exposure (Szafran, Borazjani et al. 2015); however, this study focused on the carboxylesterase
CES1 in human PBMCs, which is orthologous to Ces1d in mice (Holmes, Wright et al. 2010).
In contrast to Ces1d, which is poorly expressed in mouse macrophages (Quiroga and Lehner
2011), it is known that CES1 is present in abundance in human macrophages and monocytes
(Ghosh 2000, Xie, Borazjani et al. 2010, Wang, Borazjani et al. 2013). THP-1 cells, a well76

established model of human macrophages, express CES1 but not CES2, and CES1 has been
shown to efficiently hydrolyze 2-AG in intact cells (Xie, Borazjani et al. 2010, Wang, Borazjani
et al. 2013). However, monocytes only constitute ~5–10% of the PBMC population (Autissier,
Soulas et al. 2010, Corkum, Ings et al. 2015), thus possibly limiting their role in 2-AG
catabolism by CES1. On the other hand, MAGL has been reported to be expressed in human T
cells, which constitute ~60–70% of the PBMC population (Coopman, Smith et al. 2007). In the
present study, we confirmed the expression of both CES1 and MAGL in monocytes and
lymphocytes by flow cytometry. In agreement with the literature (Ghosh 2000), CES1 was
highly abundant in monocytes, whereas its levels in lymphocytes were lower. We also
determined that MAGL is expressed at higher levels in monocytes as compared to lymphocytes.
The fact that MAGL and CES1 are both expressed in PBMCs but MAGL is the main
metabolizing enzyme of 2AG was a somewhat surprising result, especially because the catalytic
efficiencies (kcat/Km) of recombinant human CES1 and human MAGL toward 2-AG are
comparable to each other (Xie, Borazjani et al. 2010). The most likely reason is that the 2-AG
hydrolytic activities of enzymes within cell lysates are different from those of purified enzymes.
It is possible that accessory proteins and/or lipid membranes that MAGL and CES1 associate
within cell lysates influence their ability to hydrolyze the 2-AG substrate (i.e., affect their
catalytic efficiency). The topology of the enzymes within the cell (and the resulting cell lysates)
might also play a role. For example, CES1 is found within the ER lumen tethered to integral
membrane proteins called KDEL receptors via its C-terminal ER retention signal peptide
(Gilham, Alam et al. 2005), whereas MAGL is loosely associated with plasma and endoplasmic
reticulum membranes on the leaflet facing the cytoplasm (Blankman, Simon et al. 2007). The

77

way these enzymes are oriented may influence their interaction with exogenously added 2-AG
substrate.
Although this study is limited in the number of individuals that were evaluated, several
important observations were made. First, MAGL and CES1 were both detected in human
PBMCs from both non-HD and HD individuals. Second, the levels of endocannabinoid enzymes
expressed in human PBMCs are variable. Third, MAGL and CES1 are more highly expressed in
monocytes as compared to lymphocytes. Finally, MAGL is the predominant enzyme for 2-AG
hydrolysis in human PBMCs and a potential target of inhibitors to increase levels of 2-AG in
circulating immune cells.
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Figure 3.1

Interleukin-6 (IL-6) levels in non-Huntington’s disease (HD) and HD individuals

(A) Plasma was isolated from whole blood of individuals, and plasma IL-6 was measured by
ELISA (n = 5). (B) Peripheral blood mononuclear cells (PBMCs) were stimulated with CpG in
the presence and absence of anti-IL-6 neutralizing antibody (n = 7 non-HD individuals, n = 6 HD
individuals). For a few subjects, a comparison between CpG and lipopolysaccharide (LPS) was
made to optimize IL-6 stimulation conditions because it was noted that CpG-induced IL-6 levels
were relatively low. * p < 0.05 as compared to the other treatment groups. (C) In follow-up
studies, PBMCs from non-HD and HD individuals were stimulated with LPS or were left
untreated (naïve) in the presence and absence of IL-6 neutralizing antibody or IgG isotype
control; n = 6 for all treatments, except for those treatments that utilized LPS alone (n = 2). * p <
0.05 as compared to LPS + Iso of same treatment group, ** p < 0.05 as compared to Iso, *** p <
0.05 as compared to Naïve. For (B,C), IL-6 was detected in supernatants by ELISA and
normalized to mg protein in the culture well. Differences between groups and treatments were
assessed by Student’s t-test (A) and two-way analysis of variance (B,C).
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Figure 3.2

2-arachidonoylglycerol (2-AG) hydrolytic activity and carboxylesterase (CES)
activity in human PBMCs.

Cell lysates were pre-incubated for 5 min at 37 °C, then supplemented with 2-AG (final
concentration, 50 µM). Incubation proceeded for 10 min before quenching the reaction, and
arachidonic acid (AA) levels were quantified by LC/MS-MS using AA-d8 as internal standard.
PBMCs treated with CpG (1 µM) or CpG with an IL-6 neutralizing antibody were utilized (A; n
= 6) or PBMCs treated with LPS, an IL-6 neutralizing antibody, or an isotype control were
utilized (B; n = 5 for all groups except the group treated with LPS alone, n = 2). (C) Cell lysates
from non-HD and HD individuals (n = 5) were pretreated with inhibitors of CES1 (WWL113)
and monoacylglycerol lipase (MAGL) (JZL184) (final concentration, 1 µM) or 0.1% DMSO for
30 min at 37 °C prior to adding 2-AG. (D) Cell lysates from commercially obtained healthy
PBMCs (n = 5 individuals) confirmed the results observed with non-HD and HD individuals. (E)
CES activity of commercially obtained PBMCs (n = 5 individuals) was determined by measuring
the hydrolysis of the pan-CES substrate pNPVa (final concentration, 500 µM). JZL184 or
WWL113 (final concentration, 1 µM) was utilized in some experiments to inhibit CES activity.
Three technical replicates were run for each individual. * p < 0.05 as compared to DMSO of
same treatment group. Differences between groups and treatments were assessed by one-way
analysis of variance (D,E) and two-way analysis of variance (A–C).
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Figure 3.3

Western blots of CES1 and MAGL in human PBMCs and correlation analysis.

(A) Commercially obtained PBMC lysates (25 μg of protein per sample; n = 5 individuals) and a
monocyte-depleted PBMC lysate (25 μg of protein per sample; n = 1 individual) were separated
by SDS-PAGE and probed with antibodies against CES1, MAGL, and β-actin. β-Actin was used
as a loading control. THP-1 monocytic cell lines with high and low levels of CES1 expression
(control and CES1 knockdown (KD), respectively; (Wang, Borazjani et al. 2013)) were used as
positive and negative controls. (B) The band density for MAGL in each individual (n = 5) in the
Western blot was correlated with its corresponding 2-AG hydrolytic activity. (C) The band
density for CES1 in each individual (n = 5) in the Western blot was correlated with its
corresponding 2-AG hydrolytic activity (25 µg protein per sample for Western and 2-AG
hydrolytic activity). Spearman regression correlations were determined for both enzymes. p =
0.001 for MAGL; p > 0.05 for CES1.
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Figure 3.4

CES1 and MAGL are more highly expressed in monocytes than in lymphocytes.

Commercially obtained PBMCs were stained extracellularly for various cell populations
(monocytes, CD14 or CD11b), T cells (CD4 or CD8), and B cells (CD19)) and intracellularly for
CES1 (A,C) or MAGL (B,D). Significantly more fluorescence was detected between the primary
antibodies (CES1 or MAGL) than for the secondary antibody alone (A,B). p < 0.5 by two-way
analysis of variance for all cell populations except MAGL intracellular staining of CD4+ T cells
(p = 0.1158), CD8+ T cells (p = 0.2618), and CD19+ B cells (p = 0.0723). Representative
histograms from one donor are provided in (C,D).
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CHAPTER IV
BIOCHEMICAL EFFECTS OF ORAL CHLORPYRIFOS IN LUNGS OF NEONATAL AND
ADULT WILD TYPE AND CNR1-/- MICE
Introduction
Despite restrictions limiting its use in commercial and household settings, chlorpyrifos
(CPF) remains a commonly used organophosphate (OP) insecticide and it continues to be a
potential exposure risk for those living in agricultural communities (Grube, Donaldson et al.
2011). Outside of the occupational risks from working with CPF, there is also evidence of
exposure to organophosphates, including CPF, in children (Koch, Lu et al. 2002, Arcury,
Grzywacz et al. 2007, Tamaro, Smith et al. 2018). Furthermore, exposure to CPF during
childhood has been linked to developmental neurotoxicity such as altered brain morphology and
decreased cognitive abilities, motor skills, IQ, and working memory (Rauh, Garfinkel et al. 2006,
Rauh, Arunajadai et al. 2011, Rauh, Perera et al. 2012). Following exposure to CPF, it is
metabolized into a bioactive metabolite – termed chlorpyrifos-oxon (CPO; Figure 1.1) – that can
inhibit acetylcholinesterase (AChE) in the central nervous system (CNS) and neuromuscular
junctions when administered at high doses, thereby inducing acute signs of cholinergic crisis
(Hulse, Davies et al. 2014, Shaffo, Grodzki et al. 2018). However, non-cholinergic serine
hydrolases are highly susceptible to inhibition by CPF at doses that cause minimal or no AChE
inhibition, particularly those enzymes such as fatty acid amide hydrolase (FAAH) and
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monoacylglycerol lipase (MAGL), which metabolize lipid mediators called endocannabinoids
(eCBs) (Quistad, Klintenberg et al. 2006, Quistad, Liang et al. 2006).
Since its discovery in both central and peripheral tissues in the 1990s, the eCB system has
been found to play important roles in a wide range of physiological processes, including those
involved in brain development, immunity, and energy metabolism (Pacher, Bátkai et al. 2006, Lu
and Mackie 2016). Given the sensitivity of eCB metabolizing enzymes to inhibition by oxon
metabolites (Crow, Bittles et al. 2012), the possible dysregulation of the eCB system following
OP exposures could lead to detrimental effects in multiple ways. For example, previous studies
from our group demonstrated that juvenile rats exposed to sub-chonic low-dose CPF exhibited
marked reductions in FAAH and MAGL activities in brain, whereas AChE activity was not
altered (Carr, Adams et al. 2013, Carr, Graves et al. 2014, Carr, Armstrong et al. 2017). At the
same time, the respective eCB substrates for these enzymes, anandamide (AEA) and 2arachidonylglycerol (2-AG), were significantly increased in brain as a result (Carr, Adams et al.
2013). Interestingly, these biochemical effects were found to be correlated with decreased
measures of juvenile rat anxiety (Carr, Armstrong et al. 2017). eCBs also have important roles in
the immune system, although several contradictory effects have been reported (Turcotte,
Chouinard et al. 2015). Immunomodulatory effects induced by eCBs have typically been
reported to be anti-inflammatory, in particular their ability to decrease pro-inflammatory
cytokines (Gallily, Breuer et al. 2000, Facchinetti, Del Giudice et al. 2003, Alhouayek, Lambert
et al. 2011, Rettori, De Laurentiis et al. 2012). On the other hand, eCBs have also been shown to
be pro-inflammatory in the context of atherosclerosis and allergic inflammation (Mach and
Steffens 2008, Mimura, Oka et al. 2012). Thus, the physiological actions exerted by the eCB
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system are complex and more needs to be understood about it, particularly in settings of
environmental toxicant exposures.
The objective of the present study was to determine whether sub-acute low-dose CPF
exposure inactivates eCB metabolizing enzymes in various tissues of neonatal and adult mice to
lay the groundwork for future immune studies. First, the effect of oral CPF treatment on eCB
metabolic enzyme activity and eCB levels in brain, liver, lung, and spleen was determined. For
the remainder of the study, based on the initial results from the enzyme assays, the focus shifted
to that of the lung. Next, activity-based protein profiling (ABPP) identified serine hydrolases in
lung that were inhibited by CPF treatment. Finally, selective small-molecule inhibitors of Magl
and Ces1d were also used to identify the 2-AG metabolizing enzymes in the lung. Cnr1-/- mice
were included in certain experiments to determine whether the absence of the CB1 receptor
influenced eCB metabolism and eCB levels in the setting of CPF exposure.
Materials and Methods
Chemicals and Reagents
CPF (>99%) was a generous gift from DowElanco Chemical Company (Indianapolis,
IN). Antibodies for flow cytometry and ELISA were purchased from Biolegend. Authentic
standards of lipid mediators and endocannabinoids were purchased from Cayman Chemical (Ann
Arbor, MI). Solvents for LC-MS/MS were from Thermo Fisher. p-Nitrophenyl valerate (pNPVa)
and Lipopolysaccharide (LPS) was from Sigma (St. Louis, MO, USA). Antibodies for Western
blots were from Abcam (Cambridge, MA, USA). Fluorophosphonate-biotin (FP-biotin) was
from Toronto Research Chemicals (North York, ON). Reagents for ABPP-mass spectrometry
(MS) were from sources described in Wang et al. (Wang, Borazjani et al. 2013).
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Treatment of Mice
C57BL/6 wildtype (WT) mice were obtained from Jackson laboratories (Bar Harbor,
ME) and used to establish a breeding colony in a murine norovirus-free facility. Adult WT mice
(7-8 weeks) were bred on site or purchased and acclimated for one week before experiments.
Cnr1-/- mice were obtained from NIH and used to establish a breeding colony. All Cnr1-/- were
bred on site. Mice were housed in temperature- and humidity-controlled AAALAC-approved
facilities (20-25°C and 40-60% humidity) under a 12-h light cycle and used in accordance with
the Mississippi State University Institutional Animal Care and Use Committee.
CPF was dissolved in corn oil (CO) and administered at a volume of 1 mL/kg body
weight for adult mice or 0.5 mL/kg for neonatal mice. Adult mice (n=5/sex/group) or neonatal
mice (PND 4-10 or 10-16, n=4-8, randomized from 2-3 litters) received either CO or CPF (2.5
mg/kg) by oral gavage every day for 7 days. This CPF dose was chosen on the basis that it does
not significantly alter brain AChE activity (Ricceri, Markina et al. 2003, Ricceri, Venerosi et al.
2006, Cometa, Buratti et al. 2007, Howell, Kondakala et al. 2018). Four h after the final dose,
mice were sacrificed by cervical dislocation and tissues (lung, liver, spleen, and brain) collected
and flash frozen in liquid nitrogen. In some studies, trunk blood was collected immediately
following cervical dislocation and serum prepared by centrifuging the clotted blood (4°C, 10
min, 3,000 x g). All frozen tissues and sera were stored at -80°C until further use.
Splenocyte Culture and ELISA
Splenocytes from naïve wild-type C57Bl/6 mice were prepared in a single cell suspension
by mechanical disruption. Cells were seeded at 2 × 107 cells/well in complete media (1X RPMI
containing 1% v/v bovine calf serum, 1% w/v penicillin-streptomycin and 50 μM 2mercaptoethanol). Splenocytes received one of the following treatments: Vehicle, CPO (1 µM)
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LPS (1 μg/ml), or a combination of CPO and LPS for 3.5 hr after which cells were lysed in icecold 50 mM Tris-HCl (pH 7.4) buffer by sonication. The lysates were assayed for 2-AG
hydrolytic activity, as described below. IL-6 levels in the media was measured as previously
described (Szafran, Lee et al. 2018) utilizing the appropriate anti-mouse antibodies.
Preparation of Tissue Homogenates
Whole-tissue homogenates (lung, liver, spleen, and brain) were prepared on ice at
approximately 20% w/v in 50 mM Tris-HCl (pH 7.4) buffer using a Dounce homogenizer. The
crude homogenates were centrifuged at low speed to remove debris (4°C, 20 min, 1,000 x g). For
some studies, lung subcellular fractions were prepared: lungs were homogenized in 20% w/v
sucrose buffer (50 mM Tris-HCl, 0.32 M sucrose, pH 7.4), centrifuged at low speed (4°C, 5 min,
1,000 x g), and the resulting supernatant centrifuged at high speed (4°C, 60 min, 100,000 x g).
The resulting pellet was washed and resuspended in sucrose buffer by sonication, then recentrifuged (4°C, 60 min, 100,000 x g); this wash step is critical for removing contaminating
blood components. The final pellet was sonicated in 400 µL of sucrose buffer to give washed
lung microsomes. All homogenates and microsomes were stored at -80°C until analysis. Protein
concentrations were determined using the BCA reagent (ThermoPierce) with bovine serum
albumin standards.
Determination of Forebrain AChE Activity
The forebrain was homogenized as previously described (Buntyn, Alugubelly et al.
2017), and an aliquot of homogenate was diluted in cold 0.05 M Tris-HCl buffer (pH 7.4 at
37°C) to a final tissue concentration of 0.625 mg/mL. AChE activity was measured
spectrophotometrically using a modification (Chambers, Wiygul et al. 1988) of Ellman et al.
92

(Ellman, Courtney et al. 1961) with acetylthiocholine as the substrate (1 mM final concentration)
and 5,5-dithiobis(nitrobenzoic acid) as the chomogen. Protein concentrations were quantified
with the Folin phenol reagent using bovine serum albumin as a standard (Lowry, Rosebrough et
al. 1951).
Endocannabinoid Hydrolysis Reactions
50 µg of tissue homogenate or microsomal protein was added to 100 µL of 50 mM TrisHCl (pH 7.4) buffer. Samples were pre-incubated for 5 min at 37°C, then 2-AG or AEA were
added to a final concentration of 50 µM and the samples incubated at 37°C for 20 min. The
reactions were quenched with 200 µL of cold acetonitrile containing an internal standard (2.5
µM of arachidonic acid-d8). After sitting on ice for 10 min, the samples were centrifuged at full
speed (4°C, 10 min, 16,100 x g), and the resulting supernatant transferred to HPLC vials
containing volume-reducing inserts. The samples were stored at -20°C until analysis by LCMS/MS. ‘Blank’ samples of each tissue homogenate (i.e., not supplemented with exogenous 2AG or AEA) were prepared to account for endogenous arachidonic acid levels. Non-enzymatic
control samples were also prepared; these contained 2-AG or AEA but not tissue homogenate.
For some reactions using lung homogenates, the samples were preincubated with vehicle
(DMSO), WWL113 (Ces1d inhibitor, 1 or 10 µM), JZL184 (Magl inhibitor, 1 or 10 µM), CPO
(1 µM), or paraoxon (PO, 1 µM) for 30 min before adding exogenous 2-AG substrate.
Determination of Ces Activity Using pNPVa
An appropriate amount of tissue homogenates, serum, or microsomes were diluted in 50
mM Tris-HCl (pH 7.4) and pre-incubated for 5 min at 37°C. pNPVa was added to reactions at a
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final concentration of 750 µM, and the production of the hydrolysis product (para-nitrophenol)
was monitored at 405 nm for a period of 5 min. Enzyme activities were normalized on protein
amounts to give specific enzyme activities.
Gel-based Activity-Based Protein Profiling and Western Blotting
Lung homogenates were diluted in 50 mM Tris-HCl (pH 7.4) to yield a final protein
concentration of 1 mg/mL in a 50-µL reaction volume. FP-biotin was added to give a final
concentration of 8 µM and the samples allowed to react at room temperature for 1 h. Negative
control reactions were heated for 5 min at 90°C before adding FP-biotin. All reactions were
quenched by adding 10 µL of 6x SDS-loading buffer (reducing) then heating at 90°C for 5 min.
After samples cooled, proteins were separated on a 10% SDS-PAGE gel (25 µg protein per well)
and transferred to a PDVF membrane. After blocking the membrane with 5% w/v non-fat milk
in Tween buffer, biotinylated proteins were detected with using avidin-peroxidase (Sigma,
1:1000 v/v diluted in Tween buffer) and Thermo Supersignal West Pico ECL reagent.
Chemiluminescent signals were visualized on film and serine hydrolases tentatively identified
based on their molecular weight and by comparison to previous publications (Long, Nomura et
al. 2009, Carr, Borazjani et al. 2011, Szafran, Borazjani et al. 2015). After visualizing the
biotinylated proteins, the PDVF membranes were stripped and re-probed with a rabbit
monoclonal anti-human CES1 antibody (Abcam; cross-reacts with mouse Ces1 isoforms).
Activity-Based Protein Profiling (ABPP-Mass Spectrometry)
Lung Proteomics: Lung proteomes were adjusted to a total volume of 1 mL containing 1
mg/mL protein concentration in 50 mM Tris-HCl (some samples were diluted to a lower
concentration due to limited samples, but this was taken into account in the results). Samples
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were prepared for proteomic analysis as previously described until the desalting step (Szafran,
Borazjani et al. 2015). Samples were desalted using Thermo Scientific Pierce Peptide Desalting
Spin Columns following the manufacturer’s instructions, and solvents were evaporated in a
Speedvac concentrator. Samples were sent to the UC Davis Proteomics facility for analysis and
data was analyzed as previously described (Wang, Borazjani et al. 2013).
Immunophenotyping of the Adaptive Immune Response by Flow Cytometry
A portion of whole tissue (liver, lung, spleen) was homogenized in RPMI and strained
through a 70 µm sieve. Individual cells were stained with extracellular antibodies for CD4
(PECy5), CD8 (PECy7), and CD19 (BV650). Cells were fixed in BD Cytofix™ (BD
Biosciences) following staining. An ACEA Novocyte Flow Cytometer was used to analyze the
stained and fixed cells. Antibody capture beads were used as compensation and fluorescentminus one controls were used to set gates. Adaptive immune cells were identified as cytotoxic T
cells (CD8+), T helper cells (CD4+), or B cells (CD19+) and quantified by percent parent
lymphocyte.
Extraction of Endocannabinoids
Half of whole tissues (liver, lung, brain, spleen) were weighed and prepared on ice in 1:1
hexane:ethyl acetate (containing 0.1% acetic acid) plus deuterated standards (13.3 or 100 µM 2AG-d8, PEA-d4, OEA-d4, and AEA-d8) using a Dounce homogenizer. The crude homogenates
were centrifuged at low speed to remove debris (4°C, 30 min, 2,000 x g). 1 mL of highperformance liquid chromatography (HPLC) water was added to the supernatants which were
vigorously vortexed and then centrifuged at 800g for 5 min. The organic top layer was
transferred to a new, clean tube, and an additional 1 mL of 1:1 hexane:ethyl acetate was added to
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the inorganic layer. After another round of centrifugation, the organic top layer was once again
transferred to the new tube, and the combined organic layers were dried under nitrogen gas. 100
µL of MeOH was added to the dried sample and then transferred to an HPLC vial with reducing
insert for analysis by HPLC-MS/MS as previously described [30]. The resulting quantification
was standardized using initial tissue weights for all tissues and groups except the adult lungs.
Adult lung eCB levels are presented as the ratio of eCB to internal standard.
Statistical Methods
The mean and standard deviation (or standard error of mean) was calculated for each
group. A Student’s t-test, one-way ANOVA, or two-way ANOVA was used to assess
differences between groups when appropriate utilizing GraphPad Prism Software (Version 7, San
Diego, CA, USA), SigmaPlot Software (Version 11.0, San Jose, CA, USA). Grubb’s outlier test
was utilized to identify outliers in data sets. Data from flow cytometry was log-transformed
before analysis. A p-value of <0.05 was considered significant.
Results
Low-Dose CPF Treatment Did Not Alter Mouse Weight
Treatment of mice with 2.5 mg/kg CPF (oral) for 7 consecutive days did not alter the
weights of adults of either sex compared to CO controls (Figure 4.1 A). In addition, no
differences were noted in the rates of weight gain of neonatal mice treated with CPF and CO
during the PND 10-16 and PND 4-10 periods (Figure 4.1 B,C).
Low-Dose CPF Treatment Did Not Inhibit Brain AChE Activity
CPF treatment did not inhibit brain AChE activity in either neonate or adult mice when
compared to their corresponding CO controls in either WT or Cnr1-/- mice (Figure 4.2).
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Low-Dose CPF Had Minimal Effects on Endocannabinoid Hydrolysis Activity
The 2-AG hydrolysis activities in neonate WT mouse tissues under control (CO)
conditions followed the rank order: brainspleen>>liver>lung (Figure 4.3 C), whereas in WT
adult female the 2-AG hydrolysis activity in brain was higher than those in liver, lung, and
spleen, each of which had comparable activities (Figure 4.3 B). Females were used for initial
evaluation of adult mice because female mice have been shown to be more susceptible to some
types of pulmonary disease (Melgert, Postma et al. 2005, Tam, Churg et al. 2016). Moreover,
CPF treatment did not alter the 2-AG hydrolytic activities in liver, spleen, and brain of neonatal
mice (dosed PND 10-16) and adult mice (Figure 4.3 A,B,C) regardless of genotype. However, it
slightly inhibited 2-AG hydrolytic activity in adult female lung (p=0.0495, Figure 4.3 B), but not
in neonatal lung. In addition, the 2-AG hydrolytic activity was lower in spleens from neonatal
Cnr1-/- mice versus WT mice (Figure 4.3 A). Because Ces isoforms and Magl are primarily
located in membranes (microsomes) of tissue subcellular fractions, the 2-AG hydrolysis activity
of lung microsomes was determined for all age groups in WT mice (Figure 4.3 D). However, we
observed that CPF treatment did not alter the 2-AG hydrolytic activity of lung microsomes
obtained from either adult or neonatal WT mice. Both male and female adult mice were used for
these experiments, but no sex differences were detected. Lung and brain AEA hydrolysis
activities were comparable to each other in both neonate and adult mice, whereas the spleen
exhibited much lower activity (Figure 4.3 G,H). CPF treatment also did not alter AEA
hydrolytic activities in lung, spleen, and brain in neonate and adult female WT mice (Figure 4.3
G,H); however, there were some differences between genotypes. Untreated Cnr1-/- neonatal
mice had lower brain AEA hydrolysis activity compared to WT controls, and this activity was
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significantly induced by CPF. Additionally, CPF slightly inhibited lung AEA hydrolysis in adult
female Cnr1-/- mice.
Pharmacological inhibitors of Ces1c, Ces1d, and Magl were utilized to identify the 2-AG
hydrolytic enzyme in WT lung microsomes (Figure 4.3 E). JZL184 (Magl inhibitor) inhibited 2AG hydrolytic activity >50% at concentrations of 1 and 10 µM (only 10 µM in adults).
WWL113 (Ces1c and Ces1d inhibitor), on the other hand, had minimal effects (<20% inhibition
at 10 µM). CPO, which is a promiscuous inhibitor of serine hydrolases (Quistad, Liang et al.
2006), caused the greatest degree of inhibition (~80%); whereas PO, which is a more selective
inhibitor than CPO at 1 uM (Xie, Borazjani et al. 2010), inhibited ~25% of the 2-AG hydrolytic
activity in neonates. These results suggested that Magl is the primary 2-AG hydrolytic enzyme in
lung microsomes, although other enzymes such as Ces1d and Ces1c probably have a minor role
in metabolizing 2-AG.
Low-Dose CPF Altered Carboxylesterase Activity
CPF treatment significantly inhibited Ces activity (assessed using the pan-Ces substrate
pNPVa; (Ross and Borazjani 2007)) in whole tissue homogenates of lungs from neonatal and
adult female WT and Cnr1-/- mice (Figure 4.4 A,B), whereas it did not alter Ces activity in brain
and spleen except for an inhibition of Ces activity in the spleen of Cnr1-/- neonatal mice. Ces
activity in adult WT and Cnr1-/- liver was inhibited by CPF, whereas it was slightly induced in
neonate liver (Figure 4.4 A,B). The only genotype-related differences in Ces activity were
present in neonatal tissues. Control lung Ces activity was higher and spleen Ces activity lower in
WT control neonates versus Cnr1-/- neonates. This difference was not present in CPF-treated
neonatal mice (Figure 4.4 A,B). Ces activities in lung microsomes (Figure 4.4 C) and serum
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(Figure 4.4 D) in neonatal and adult WT mice of both sexes were markedly inhibited by CPF
treatment.
Low-Dose CPF Inhibited Multiple Ces1 Isoforms in Lung in an Age-Dependent Manner
We employed the ABPP approach, which evaluates enzyme activities in tissues, by using
activity probes that assess their conserved catalytic mechanisms [64]. For example, the catalytic
serine residue in the active site of serine hydrolases are covalently labeled by FP-biotin, whereas
inactive enzymes do not react with this probe. ABPP-MS of lung microsomes obtained from COand CPF-treated mice detected 32, 16, and 31 serine hydrolases in adult male, adult female, and
neonatal mice, respectively (Figure 4.5 A-C). The smaller number detected in female mice was
likely due to the lower protein yield in the microsomal preparation. CPF treatment inactivated
Ces1d, Ces1c, and Ces1b in neonatal mice. In adult female mice, CPF inactivated Ces1c and
Ces1b, whereas in adult male mice Ces1c and butyrylcholinesterase (BChE) were inactivated.
Thus Ces1 isoforms in lung are prominent targets for inhibition, while Magl was not inactivated
following CPF treatment. In addition, Faah was undetectable in mouse lungs from all age groups,
whether from animals treated with CPF or not.
Low-Dose CPF Inhibited Lung Ces1 Activity Without Altering Ces1 Protein Levels
Gel-based ABPP, where probe-labeled proteins are separated by SDS-PAGE, could
detect Ces1 (which constitute multiple isoforms ~60 kDa), Magl, and Nceh1 (also called
KIAA1363) in lung proteomes (Figure 4.5 D). Of these, Ces1 isoforms were the only ones
inactivated in neonatal and adult lungs following CPF treatment. Ces1 proteins were also
detected in the same lung proteome samples using an antibody that recognizes murine Ces1
orthologues. Importantly, CPF treatment did not alter the abundance of the Ces1 protein(s), as
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indicated by its consistent signal intensity in control and CPF lung proteomes (Figure 4.5 D,
Western blot, bottom).
Low-Dose CPF does not alter the adaptive immunophenotype
CPF treatment did not alter the distribution of adaptive immune cells in the spleens of
neonatal or adult regardless of mouse genotype (Figure 4.6, A,B). This assay was further
explored in the livers and lungs of female adult WT and Cnr1-/- mice, and no difference was
detected by either treatment or genotype (Figure 4.6 C, D).
Low-Dose CPF does not alter murine 2-AG or AEA levels
CPF treatment did not alter neonatal liver, lung, or brain 2-AG or AEA levels regardless
of genotype (Figure 4.7 A). There were also no alterations in cannabinoid-like
oleoylethanolamine (OEA) and palmitoylethanolamine (PEA) levels in the brain or lung;
however, OEA and PEA levels were significantly increased or trended upward in the livers of
neonatal WT and Cnr1-/- mice with CPF treatment (Figure 4.7 A). CPF did not alter female adult
lung or spleen 2-AG or AEA levels regardless of genotype (Figure 4.7 B). There were no
alterations in lung or spleen OEA levels in either genotype, but PEA levels were decreased or
trended downward in the lungs of Cnr1-/- mice compared to WT controls. In the spleens of adult
mice, CPF decreased PEA levels in WT mice only, and control WT mice had higher levels of
PEA than their Cnr1-/- counterparts (Figure 4.7 B). However, there was significant variation
between PEA WT control samples.
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CPO Inhibits 2-AG Hydrolytic Activity in Splenocytes
Although CPO treatment significantly inhibited splenocyte 2-AG hydrolytic activity
independent of LPS stimulation (Figure 4.8 A), CPO treatment of LPS-stimulated murine
splenocytes did not affect IL-6 levels in vitro (Figure 4.8 B).
Discussion
CPF is still widely used in agriculture because of its efficacy in controlling insects that
damage crops (Grube, Donaldson et al. 2011). However, it has also been associated with adverse
neurotoxic effects in humans and in laboratory animals (Rauh, Garfinkel et al. 2006, Rauh,
Arunajadai et al. 2011, Rauh, Perera et al. 2012, Carr, Adams et al. 2013, Carr, Graves et al.
2014, Carr, Armstrong et al. 2017), raising issues regarding its registration with regulatory
bodies (Centner 2018). OP insecticides as class have also been linked to adverse human immune
effects in epidemiological studies, but laboratory animal studies that assess the biological
plausibility of such effects have been limited. Exposure to OPs such as CPF can inhibit eCB
metabolizing enzymes in animal models at dose levels that do not inhibit AChE, causing
subsequent increases in eCB levels (Carr, Adams et al. 2013, Carr, Graves et al. 2014, Buntyn,
Alugubelly et al. 2017, Carr, Armstrong et al. 2017, Howell, Kondakala et al. 2018). The effects
of eCBs on immune function are complicated. For example, they can either attenuate
(Panikashvili, Shein et al. 2006, Rettori, De Laurentiis et al. 2012) or augment (Mimura, Oka et
al. 2012) the mRNA expression and protein levels of pro-inflammatory cytokines. Here, we have
identified putative eCB metabolizing enzymes – Ces1d, Ces1c, and Ces1b – in murine lung that
were inactivated following oral CPF exposures.
We initially assessed the 2-AG and AEA hydrolysis activities in lung, liver (2-AG only),
brain, and spleen following CPF exposures in neonatal (PND 10-16 dosing) and adult female
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WT and Cnr1-/- mice. Although CPF caused a slight but significant reduction in 2-AG
hydrolysis activity in adult WT female whole-lung homogenates, this effect was not observed in
lung microsomes of Cnr1-/- female mice. It is possible that adult lung has a 2-AG hydrolytic
enzyme not found in lung microsomes that is CB1-dependant and inhibited by CPF.
Alternatively, it is possible that a blood esterase (perhaps a soluble plasma carboxylesterase or
butyrylcholinesterase), which can hydrolyze 2-AG and is inhibited by CPO, had contaminated
the whole-lung homogenate. Overall, our results in neonatal mice differ from those in neonatal
rats where doses of CPF as low as 1 mg/kg could disrupt 2-AG and AEA hydrolysis in brain,
liver, and spleen (Buntyn, Alugubelly et al. 2017), but they are in agreement with previous
results showing that repeated oral doses of 2 mg/kg CPF had no effect on 2-AG hydrolysis
activity in liver of adult mice (Howell, Kondakala et al. 2018). Thus, our results indicate that
there are differences between mice and rats with respect to the degree of inhibition of 2-AG and
AEA hydrolytic enzymes caused by CPF exposure under comparable conditions.
CPF exposures also significantly inhibited Ces activity in lung and serum of each
genotype and age group and in liver of adults of each genotype, whereas it slightly induced Ces
activity in neonate liver of each genotype. The baseline level of liver Ces activity in neonatal
mice is markedly lower than in adult mice (our data and (Karanth and Pope 2000)), so one
possible explanation for the increased liver activity in CPF-treated neonate mice is the induction
of an adaptive response in order to detoxify the compound. In one study, repeated dosing (10
days) of CPF (2 mg/kg) in adult mice caused hepatic Ces activity to be inhibited (Howell,
Kondakala et al. 2018), whereas, in another, it was found that decreased hepatic Ces activity in
adult mice was only reached after 13 consecutive days of dosing with 6.25 mg/kg CPF (Cometa,
Buratti et al. 2007). Possible reasons for the difference between our study and Cometa et al.
102

(Cometa, Buratti et al. 2007) is that we used C57BL/6 mice and measured Ces activity by
measuring the hydrolysis of pNPVa, whereas they utilized a malathion hydrolysis assay and CD1 mice.
A previous study comparing the effects of CPF (acute, up to 300 mg/kg subcutaneously)
in WT and Cnr1-/- mice found no differences in acute toxicity between genotypes (Baireddy, Liu
et al. 2011). The only minor difference was that WT mice were more sensitive to the acute
effects of CPF on AChE in specific regions of the brain (Baireddy, Liu et al. 2011). In our study,
we found no differences in AChE brain activity following CPF exposure in neonates and adults
of both genotypes. However, neonatal 2-AG spleen hydrolysis activity was lower in the Cnr1-/mice compared to WT control and CPF-treated mice (Figure 4.3 A), and AEA brain hydrolysis
activity was lower in Cnr1-/- control mice compared to WT control mice. Genotype-related
differences were minimal when Ces activity was examined; however, spleen Ces activity was
inhibited by CPF in Cnr1-/- but not WT neonatal mice. Lung Ces activity was lower in neonatal
control Cnr1-/- mice compared to WT controls. Because 2-AG is a full agonist of CB1 (Kaplan
2013) and Cnr1-/- mice do not have CB1 receptors to engage with 2-AG, there could be higher
levels of 2-AG available for metabolism. The lower overall eCB metabolic activity in Cnr1-/mice compared to WT mice could be a mechanism to limit 2-AG metabolism. However, these
observations were not present in every tissue and fewer animals were available for the Cnr1-/assays (n=3 for neonatal control Cnr1-/- mice).
Ces enzymes exhibit high levels of activity in rat lung (Imamura, Schiller et al. 1983,
Karanth and Pope 2000) and mouse lung (our results). For example, our ABPP-MS data showed
that Ces isoforms accounted for 3 or 4 of the most active serine hydrolases in murine lung. Ces
isoforms are also intrinsically more sensitive targets of oxon-dependent inhibition than Magl and
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Faah (Casida and Quistad 2004, Casida and Quistad 2005, Quistad, Liang et al. 2006). This was
corroborated in our study because lung Magl was not inhibited by CPF treatment in vivo,
whereas Ces1b, Ces1c, and Ces1d were. Notwithstanding this finding, in vitro experiments using
selective chemical inhibitors showed that Magl was the primary 2-AG hydrolytic enzyme in
murine lung. Together these findings probably explain why the 2-AG hydrolytic activity in lung
microsomes was not altered following in vivo CPF treatment. In addition, although Faah was not
detected by ABPP-MS, AEA hydrolysis activity in lung was measurable and it was not altered
by CPF treatment. Consistent with these findings, the levels of 2-AG and AEA in lung were also
not altered by CPF treatment. Thus, the dosing regimen used did not alter endocannabinoid
metabolism in lung or its ligands, as was hypothesized.
In general, CPF-mediated inhibition of lung Ces activity indicated that neonates were
more sensitive than adults. As the lung matures there is a steady increase in Ces expression
(Karanth and Pope 2000) and differences in the maturation stage and relative expression of
individual Ces isoforms in lung could be one reason for the age-related difference in sensitivity
to toxicants, such as CPF (Karanth and Pope 2000). Ces isoforms are also distributed in different
lung subcellular fractions (Gaustad, Johnsen et al. 1991), thus it is feasible that some Ces
isoforms in lung might be inaccessible to the reactive oxon. If the various Ces isoforms differ in
their subcellular localization during development (Gaustad, Johnsen et al. 1991), it could explain
the differential sensitivities of the lung isoforms toward CPF-dependent inactivation in neonatal
and adult mice (Figure 4.5).
In previous studies from Carr et al., inhibition of eCB hydrolysis activity induced levels
of eCBs in the juvenile rat brain following CPF exposure (Carr, Adams et al. 2013). As there
were minimal differences in 2-AG and AEA hydrolysis activities in various tissues, we would
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expect minimal differences in 2-AG and AEA levels in the liver, lung, brain, and spleen (Figure
4.7). Indeed, there were minimal differences in eCB levels, and these differences did not
correlate to differences in eCB metabolic activity. The only effect on eCB levels following CPF
exposure in neonatal mice (of both genotypes) was an increase in liver OEA and PEA levels.
PEA levels were decreased by CPF in the spleens of adult WT mice, and there was a slight
decreased trend in spleen and lung PEA levels between WT and Cnr1-/- mice. OEA and PEA are
both cannabinoid-like substances that lack the ability to activate cannabinoid receptors (Ramer,
Schwarz et al. 2019). Both OEA and PEA have been associated with lower levels of AEA in
human meningiomas and gliomas (Maccarrone, Attinà et al. 2001, Ramer, Schwarz et al. 2019);
however, AEA levels were not decreased by CPF in the present study (Figure 4.7).
One mechanism by which eCBs can alter immune responses is through their engagement
with cannabinoid receptors, particularly those that alter T and B cell function and cytokine
release (Kaplan 2013). In the present study, we used flow cytometry to identify the percentages
of T helper cells, cytotoxic T cells, and B cells in the spleen, liver (adult only), and lung (adult
only) of WT and Cnr1-/- mice following exposure to CPF (Figure 4.6). While this did not allow
us to explore of the function of these cells, we were able to determine the naïve adaptive
immunophenotyping and if there were differences following CPF treatment or between
genotypes. Due to minimal differences in eCB levels and metabolizing activity caused by CPF
treatment, differences in the immunophenotypes of these tissues following CPF treatment were
not anticipated. Although CB2 is the most abundant CB receptor in immune cells, CB1 is
present in most immune cells (Kaplan 2013) and could alter tissue immunophenotype. However,
there were no differences in the naïve immunophenotype of the various tissues between WT and
Cnr1-/- mice. Additionally, we treated splenocytes in vitro with CPO, LPS, or a combination of
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the two. Although CPO significantly inhibited the 2-AG hydrolytic activity in these cells, it did
not alter the levels of LPS-induced IL-6 (Figure 4.8).
In conclusion, this is the first study to identify the Ces isoforms in mouse lung that are
targeted by the oxon metabolite of CPF. Our most important finding was that subacute, low-dose
CPF exposure can inhibit pulmonary Ces isoforms in an age-dependent manner at doses that are
too low to inhibit brain AChE. Neonatal mice were more sensitive to this inhibition, with both
Ces1c and Ces1d isoforms in lung found to be inactivated, whereas inhibition of Ces1c was only
seen in adult mice. The inhibition of Ces did not alter the metabolism of endocannabinoids in
lung microsomes, but this was not surprising given that Magl is the primary 2-AG hydrolytic
enzyme in the murine lung and it was not inhibited by CPF treatment. Because Ces enzymes are
believed to play a role in immunity, the next chapter will explore a role for lung Ces1d and
Ces1c inhibition by CPF in an LPS model of inflammation.
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Figure 4.1

Daily mouse weights during the treatment regimen with CPF or vehicle.

Mice were weighed every day before oral dosing with CPF. Weights of adult mice (n=5 per
condition) (A) and neonatal mice dosed PND 10-16 (n=4-5 per condition) (B) or PND 4-10
(n=7-8) (C) are indicated. Weights are expressed as mean ± SD.

Figure 4.2

AChE activities of brain samples

AChE activity was measured in the brain of neonatal (A) and adult female (B) WT and Cnr1-/(KO) samples. Specific activities were calculated as nmoles of product produced in mg protein−1
min−1. Data are expressed as mean ± SD.
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Figure 4.3

2-AG and AEA hydrolysis activity

2-AG hydrolysis activities in whole-tissue homogenates of brain (adult only), liver, lung, and
spleen from neonatal (A) and adult female (B) WT and Cnr1-/- mice (KO). (C) WT neonatal 2AG hydrolysis activities including brain samples. (D) 2-AG hydrolysis activities in lung
microsomes from neonate (PND 4-10 or 10-16) and adult WT mice (AF, adult female; AM, adult
male). AEA hydrolysis activities in in whole-tissue homogenates of brain from neonatal (F) and
brain, lung, and spleen from adult female (G) WT and Cnr1-/- mice. (H) AEA hydrolysis activity
in the lung, spleen, and brain of WT neonatal mice. Data are presented as mean ± SD (n=4-8
mice per condition), *p<0.05 relative to CO control. (E) 2-AG hydrolytic enzyme in neonatal
and adult lung. Lung microsomes (n=2 or 4 per condition) were pre-incubated with vehicle
(DMSO) or inhibitors prior to adding 2-AG. Data are expressed as percent vehicle control.
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Figure 4.4

Ces activity

Whole-tissue homogenates of liver, lung, spleen, and liver from neonatal (A) and adult female
(B) WT and Cnr1-/- (KO) mice. Ces activity in lung microsomes (C) or plasma (D) from WT
neonatal mice exposed during PND 4-10 and PND 10-16, or during adulthood. Data are
presented as mean ± SD (n=4-8 mice per condition), *p<0.05 relative to CO control.
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Figure 4.5

Activity-Based Protein Profiling (ABPP), ABPP-MS, and Ces1 Western Blot of
mouse lung tissue

Lung homogenates or microsomes were incubated with FP-biotin for 1 hour. Following this
incubation, microsomes were prepared for proteomic analysis (ABPP-MS). All serine hydrolases
identified in murine lungs from neonatal mice (A, n=7), adult female mice (B, n=5), and adult
male mice (C, n=6) are pictured. Data are expressed as mean ± standard deviation, and a p<0.05
was considered significant. To determine if Ces1 proteins were affected by CPF treatment, after
incubation with FP-biotin, an SDS-PAGE gel with lung homogenates was used to detect Ces1
and Magl activity. Following this procedure, the resulting membrane was stripped, and western
blotting was used to detect ces1 protein levels. The displayed results include one representative
neonatal (dosed PND 10-16) and adult female sample from each treatment group.
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Figure 4.6

Adaptive immune responses by flow cytometry

Cells from WT and Cnr1-/- (KO) neonatal spleens (A, n=3-5) were stained for extracellular
markers to identify T helper cells (CD4), cytotoxic T cells (CD8), and B cells (CD19).
Additionally, cells from WT and Cnr1-/- (KO) adult spleens (B, n=4-9), liver (C, n=4-5), and
lung (D, n=4-5) were similarly stained. Data are expressed as the mean of percent lymphocyte
gated ± SD.
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Figure 4.7

Endocannabinoid levels as measured by LC-MS/MS

One half of the liver (neonate only), lung, brain (neonate only), and spleen (adult only) was
extracted for endocannabinoids and quantified using deuterated standards in WT and Cnr1-/(KO) mice (n=3-5). The resulting values were standardized by tissue weight except in the adult
lungs. Adult lung values are expressed as the ratio of endocannabinoid to deuterated standard.
Data are expressed as mean ± SD, *p<0.05, #p<0.05.
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Figure 4.8

2-AG hydrolytic activity and IL-6 ELISA of treated adult splenocytes

Murine splenocytes were isolated from naïve mice and treated with vehicle, LPS (1 µg/mL),
CPO (1 µM), or a combination of LPS and CPO. After 3.5 hours, the media was utilized to
measure 2-AG hydrolytic activity by LC-MS/MS (A) and IL-6 levels by ELISA (B),
respectively. Data are expressed as mean ± SD (n=3), *p<0.05.
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CHAPTER V
IMMUNE EFFECTS OF CARBOXYLESTERASE INHIBITION CAUSED BY ORAL
CHLORPYRIFOS IN LUNGS OF NEONATAL AND ADULT MICE
Introduction
Several epidemiological studies have suggested a link between exposure to pesticides and
respiratory illness, chronic bronchitis, airway hypersensitivity, and asthma (Hernandez, Parron et
al. 2011, Gascon, Morales et al. 2013, Ye, Beach et al. 2013, Doust, Ayres et al. 2014, Mamane,
Raherison et al. 2015). Although the exact mechanisms for these effects are not established, OP
pesticides can cause airway hypersensitivity though a mechanism that does not involve direct
AChE inhibition, whereas it might involve inactivation of neuronal M2 muscarinic receptor
function (Fryer, Lein et al. 2004, Lein and Fryer 2005, Shaffo, Grodzki et al. 2018). In addition,
there is evidence that CPF can induce pro-inflammatory cytokines in human THP1 cells
(Proskocil, Grodzki et al. 2019), and the pro-inflammatory cytokines IL-1β and TNFα have been
shown to downregulate M2 receptors in guinea pig lung and a human embryonic lung cell line
(Haddad, Rousell et al. 1996, Nie, Jacoby et al. 2009). How pesticides such as CPF activate
inflammatory cells and induce cytokine production has yet to be established (Shaffo, Grodzki et
al. 2018).
Outside of asthma, a few studies have focused on a link between pesticides and
respiratory illness. One study found no difference in LPS-induced lung inflammation following
a 90-day oral exposure to 2 or 4 mg/kg of ethion in mice (Verma, Mukhopadhyay et al. 2019),
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but in a follow-up study, a combination of a one-time dose of 8mg/kg ethion and intranasal LPS
(80 μg) induced Tnfα gene expression compared to a control (Verma and Sethi 2020). Neither
treatment alone had the same effect (Verma and Sethi 2020). On the other hand, mice exposed
to methamidophos in water from gestation day 10 to postnatal day 21 had lower levels of IL-6
following infection with respiratory syncytial virus (Watanabe, Yoshida et al. 2013).
In Chapter 4, Ces1c and Ces1d were identified as specific targets of CPF in the murine
lung. Given that Ces enzymes are present in human macrophages and can metabolize lipid
mediators (Ghosh 2000, Xie, Borazjani et al. 2010, Wang, Borazjani et al. 2013), rat alveolar
macrophages possess Ces enzyme activity capable of hydrolyzing pestcides (Imamura, Schiller
et al. 1983) , and there is some evidence that pesticides can alter viral respiratory immune
responses (Watanabe, Yoshida et al. 2013), we opted to initially explore the ability of CPF to
alter lung immune responses through a mechanism involving the eCB system in a murine model
of LPS-induced inflammation. The objective of the present study was to determine whether Ces
inhibition by sub-acute low-dose CPF exposure modulates LPS-induced inflammation. To do
this, we assessed whether CPF could modulate the immune responses in mouse lung following
an LPS challenge administered after seven consecutive days of CPF treatment, and whether any
of the observed effects could be connected to CPF-dependent inactivation of Ces enzymes. Lung
immune responses were determined by assessing cytokine levels, lipid mediator levels, and the
lung immunophenotype by flow cytometry.
Materials and Methods
Chemicals and Reagents
CPF (>99%) was a generous gift from DowElanco Chemical Company (Indianapolis,
IN). Antibodies for flow cytometry and ELISA were purchased from Biolegend. Authentic
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standards of lipid mediators and endocannabinoids were purchased from Cayman Chemical (Ann
Arbor, MI). Solvents for LC-MS/MS were from Thermo Fisher. p-Nitrophenyl valerate (pNPVa)
and Lipopolysaccharide (LPS) was from Sigma (St. Louis, MO, USA). Antibodies for Western
blots were from Abcam (Cambridge, MA, USA). Fluorophosphonate-biotin (FP-biotin) was
from Toronto Research Chemicals (North York, ON). Reagents for ABPP-MS were from
sources described in Wang et al. (Wang, Borazjani et al. 2013).
Treatment of Mice
C57BL/6 wildtype (WT) mice were obtained from Jackson laboratories (Bar Harbor,
ME) and used to establish a breeding colony in a murine norovirus-free facility. Adult WT mice
(7-8 weeks) were bred on site or purchased and acclimated for one week before experiments.
Ces1d-/- mice on a C57BL/6 background were obtained from Dr. Richard Lehner (University of
Alberta, Canada) and used to establish a breeding colony in a separate facility due to their origin
from a facility where murine norovirus is endemic. Mice from the WT breeding colony were
relocated to this separate facility to establish a breeding colony to serve as controls for the
knockout mice. Mice were housed in temperature- and humidity-controlled AAALAC-approved
facilities (20-25°C and 40-60% humidity) under a 12-h light cycle and used in accordance with
the Mississippi State University Institutional Animal Care and Use Committee.
CPF was dissolved in corn oil (CO) and administered at a volume of 1 mL/kg body
weight for adult mice or 0.5 mL/kg for neonatal mice. Adult mice or neonatal mice received
either CO or CPF (2.5 mg/kg) by oral gavage every day for 7 days. One-half h after the final
dose of CPF or CO, adult mice (n=5/sex/group, repeated 3x in males) or neonatal mice (PND 1016, n=9-13/group, randomized from 6 litters) were injected with LPS (1.25 mg/kg, i.p.) or saline
in a volume of 100 µL/adult and 50 µL/neonatal mouse. The LPS dose was the same as that of
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our previous studies (Szafran, Borazjani et al. 2015). Six h after LPS injection, mice were
sacrificed by cervical dislocation and tissues collected. The right inferior lung lobe was placed in
1xPBS and stored on ice until further processing immediately following collection of all tissues.
The right middle lung lobe was placed in RNA laterTM (Thermo Fisher) before flash-freezing and
storing at -80°C until use. The remaining lung lobes and additional tissues were flash-frozen and
stored at -80°C until use. In studies involving Ces1d-/- mice, immune studies used adult
(n=4/group, only LPS treatments in WT mice) or neonate (PND 10-16, n=5/group, randomized
from 4 litters for each genotype) WT or Ces1d-/- mice.
For some studies, adult WT mice (n=5 per group) were injected with 30 mg/kg WWL229
(30 mg/kg i.p., once) , JZL184 (30 mg/kg i.p., once), or vehicle (15:1:1 v/v/v
emulphor:ethanol:saline for WWL229 studies or 0.5% hydroxymethylpropylcellulose in saline
for JZL184 studies) followed by LPS (1.25 mg/kg i.p., once) 30 min later. In another study, WT
and Ces1d-/- mice (n=5 per group) were injected once with LPS (1.25 mg/kg i.p.). Mice were
sacrificed 6 h post-injection, and tissues were collected for analysis.
Collection and Culture of Alveolar Macrophages
Alveolar macrophages were obtained and pooled from untreated C57BL/6 wild-type
adult mice by bronchoalveolar lavage. Following sacrifice by cervical dislocation, the trachea
was exposed, and a 22g catheter was inserted into the trachea. 1 mL aliquots of 1x PBS
containing 3% FBS were injected into the lungs and subsequently withdrawn for a total of 5-7
times per mouse. The pooled BAL fluid was washed, plated, and incubated overnight at 37 °C to
allow for the macrophages to adhere to the plate. Cells were left as naïve or treated with LPS
(100 ng/mL) for 24 h at 37 °C. After 24 h, RNA was extracted for RT-qPCR as described
below.
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Lung Immunophenotype by Flow Cytometry
The right inferior lung lobe was homogenized in 1x PBS and the homogenate pushed
through a 70 µm sieve first, followed by a 35 µm mesh strainer. Individual cells were stained
using one of two protocols. To detect adaptive immune cells, the lung cells were stained with
extracellular antibodies for CD4 (PECy5), CD8 (PECy7), and CD19 (BV650). Innate immune
cells were stained with extracellular antibodies for CD49b (FITC), F4/80 (PECy7), CD11b
(APC), CD11c (PE), and Gr1 (PacBlue). Cells were fixed in BD Cytofix™ (BD Biosciences)
following staining. An ACEA Novocyte Flow Cytometer was used to analyze the stained and
fixed cells. Antibody capture beads were used as compensation and fluorescent-minus one
controls were used to set gates. Adaptive immune cells were identified as cytotoxic T cells
(CD8+), T helper cells (CD4+), or B cells (CD19+) and quantified by percent parent lymphocyte
(Figure 5.1A). Using previously reported staining protocols (Misharin, Morales-Nebreda et al.
2013, Yu, Hotten et al. 2016), innate immune cells were identified as natural killer cells (CD49+,
CD11b-), alveolar macrophages (F4/80+, CD11c+, CD11b-), monocytes (F4/80+, CD11b+, Gr1), dendritic cells (CD11b+, CD11c+), or neutrophils (CD11b+, CD11c-, Gr1+) and quantified by
percent parent of immune cells gated (Figure 5.1B).
Analysis of Lung Lipid Mediators
The right superior lung lobe was rinsed in 1x PBS, blotted dry, weighed, and
homogenized in 3 mL of ice-cold 2:1 v/v methanol:water (containing 0.02% w/v
triphenylphosphine and internal standards) using a metal blade homogenizer. The following
internal standards were added to each sample: AA-d8, PGE2-d4, and 2-AG-d8 (13.3 pmol each)
and PEA-d4, OEA-d4, and AEA-d8 (100 pmol each). Homogenized samples were chilled at 80°C for one h before centrifugation at 3,000 x g and 4°C for 20 min. The supernatants were
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vortexed with 2 mL of 1:1 v/v hexane:ethyl acetate (containing 0.1% acetic acid) and 1 mL of
water, then centrifuged at 800g for 5 min. The top organic layer was transferred to a fresh tube
and an additional 1 mL of 1:1 hexane:ethyl acetate added to the aqueous layer and mixed. After
another round of centrifugation, the organic top layer was combined with the first organic extract
and evaporated under nitrogen gas. One-hundred µL of MeOH was added to the dried sample
and transferred to an HPLC vial with reducing insert for analysis by LC-MS/MS as previously
described (Wang, Borazjani et al. 2013).
Lung mRNA Extraction and Gene Expression Analysis by Quantitative RT-PCR
Total RNA from the right middle lung lobe (or a random sampling of the whole lung in
studies involving WWL229 and JZL184) was extracted following the manufacturer’s
instructions utilizing a RNeasy Plus Mini Kit (Qiagen). RNA was quantified on a NanoDrop
ND-1000 spectrophotometer before preparing cDNA with a RevertAid First Strand cDNA
synthesis kit (Thermo Scientific) following the manufacturer’s instructions. Real-time PCR was
performed with SYBR Green PCR Master Mix (Qiagen) on a Stratagene Mx3005P
thermocycler. GAPDH was used as the reference gene and the comparative cycle theshold
(ΔΔCT) was used to determine gene expression changes, with results compared to the control
condition [(2-ΔΔCT)]. WT control mice from each experiment were utilized as the control
condition except in the experiment utilizing adult Ces1d-/- mice, where Ces1d-/- mice treated with
CO and saline were set as the control due to the lack of a WT saline group.
Cytokine Determination by ELISA
The left lung lobe was homogenized, lysed, and prepared for ELISA as previously
described (Amsen, de Visser et al. 2009). IL-6 was measured by sandwich-based ELISA utilizing
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a previously described protocol and anti-mouse IL-6 antibodies (Biolegend) (Szafran, Lee et al.
2018). IL-1β and TNFα were measured by ELISA using the manufacturer’s protocol (Thermo
Fisher).
Determination of Forebrain AChE Activity
Forebrain AChE activity was determined as previously described in Chapter 4.
Activity-Based Protein Profiling (ABPP-Mass Spectrometry)
Mice from a separate experiment were injected IP with saline or LPS (1.25 mg/kg). Mice
were sacrificed 6 h post-injection, and following harvesting, lungs were prepared for ABPP-MS
as described in Chapter 4.
Statistical Methods
The mean and standard deviation (or standard error of mean) was calculated for each
group. A Student’s t-test, one-way ANOVA, or two-way ANOVA was used to assess
differences between groups when appropriate utilizing GraphPad Prism Software (Version 7, San
Diego, CA, USA), SigmaPlot Software (Version 11.0, San Jose, CA, USA). Grub’s outlier test
was utilized to identify outliers in data sets. Data from flow cytometry was log-transformed
before analysis. A p-value of <0.05 was considered significant.
Results
Low-Dose CPF Did Not Alter the Lung Immunophenotype Following LPS Challenge
CPF did not alter the distribution of adaptive and innate immune cells that develop in
response to LPS treatment in the neonate lung (Figure 5.2 A,D), adult male lung (Figure 5.2
B,E), or adult female lung (Figure 5.2 C,F), except for a slight increase in the percentage of
dendritic cells in adult female mice (Figure 5.2 G). In the absence of LPS treatment, CPF slightly
decreased the percentage of CD4+ T cells, CD19+ B cells, and monocytes in adult male lung,
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and there was a decreased trend in neonate and adult female lungs (Figure 5.2 B,C). The
percentage of neutrophils (CD11b+, CD11c-, Gr1+) in all age groups and sexes increased
following LPS challenge, whether or not mice were treated with CPF (Figure 5.2 D-F).
Monocytes (F4/80+, CD11b+, Gr1-) and dendritic cells (CD11b+, CD11c+) in adult mice of
either sex were also increased by LPS (Figure 5.2 E,F). In adult mice, the percentage of NK
cells (CD49+, CD11b-) was significantly decreased in response to LPS, whether or not CPF was
included, while the percentage of alveolar macrophages (F4/80+, CD11c+, CD11b-) remained
consistently similar in all treatment and age groups (Figure 5.2 D-F). LPS treatment also
decreased the percentage of T helper cells (CD4+) and B cells (CD19+) in all ages and sexes
regardless of whether CPF was used, while the percentage of cytotoxic T cells (CD8+) also
decreased or trended downward in neonate or adult lungs (Figure 5.2 A-C).
Because Ces enzymes have important roles as stoichiometric inactivators of oxons, we also
treated neonate and adult male Ces1d-/- mice with CPF to assess whether the absence of this
detoxication enzyme might unmask immunomodulatory effects in lung following subsequent
LPS challenge. In general, similar trends were noted in the distribution of adaptive and innate
cells in the lungs of neonatal and adult WT and Ces1d-/- mice (Figure 5.2 H-J). The only
difference between genotypes was the lower percentage of monocytes in neonatal WT lungs
compared to neonatal Ces1d-/- lungs, an effect that was independent of CPF or LPS treatments.
Low-Dose CPF Did Not Alter LPS-Induced Cytokines in Murine Lung
Cytokine levels in neonate and adult mouse lungs were evaluated by gene expression and
ELISA (Figure 5.3 A-F). LPS challenge induced a robust increase in all lung cytokines;
however, CPF did not alter their levels regardless of age or sex.
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In a separate experiment using neonate and adult male WT and Ces1d-/- mice, CPF
decreased the LPS-induced mRNA levels of Tnfa in both WT and Ces1d-/- neonatal mice (Figure
5.4 A), whereas it increased Tnfa expression in adult Ces1d-/- mice but not WT mice (Figure 5.4
C). However, this difference was not seen by TNF-α ELISA (Figure 5.4 B,D). In addition, CPF
did not alter mRNA levels of Il1β or Il6 in response to LPS regardless of genotype (Figure 5.4
A,C).
Low-Dose CPF Did Not Alter Ces or SP Gene Expression in Murine Lung
The expression of Ces isoforms in lung shown to be inactivated by CPF or LPS
treatments were examined. Ces1c, Ces1d, and Ces2g mRNA expression were evaluated in WT
neonate and adult male lungs (Figure 5.5 A,B). Although Ces1c and Ces1d gene expression in
neonate and adult lung were not altered by CPF and/or LPS treatment, LPS was shown to
downregulate Ces2g gene expression in both age groups, independent of CPF treatment (Figure
5.5 A,B). This result explains the reduced Ces2g activity in lung following treatment of mice
with LPS (Figure 5.6). The genes that encode the surfactant proteins A, B, C, and D were also
evaluated in neonatal and adult male lungs (Figure 5.5 C,D). Although CPF treatment alone had
no effect on surfactant protein gene expression, Sftpb and Sftpc were slightly but significantly
downregulated following LPS challenge in CPF-treated neonatal mice (Figure 5.5 C). In
addition, Sftpb was downregulated following LPS challenge in CO-treated adult male mice.
Ces1c and Ces2g were not affected by CPF or LPS treatments in WT and Ces1d-/- neonatal mice,
but there was a significant difference in Ces1c mRNA levels between WT and Ces1d-/- mice
when treated with CPF and LPS (Figure 5.5 E). Ces1c mRNA expression was significantly
lower or trending lower in adult Ces1d-/- mice than in adult WT mice, and Ces2g was
downregulated by the LPS challenge independent of CPF treatment (Figure 5.5 F).
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Low-Dose CPF Did Not Alter the Lung Lipid Profile
In general, CPF on its own minimally altered the lung endocannabinoid (2-AG, AEA)
and N-acylethanolamine levels (OEA, PEA) in neonate and adult mice, regardless of whether
LPS was present or not (Figure 5.7 A-C). On the other hand, LPS challenge did increase lung
OEA levels in neonate mice treated with CO vehicle (Figure 5.7 A). In adult male mice, CPF
alone increased AA levels and LPS induced AEA and OEA levels independent of CPF (Figure
5.7 B). The most striking effects were found in the adult female mouse lungs. For example, LPS
induced 2-AG levels in CO-treated mice, but not in CPF-treated mice (Figure 5.7 C). Moreover,
CPF was found to augment the levels of LPS-stimulated lipid mediators PGE2, PGD2, and 12HETE. In addition, there were minimal differences in the lung lipid profiles between WT and
Ces1d-/- mice, regardless of CPF treatment or exposure to LPS (Figure 5.8). The only significant
difference noted was that CO-treated neonate Ces1d-/- mice had higher levels of PGD2 than their
CO-treated WT counterparts following LPS challenge.
LPS Inhibits Several Lung Ces Enzymes
A separate cohort of mice were treated with LPS only (no CPF) to assess the effect of
acute lung inflammation on serine hydrolase activities. Six hours after LPS injection, ABPP-MS
analysis demonstrated that Ces2g, Ces2b, and Ces2e activities in lung of adult female mice were
significantly decreased compared to those in lung of saline controls (Figure 5.6). LPS caused
Ces1d activity to trend downward (p=0.11) while Ces1c activity was unaffected.
Mouse Genotype Did Not Alter AChE Activity or Serum Ces Activity in Response to LowDose CPF
Treatment with CPF, LPS, or a combination of the two did not inhibit brain AChE
activity in either neonate or adult mice when compared to their corresponding CO controls
128

(Figure 5.9). Additionally, there was no difference in AChE activity between mouse genotypes.
In adult mice, there was no genotype-related differences in the LPS-induced serum Ces activity
between CPF and CO- treated animals (Figure 5.10A). Additionally, LPS did not alter the
inhibition of Ces activity by CPF in the serum of Ces1d-/- mice (Figure 5.10B).
Mouse Pulmonary Alveolar Macrophages Express Ces1d but not Ces1c or Ces2g
Treatment of murine alveolar macrophages with LPS significantly induced or trended
upward the expression of pro-inflammatory cytokines Il1β, Il6, and Tnfa (n=2, Figure 5.11).
Most importantly, alveolar macrophages were not found to express Ces1c or Ces2g mRNA, but
they expressed Ces1d mRNA that was downregulated by LPS treatment (Figure 5.11).
Inhibition of Ces1d and Magl in Female Mice Alter Lung LPS-Induced Cytokines
In Chapter 4, CPF was found to inhibit Ces1c and Ces1b in the lungs of adult female at
2.5 mg/kg. To determine if inhibition of Ces1d and Magl alter the LPS-induced cytokine
expression, adult female mice were treated with WWL229 (Ces1d inhibitor) or JZL184 (Magl
inhibitor). WWL229 exacerbated the LPS-induced mRNA expression of Il1b, Il6, and Tnfa in
the adult female lung (Figure 5.12A). Inversely, JZL184 attenuated the LPS-induced mRNA
expression of Il1b and Il6 (Figure 5.12B). Finally, Ces1d-/- mice treated with LPS had a higher
expression of Il6 compared to WT controls (Figure 5.12C).
Discussion
A possible link exists between OP exposure and development of respiratory illness,
chronic bronchitis, airway hypersensitivity, and asthma that is independent of AChE inhibition
(Hernandez, Parron et al. 2011, Gascon, Morales et al. 2013, Ye, Beach et al. 2013, Doust, Ayres
et al. 2014, Mamane, Raherison et al. 2015). Thus, we have examined whether CPF exposure
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during different life stages could modulate immune responses in the murine lung following a
subsequent LPS challenge.
Ces/CES metabolize 2-AG and other immunomodulatory lipids such as prostaglandin
glyceryl esters (PG-Gs) (Xie, Borazjani et al. 2010, Wang, Borazjani et al. 2013, Mangum, Hou
et al. 2018) and the inactivation and overexpression of Ces/CES enzymes can alter immune
responses in macrophages (Bie, Zhao et al. 2010, Hunerdosse, Morris et al. 2014). However,
CPF treatment did not alter the levels of LPS-induced cytokines or the immunophenotype in
neonatal and adult lungs, except for an increase in the percentage of LPS-induced dendritic cells
in female lungs. In the cohort of Ces1d-/- and WT mice studied together, CPF treatment did
attenuate LPS-induced Tnfa mRNA levels in neonate lungs irrespective of genotype. On the
other hand, in the setting of LPS exposure, CPF treatment augmented Tnfa mRNA in adult lung
of Ces1d-/- mice but not WT mice. It should be pointed out that the mice used to compare
cytokine responses in WT and Ces1d-/- genetic backgrounds (Figure 5.4) were housed and treated
in a different facility than the first animal studies (WT mice only, Figure 5.3), thus we cannot
dismiss the possibility that some uncontrolled factor contributed to the different results regarding
Tnfa mRNA levels.
Our findings are similar to those of a previous study that showed 90-day treatment of
mice with 2 and 4 mg/kg oral ethion did not alter LPS-induced pro-inflammatory cytokine levels
compared to LPS alone (Verma, Mukhopadhyay et al. 2019). On the other hand, Tnfa mRNA
and/or protein levels were induced in guinea pig alveolar macrophages and differentiated human
THP-1 cells following exposures to OPs in the absence of other immune stimulus (Proskocil,
Bruun et al. 2013, Proskocil, Grodzki et al. 2019). Another study found altered levels of
circulating monocytes and macrophages in an experimentally-induced colitis mouse model
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following CPF treatments ranging from 1-5 mg/kg (Huang, Pai et al. 2019). Other evidence of
immune effects following CPF exposure involve adaptive immune cells. In one study, rats dosed
with CPF (5 mg/kg, twice weekly for a period of 28 days) exhibited altered T-lymphocyte
blastogenesis in response to concanavalin A, whereas B-lymphocyte blastogenesis in response to
LPS was normal (Blakley, Yole et al. 1999). In addition, neonatal rats exposed to low doses of
CPF had impaired T-cell responses in adulthood (Navarro, Basta et al. 2001), while mice
exposed in-utero and from PND 7-42 had a significantly decreased spleen lymphoproliferative
response to LPS (Singh, Parashar et al. 2013). Therefore, several reports indicate that CPF
exposure can lead to altered immune responses. In our study, however, we have only assessed
lung immune responses at 6 h following LPS challenge, which is approximately at the height of
the inflammatory (innate immune) response, so it is difficult to compare our results to these
previous studies. Additionally, our study was limited by a single CPF dose level (2.5 mg/kg) and
the subacute dosing regimen.
eCBs, AA, and eicosanoids are immunomodulatory lipids that have varied roles in proand anti-inflammatory processes (Joshi, Zhou et al. 2001, Yakar, Melamed et al. 2003,
Nazarewicz, Zenebe et al. 2007, Scher and Pillinger 2009, Mabalirajan, Rehman et al. 2013,
Nakanishi and Rosenberg 2013, Sun, Xu et al. 2015). The biological activities of these lipid
mediators are tightly regulated by their biosynthesis and degradation. CPF treatment, however,
produced only minor alterations in the lung lipid profile. There was, however, an increased trend
in several anti- and pro-inflammatory lipid mediators following LPS stimulation, which in some
cases (e.g., PGE2, PGD2, and 12-HETE) were shown to be augmented by CPF treatment. These
increases might be part of a feedback system activated during LPS-induced inflammation
(Szafran, Borazjani et al. 2015). The levels of lung endocannabinoids (2-AG and AEA) were
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mainly unaffected by CPF treatment and restricted to LPS-induced increases, which is consistent
with the fact that CPF did not alter lung 2-AG and AEA hydrolytic activities in this tissue, and
that Magl was not inhibited based on ABPP-MS results. A previous study had demonstrated that
2-AG and AEA levels in brain were increased following CPF treatment, which was associated
with inhibited MAGL and FAAH, respectively (Carr, Adams et al. 2013). CES1 inhibition in
human cell lines or primary macrophages was also associated with altered lipid metabolism (Xie,
Borazjani et al. 2010, Wang, Borazjani et al. 2013, Mangum, Hou et al. 2018), but the impact of
CPF on lipid mediators is not straightforward. Because the levels of lipid mediators were only
measured at 6 h post-LPS treatment in the current study, alterations in lipid metabolism may not
have been apparent at this time point.
Surfactant proteins play important roles in lung immunity, phospholipid metabolism, and
ensure efficient gas exchange (Weaver and Whitsett 1991, Griese 1999). Reductions of SP-A and
SP-D levels contribute to the development of asthma (Mackay, Grainge et al. 2016, Su, Shi et al.
2017, Dy, Tanyaratsrisakul et al. 2018, Sorensen 2018) and disrupted production of SPs increase
airway resistance (Weaver and Whitsett 1991, Enhorning, Yarussi et al. 1996). Other studies
demonstrate that SP-A, SP-C, and SP-D have the ability to recognize and bind to LPS as part of
the lung’s antimicrobial defense system (Augusto, Le Blay et al. 2001, Augusto, Li et al. 2002).
Further, adult rats exposed to high doses of CPF exhibited increased airway resistance (Shaffo,
Grodzki et al. 2018). Our results suggested that LPS could reduce expression of Sftpb and Sftpc,
and are consistent with another report suggesting that Sftpb was downregulated by LPS (Bein, Di
Giuseppe et al. 2013). However, in our study, LPS-dependent reduced expression of Sftpb and
Sftpc was only apparent in the CPF-treated animals. Thus, co-exposures to endotoxins (LPS) and
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CPF might be a useful variable to evaluate in farmworkers and pesticide applicators when
assessing lung health.
Ces1d, Ces1c, and Ces2g are expressed at reasonably high levels in murine lung (Jones,
Taylor et al. 2013) (and Ct values not shown). Furthermore, Ces1d is also expressed in
pulmonary alveolar macrophages (Figure 5.11), which is consistent with a study showing that rat
alveolar macrophages exhibit carboxylesterase activity (Imamura, Schiller et al. 1983). Based on
RT-qPCR analysis, CPF treatment did not alter the expression of Ces1d, Ces1c, and Ces2g in
lung. However, LPS downregulated Ces2g mRNA expression and its activity irrespective of CPF
treatment and genotype (WT vs Ces1d-/-). This is consistent with our previous study, where
Ces2g activity in murine spleen was shown to be significantly downregulated following LPS
treatment (Szafran, Borazjani et al. 2015). Thus, LPS-induced inflammation seems to reduce the
transcription of the Ces2g gene in multiple tissues. Furthermore, ex vivo treatment of alveolar
macrophages with LPS reduced the expression of Ces1d (Figure 5.11); however, the mechanism
for these effects are unclear.
Although the limitations of a single CPF dose level (2.5 mg/kg) and time point (6 h postLPS challenge) may have prevented us from detecting CPF-associated alterations in lung
immunity, an alternative explanation is that lung Ces isoforms have an important protective
function that prevents CPF-mediated immunotoxic effects, much like it protects AChE from the
toxic effects of oxons by stoichiometrically binding these reactive molecules (Chanda,
Mortensen et al. 1997, Karanth and Pope 2000, Cometa, Buratti et al. 2007). This is supported
by the fact that Ces isoforms were the most likely to be inactivated in lung (Chapter 4). Studies
in guinea pigs and rats have also suggested that the lung might be an alternative site for the
detoxification of OPs (Gaustad, Johnsen et al. 1991, Karanth and Pope 2000). Additionally, a
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study in rats had found that pre-inhibiting carboxylesterases with CBDP or iso-OMPA prior to
exposure to paraoxon caused death in rats at doses that did not normally induce signs of toxicity
(Yang and Dettbarn 1998). To further explore Ces as a protective enzyme from CPF-mediated
effects, we repeated our immune experiments in Ces1d-/- mice because Ces1d is the murine
orthologue of human CES1 (Lian, Nelson et al. 2018) and the most abundant Ces isoform
detected in lung by ABPP-MS (our study). However, there were no immune alterations in
response to LPS that were different between Ces1d-/- and WT mice, except for an upregulation of
LPS-induced Tnfa mRNA expression in lungs of adult Ces1d-/- mice treated with CPF (Figure
5.4). Thus, loss of Ces1d did not appear to unmask a CPF-dependent “toxic effect” in lung, save
for the Tnfa induction in adult male mice.
Interestingly, Ces1c was inhibited in mice of all life stages exposed to CPF. Because
Ces1c (and not Ces1d) was targeted and inactivated in adult lung following CPF exposure, it
might be the main protective enzyme against CPF-dependent immunotoxic effects. Our data
support this hypothesis, because in the setting of LPS-induced inflammation the augmented
production of Tnfa mRNA in adult Ces1d-/- mice following CPF exposure (Figure 5.4 C) seems
to parallel the downregulation of Ces1c mRNA seen in lungs of knockout mice irrespective of
CPF treatment (Figure 5.5 F). With presumably less Ces1c in the Ces1d-/- lung compared to WT
lung, the knockout mice might be even more vulnerable to CPF-mediated effects. The
downregulation of Ces1c mRNA was not as pronounced in the neonatal Ces1d-/- mice, and
likewise, there was no genotype-related differences in Tnfa expression following CPF treatment,
indicating an age-related difference in the activity and expression of this Ces isoform. In adult
mice, there was not a genotype-related difference in Ces1c activity in serum, so the difference is
likely specific to the lung.
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Although treatment with CPF at 2.5 mg/kg did not inhibit Ces1d or Magl in the adult
lung, mice treated with inhibitors of both eCB metabolizing enzymes altered the lung’s proinflammatory cytokine response to LPS stimulation (Figure 5.12). Interestingly, inhibition of
Ces1d and Magl demonstrated opposite effects, suggesting these two enzymes play opposite
roles in their regulation of inflammation. Although Ces1d inhibition increased LPS-induced proinflammatory cytokines in female mouse lungs (Figure 5.12 A,C), this result was not present in
neonates or adult male Ces1d-/- mice (Figure 5.4). The decreased expression of Il1b and Tnfa
following inhibition of Magl is consistent with a study by Costola-de-Souza et al. (Costola-deSouza, Ribeiro et al. 2013). In this study, i.p. treatment with JZL184 reduced cytokine levels in
an LPS-induced model of acute lung injury. CB1 and CB2 were found to play a role in these
results because treatment with CB1 and CB2 inhibitors blocked the anti-inflammatory effects.
Because Magl is the primary 2-AG hydrolytic enzyme in the murine lung (Chapter 4), the antiinflammatory effects of JZL184 could be due to engagement of increased 2-AG levels with CB
receptors in the murine lung. Collectively, because CPF/CPO inhibits Magl and Ces1d under
certain conditions (i.e. higher doses, in vitro), these results provide further support for a
protective role of Ces1c from immunotoxic effects of CPF.
In conclusion, although Ces is hypothesized to play a role in immune regulation, the
inhibition of Ces by CPF treatment produced minimal or no differences in the acute lung
immune response to the pathogen-associated molecular pattern-containing molecule LPS, except
for an increase in female lung dendritic cells and a decrease in neonatal lung Tnfa mRNA. CPF
increased the expression of LPS-induced Tnfa in adult Ces1d-/- mice, which corresponded to a
decreased Ces1c expression in Ces1d-/- mice versus WT controls, suggesting Ces1c is a
protective enzyme against the toxic effects of CPF. Further studies are needed to determine if
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Ces1c is the principal Ces isoform in lung that detoxifies reactive oxons, or if inhibition of Ces
isoforms following CPF exposure alters immune responses in a manner not detected by our study
design. The significance of Ces inhibition by CPF and whether it can be linked to the
development of pulmonary inflammation or asthma requires further study.
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Figure 5.1

Gating strategy for identifying lung adaptive and innate cells

T helper cells were identified as CD4+, cytotoxic T cells as CD8+, and B cells as CD19+ (A).
NK cells were identified as CD49+/CDllb-, AMs as F4/80+/CD11c+/CD11b-, Mono as
F4/80+/CD11b+/Gr1-, DCs as CD11b+/CD11c+, and Neutrophils as CD11b+/CD11c-/Gr1+ (B).
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Figure 5.2

Lung innate and adaptive immunophenotype measured by flow cytometry

Cells were stained extracellular to identify the innate lung immunophenotype of neonate (A,
n=9-13), adult male (B, n=15), and adult female (C, n=5) lungs in response to LPS. To highlight
the DC populations, a separate graph has been added with all ages and sexes (G). Cells were
also stained extracellularly to identify the adaptive lung immunophenotype of neonate (D, n=913), adult male (E, n=15), and adult female (F, n=5) lungs in response to LPS. Cells were
identified as natural killer cells (NK, CD49+, CDllb-), alveolar macrophages (AM, F4/80+,
CD11c+, CDllb-), monocytes (MONO, F4/80+, CDllb+, Gr1-), dendritic cells (DC, CDllb+,
CDllc+), neutrophils (NEU, CD11b+, CDllc-, Gr1+), cytotoxic T cells (CD8+), T helper cells
(CD4+), or B cells (CD19+). Follow-up studies evaluated the innate and adaptive lung
phenotype in Ces1d-/- and additional WT neonatal (H, J) and adult male (I, K) mice. Data is
expressed as mean of percent lymphocyte gated ± standard deviation, and a *p<0.05 was
considered significant compared to saline control. **p=0.056. #p<0.05 in indicated comparison.
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Figure 5.3

Cytokine mRNA and protein levels measured by qPCR and ELISA

RNA was extracted and quantified from the right middle lung lobe. The resulting cDNA was
used to measure Il1β, Il6, and Tnfα mRNA from neonatal (A, n=9-13), adult male (B, n=15), and
adult female (C, n=15) mice. Protein from the left lung lobe was extracted, and a sandwichbased ELISA assay was used to measure IL-1β, IL-6, and TNF-α protein from neonatal (D, n=913) and adult male (E, n=15) mice. Only IL-6 was measured by ELISA in adult female (F, n=5)
mice. A similar analysis was repeated in Ces1d-/- and additional WT neonatal (G, H) and adult
male (I, J) mice.
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Figure 5.4

Cytokine mRNA and protein levels measured by qPCR and ELISA in WT and
Ces1d-/- mice

RNA was extracted and quantified from the right middle lung lobe to prepare cDNA for qPCR.
Protein from the left lung lobe was extracted, and a sandwich-based ELISA assay was used to
measure cytokine protein. Results are shown for neonatal (A,B) and adult (C,D) WT and Ces1d/mice. Only TNF-α was measured by ELISA as it was the only LPS-induced cytokine affected
by CPF treatment. mRNA data are expressed in average fold-changes compared to
vehicle/saline control, and ELISA data as mean ± standard deviation. In Ces1d-/- neonatal mice,
data are compared to WT vehicle/saline controls. In ces1d-/- adult male mice, data are compared
to Ces1d-/- vehicle/saline controls. *p<0.05 compared to saline control. #p<0.05 in indicated
comparison.
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Figure 5.5

Ces and SP mRNA levels measured by qPCR in some of the samples

RNA was extracted and quantified from the right middle lung lobe. The resulting cDNA was
used to measure mRNA expression of ces isoforms and lung surfactant proteins A-D in neonatal
(A, C, n=7) and adult male (B, D, n=10) lungs. Additionally, Ces1c and Ces2g mRNA were
measured in WT and Ces1d-/- neonatal (E) and adult mice (F). In Ces1d-/-, neonatal mice, data
are compared to WT vehicle/saline controls. In Ces1d-/- adult male mice, data are compared to
Ces1d-/- vehicle/saline controls. mRNA data are expressed in average fold-changes compared to
vehicle/saline control. *p<0.05 was considered significant. #p=0.0623.

141

Figure 5.6

ABPP-MS profiling of serine hydrolases in female WT C57BL/6 mouse lung 6
hours after an LPS challenge (1.25 mg/kg, i.p.)

Mice were treated with either saline vehicle or LPS. Following sacrifice, lungs were harvested
and processed for ABPP-MS. Serine hydrolases are denoted by their gene symbols and those
with significantly reduced activity are denoted by an asterisk (p<0.05). p-values for Ces1d and
Apeh are indicated. Data represents the mean ± SEM of n=4-5 individual mouse lungs.
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Figure 5.7

Lung lipid mediator levels measured by HPLC-MS/MS

The right superior lung lobe was extracted for lipid mediators and quantified by LC-MS/MS
using deuterated standards. Lungs were evaluated for levels of 2-AG, OEA, PEA, AEA, AA,
PGE2, PGD2, 12-HETE, and HODE in neonatal (A, n=9-13), adult male (B, n=15), and adult
female (C, n=5) mice.
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Figure 5.8

Lung lipid mediator levels in WT and Ces1d-/- mice

The right superior lung lobe was extracted for lipid mediators and quantified by LC-MS/MS
using deuterated standards. Lipid mediator levels were determined in WT and Ces1d-/- neonatal
(A) and adult male (B) mice. Data are expressed as mean ± standard deviation. *p<0.05 was
considered significant.
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Figure 5.9

AChE activity of brain samples in WT and Ces1d-/- mice

AChE activity was measured in the forebrain of WT and Ces1d-/- neonates (A) and adults (B).
Specific activities were calculated as nmoles (AChE) of product produced in mg protein−1 min−1.

Figure 5.10

Ces activity of adult WT and Ces1d-/- serum samples

Ces activity was determined by measuring the hydrolysis of pNPVa in serum from adult mice.
Comparisons were made in LPS-treated between WT and Ces1d-/- mice treated with CO or CPF
(A). Comparisons were also made in Ces1d-/- mice between CO/Sal, CO/LPS, CPF/Sal, and
CPF/LPS treated groups (B).
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Figure 5.11

Cytokine and Ces isoform mRNA levels were quantified in mouse pulmonary
alveolar macrophages using RT-qPCR.

Macrophages were treated ex vivo with LPS (100 ng/mL, 24 h) or vehicle (saline, 24 h). Data are
expressed as mean ± SD, *p<0.05. n.d., not detected (cycle-threshold Ct>36).
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Figure 5.12

LPS-induced cytokine mRNA expression in lung following inhibition of Ces1d
and Magl

Adult mice were treated with WWL229 (Ces1d inhibitor, A) or JZL184 (Magl inhibitor, B)
followed by an injection of LPS. WT and Ces1d-/- mice were treated with LPS and sacrificed 6
hours post-injection (C). Cytokine mRNA was measured by qPCR. Il1b and Tnfa levels were
unchanged between WT and Ces1d-/- mice (data not shown). n=4-5 mice for all groups.
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CHAPTER VI
ELECTRONIC-CIGARETTE VEHICLES AND FLAVORING AFFECT LUNG IMMUNE
FUNCTION AND IMMUNE RESPONSES IN A MURINE MODEL
Introduction
This chapter was in collaboration with Louisiana State University. The project originally
began as a VSRI (veterinary student research initiative) externship to allow me to gain
experience in pathology. We (at MSU) initially exposed mice to vegetable glycerin using a fog
machine in an equine isolation stall, but this method was crude. We had concerns about how
well-received our crude methodology would be, so we reached out to a group at LSU to
collaborate on a repeat study using their inhalation facility. LSU performed the exposure for this
study, and I had the chance to travel to their facilities for the last week of the animal portion of
the project. LSU performed the lung function assays, a portion of the gene expression, and the
Ingenuity Pathway Analysis. I performed the histopathology, flow cytometry, lipid mediator
extractions, a portion of the gene expression, and the ELISAs. I wrote the initial draft of the
paper that was reviewed by all authors and underwent heavy edits from LSU.
In the past year, the general public’s perception regarding the safe use of electronic
nicotine delivery systems (ENDS) was challenged with the 2019–2020 electronic-cigarette (ecig) or vaping product use-associated acute lung injury (EVALI) outbreak, throughout the United
States. As of the end of February 2020, the Centers for Disease Control and Prevention (CDC)
had confirmed over 65 deaths and more than 2800 cases of EVALI. The CDC and Food and
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Drug Administration (FDA) are currently conducting work to determine the cause of this recent
outbreak, but the majority of the e-liquid samples tested were found to contain Vitamin E
acetate, a thickening agent used in ENDS containing delta-9-tetrahydrocannabinol (THC)
(Griese 1999, Lewis, McCaffrey et al. 2019). EVALI, however, has been diagnosed in patients
since 2015 (Modi, Sangani et al. 2015, Itoh, Aoshiba et al. 2018, Sommerfeld, Weiner et al.
2018, Arter, Wiggins et al. 2019), and is still observed in nicotine-exclusive ENDS users
(Balmes 2020). While EVALI cases have all been acute, there is limited research on the longterm safety of e-cig use, particularly regarding the use of e-cig delivery vehicles (Chun, Moazed
et al. 2017, Madison, Landers et al. 2019). ENDS e-liquid typically contains a combination of
delivery solvents, including vegetable glycerin (VG) and propylene glycol (PG), plus nicotine,
flavorings, and other additives (Sommerfeld, Weiner et al. 2018). In recent years, over 400
different brands of ENDS devices and more than 7000 flavors have been identified, with
increasing numbers monthly (Fitzpatrick B.H. 2020). This means the composition of ENDS
varies widely and can be difficult and complex to study. The addition of flavoring has made
ENDS appealing to teenagers, who perceive flavored ENDS as more enjoyable to use than
unflavored ENDS (Chen-Sankey, Kong et al. 2019), and thus, use in this age group has increased
tremendously from 1.5% in 2011 to 20.8% in 2018 (Fadus, Smith et al. 2019). ENDS were
originally marketed as a safer alternative to traditional cigarettes, but approximately 11% of adult
ENDS users and 40% of young adult ENDS-users were originally non-smokers (Fitzpatrick B.H.
2020). Since little is known regarding the long-term health effects of vaping, ENDS pose a
significant public health concern and should be evaluated further for their safety.
Scientific evidence regarding the safety of ENDS is still a matter of debate. A limited
number of studies have assessed whether ENDS cause lung inflammation. At least one study has
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found no difference in lung cytokine levels 4 months after ENDS exposure, with or without
nicotine (Madison, Landers et al. 2019). This same study, however, found differences in
inflammation and immune responses after influenza challenge (Madison, Landers et al. 2019).
In contrast, several studies have identified increases in cytokines associated with ENDS use,
including IL-6 and IL-8, in both in vivo and in vitro studies (Lerner, Sundar et al. 2015, Husari,
Shihadeh et al. 2016, Crotty Alexander, Drummond et al. 2018, Glynos, Bibli et al. 2018, Scott,
Lugg et al. 2018). Flavorings, with or without nicotine, have been reported to produce varying
effects on lung inflammation, depending on the specific flavoring (Chapman, Casey et al. 2019).
A recent study demonstrated that mice exposed to e-cig aerosols composed solely of
delivery vehicles (PG and VG), without nicotine, responded with aberrant lipidomics (Madison,
Landers et al. 2019). This study found an increase in lipid accumulation in alveolar
macrophages that was due to increases in phospholipid species that were linked to increases in
surfactant-associated lipid species and decreases in gene expression related to lung SP-A and SPD (Madison, Landers et al. 2019). Other studies have also identified atypical macrophage lipid
accumulation and aberrant lipid levels (Cardenia, Vivarelli et al. 2018, Itoh, Aoshiba et al. 2018,
Maddock, Cirulis et al. 2019, Singanayagam and Snelgrove 2019, Kooragayalu, El-Zarif et al.
2020). Pulmonary surfactant proteins (SP) are composed of 90% lipids and function to increase
pulmonary compliance, facilitate immune defenses (SP-A and SP-D), and regulate surfactant
phospholipid metabolism (Weaver and Whitsett 1991). In addition to the Madison et al.
(Madison, Landers et al. 2019) study, other studies have also evaluated the effects of ENDS on
pulmonary surfactant proteins. These in vitro studies found no differences in function at doses
consistent with typical ENDS use although the structure of the proteins was altered (Przybyla,
Wright et al. 2017, Sosnowski, Jabłczyńska et al. 2018). As multiple studies have identified a
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disruption in lipid homeostasis and pulmonary surfactant proteins due to ENDS exposure with
and without nicotine, further investigation into these findings, particularly with lipid-based
immune mediators, is warranted.
Fruit, dessert and candy, are currently the trendiest U.S. e-liquid flavor categories
(Russell, McKeganey et al. 2018). Ethyl vanillin and vanillin are characteristic aldehyde
flavoring chemicals that provide the vanilla flavor for many desert flavored e-liquids, including
vanilla cream, vanilla butternut, crème brûlée, custard, cheesecake, and cream pie (Erythropel,
Jabba et al. 2019). In the present study, we used a murine model to study the sub-acute
pulmonary effects of inhaling e-cig delivery vehicles containing 70%/30% VG/PG with or
without vanilla flavoring. We chose to investigate the effects of French vanilla flavored e-liquid,
since it is composed of widely-used flavoring chemicals (vanillin and ethyl vanillin) in popular
American e-liquids. In addition, vanilla flavoring has the potential to inhibit the activity of
monoamine oxidase (MAO) enzymes, and thus may have pharmacological/toxicological effects
(Truman, Stanfill et al. 2019). Both VG and PG are classified “generally recognized as safe”
(GRAS) by the FDA as food additives, but as substances inhaled through an ENDS device, their
safety has not yet been thoroughly assessed. Heating and aerosolizing humectants (PG and VG)
via an e-cig device allows for the formation of reactive aldehyde species, including acetaldehyde
and acrolein, which are known to have significant harm potential for the lungs (Geiss, Bianchi et
al. 2016, Sleiman, Logue et al. 2016). The pulmonary toxicity of these aldehydes can be added
to the toxicity of the parent PG component, which is considered an upper airway irritant, and has
been associated with an increased risk for asthma (Wieslander, Norbäck et al. 2001, Choi,
Schmidbauer et al. 2010, Prochaska 2019). Besides, higher VG ratios in ENDS allow for a
smoother vaping experience and produce high aerosol levels (Prochaska 2019). Unlike many
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other studies that focus on a higher concentration of PG/VG, our study focuses on a higher
VG/PG ratio. These VG skewed ratio e-liquids are popular with a growing subclass of youth and
young adult e-cig users, the “cloud chasers”, who pride themselves on the size of the exhaled
aerosol cloud that the skewed VG/PG ratios enable. Importantly, varying the ratios of PG/VG in
e-liquid formulation will cause a concomitant change in the levels of exposure to specific
harmful aldehydes produced in the e-cig aerosol (Wieslander, Norbäck et al. 2001, Choi,
Schmidbauer et al. 2010, Prochaska 2019). Moreover, the production of “flavor aldehyde—
solvent acetal” will occur in e-liquids composed of aldehyde flavoring chemicals, including ethyl
vanillin and vanillin (Erythropel, Davis et al. 2019). The carryover of the acetals from the eliquid to the e-cig aerosol is substantial—at 50%–80%—which could lead, following inhalation,
to respiratory tract irritation (Erythropel, Davis et al. 2019, Erythropel, Jabba et al. 2019).
Vanillin VG acetal and vanillin PG acetal are produced in vanillin containing e-liquids and the
vanillin PG acetal has a greater pro-inflammatory effect than vanillin (Erythropel, Davis et al.
2019, Erythropel, Jabba et al. 2019). Furthermore, the quantity of acetal present in both e-liquids
and e-cig aerosols is dependent upon the e-liquid PG/VG ratio (Erythropel, Jabba et al. 2019).
To our knowledge, no studies have investigated the effects of inhaled vanilla-flavored e-cig
aerosol, including the potential for the formation of harmful aldehydes plus vanillin PG and VG
acetals, on lung function and immune responses. The goals of this study were to (i) determine the
effect of one particular ratio of delivery vehicles, 70% VG/30% PG, on lung function, (ii)
evaluate markers of lung inflammation associated with this ratio of delivery vehicles, and (iii)
determine the effects of those delivery vehicles on inflammatory lipid mediators, with or without
vanilla flavoring. We hypothesized that sub-acute exposures to 70% VG/30% PG will disrupt
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lung function, increase lung tissue macrophages and other immune cell types, increase markers
of inflammation, and disrupt normal lung immune lipid mediators.
Materials and Methods
Chemicals and Reagents
Fluorescence antibodies used for flow cytometry and some antibodies used for ELISA
were purchased from Biolegend (San Diego, CA, USA). Authentic standards of
oleoylethanolamine-d4 (OEA-d4), palmitoylethanolamide-d4 (PEA-d4), 2-arachidonylglycerold8 (2-AG-d8), anandamide-d8 (AEA-d8), arachidonic acid-d8 (AA-d8), and prostaglandin E2-d4
(PGE2-d4) were from Cayman Chemical (Ann Arbor, MI, USA). Liquid chromatography-mass
spectrometry (LC-MS/MS) solvents (LC-MS grade) were purchased from Thermo Fisher
(Waltham, MA, USA).
Mice
The 6-week old C57BL/6 female mice were obtained from Jackson laboratories (Bar
Harbor, ME USA). We selected to conduct this study on female mice since previous
epidemiological studies reported increased e-cig use (>50%) among women (Grana, Popova et
al. 2014, Pulvers, Hayes et al. 2015, Rutten, Blake et al. 2015). Mice were shipped to Louisiana
State University and acclimated for 2 weeks before initiation of study. Subgroups of mice were
randomly distributed into their respective groups: (1) high-efficiency particulate air (HEPA)filtered air, (2) 70%30% VG/PG, and (3) 70%30% VG/PG + French vanilla flavoring (vanilla) (n
= 11–12 per group). Mice were housed and handled in accord with the National Institutes of
Health (NIH) Guide for the Care and Use of Laboratory Animals. All procedures and protocols
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were approved by the Louisiana State University Institutional Animal Care and Use Committee
(IACUC) (protocol #17-095, approval date 15 November 2017).
E-Cig Aerosol Exposures
E-cig aerosols or HEPA-filtered air exposures were conducted in 5-L whole-body
exposure chambers (Scireq, Montreal, QC, Canada) as described in Noël et al. (Noel, Verret et
al. 2018). We used e-liquids composed of 70% vegetable glycerin (VG) and 30% propylene
glycol (PG), with and without French vanilla flavoring (purchased online from EC Blend;
Medford, OR, USA). These e-liquids were analyzed independently by Bureau Veritas (Buffalo,
NY, USA) using gas and liquid chromatography (GC LC) techniques: no nicotine was detected,
and the PG concentrations were 28.1% for the VG/PG e-liquid and 19.5% for that of the VG/PG
e-liquid with French vanilla flavoring. The e-liquids were aerosolized by a Scireq® 3rd-Gen e-cig
generator with the atomizer’s resistance and battery voltage set at 1.5 Ω and 4.1 V, respectively.
Vaping was conducted under a topography profile of 3 s puff duration, and a 55-mL puff volume
every 30 s. E-cig aerosols were sampled in the airstream exiting the chamber at a flow rate of 1
L/min throughout the experiment, in a cassette holding a 25 mm hydrophilic glass fiber filter
with a 0.7 µm pore size (AP4002500, Millipore Sigma; Burlington, MA, USA) in order to
determine total particulate matter (TPM) concentration by gravimetric analysis. The TPM
concentration was also monitored continuously in real-time via a MicroDustPro (Casella;
Buffalo, NY, USA). The average TPM levels in the e-cig aerosol exposure chamber were 0.041
mg/puff ± 0.03 (standard error of the mean) (total mass collected onto the filters ~9.95 ± 1.2 mg)
for the VG/PG e-liquid and 0.035 mg/puff ± 0.03 for the VG/PG + vanilla e-liquid (total mass
collected onto the filters ~8.31 ± 1.1 mg) (Table 4.1). Mice were exposed for 2 h a day, 7 days a
week, for 6 weeks. At the end of the exposure period, the lung function of six mice from each
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group was assessed via the flexiVent® system (Scireq; Montreal, QC, Canada). The remaining
mice in each group (n = 5–6) were sacrificed by intraperitoneal injection of Beuthanasia-D
(Merck Animal Health; Kenilworth, NJ, USA) and the blood as well as the lungs were collected.
Pulmonary Function Testing
Pulmonary function testing in mice was assessed via two techniques. (1) The day before
sacrifice, whole-body plethysmography was assessed using a Buxco System (Buxco, Troy, NY,
USA) as previously described (Noël, Xiao et al. 2017). We placed the mice (n = 8 per group)
into individual chambers of the whole-body plethysmograph and we measured tidal and minute
volumes as the mice were challenged with increasing doses of aerosolized methacholine (0 to 50
mg/mL). Lung responses were recorded for readings taken over a 5 min period.
(2) Pulmonary function of mice was measured on the day of sacrifice via the flexiVent
system as described (Noël, Xiao et al. 2017). Prior to performing the flexiVent procedure, the
mice were anesthetized by a subcutaneous injection of approximately 0.1 mL per 10 g of body
weight of a ketamine—xylazine cocktail (100 mg/kg ketamine and 5 mg/kg xylazine). Briefly,
mice (n = 6 per group) were anesthetized, tracheostomized, and connected to the forced
oscillation measurements flexiVent system. Lung mechanics were determined using pre-defined
scripts from the flexiVent system, for (1) lung mechanics and (2) dose-response, which was used
with incremental doses of methacholine (0, 12.5 and 25 mg/mL). The single frequency forced
oscillation technique (FOT) was used to measure respiratory system resistance (Rrs), compliance
(C), and elastance (E), while broadband FOT was used to assess Newtonian resistance (Rn),
tissue damping (G), and tissue elastance (H). Measurements were accepted only if the coefficient
of determination was >0.95, assuring the fit of the single compartment model and the constant
phase model. For each parameter evaluated (Rrs, C, E, Rn, G, and H), at least five measurements
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were averaged. Following the lung function procedure, mice were euthanized by an
intraperitoneal injection of Beuthanasia-D.
Tissue Staining
The left lung lobe from the non-flexiVented mice was inflated and fixed in 10% normal
buffered formalin (10% NBF). Fixed lung was processed and embedded in paraffin using
standard histologic techniques. Paraffin embedded lung was cut into 5 micrometer sections and
stained hematoxylin and eosin on an automatic stainer (Leica). Stained sections of lung were
examined under a microscope and five random 400× fields, including tissues from upper, middle,
and lower lung were evaluated for the number of macrophages and then normalized to number of
macrophages per alveolus. Images of alveoli taken at 400× were examined for additional
pathology by a board-certified veterinary pathologist. Mouse heads from non-flexiVented mice
were fixed in 10% NBF and decalcified in Kristensen’s Decal Solution (50% mixture of 1N
sodium formate and 8N formic acid). Fixed decalcified tissue was then processed and embedded
in paraffin using standard histologic techniques. Paraffin embedded tissues were cut to 5 µm
sections on a microtome. Sections were placed on a glass slide and stained with hematoxylin and
eosin on an automatic stainer. Images of two random 400× nasal mucosal fields were examined
by a board-certified pathologist.
Lung Immunophenotype by Flow Cytometry
The right inferior lung lobe of the non-flexiVented mice was homogenized in 1×
phosphate-buffered saline (PBS) and an aliquot was stained via one of two staining protocols.
Adaptive immune cells were stained with extracellular antibodies for CD4 (PECy5), CD8
(PECy7), and CD19 (BV650). Innate immune cells were stained with extracellular antibodies for
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CD49b (FITC), F4/80 (PECy7), CD11b (APC), CD11c (PE), and Gr1 (PacBlue). Cells were
fixed following extracellular staining and analyzed on an ACEA Novocyte Flow Cytometer.
Compensation was set using antibody capture beads, and gates were set using fluorescence
minus one control containing cells from each set of lungs. Innate immune cells were identified as
natural killer cells (CD49+, CD11b−), alveolar macrophages (F4/80+, CD11c+, CD11b−),
interstitial macrophages (F4/80+, CD11b+, Gr1−), dendritic cells (CD11b+, CD11c+), or
neutrophils (CD11b+, CD11c−, Gr1+), by percent of parent immune cells gated (Misharin,
Morales-Nebreda et al. 2013, Yu, Hotten et al. 2016). Adaptive immune cells were identified by
percent of parent lymphocytes as T Helper Cells (CD4+), Cytotoxic T Cells (CD8+), or B Cells
(CD19+).
Extraction of Lipid Mediators
The right middle lung lobe from each non-flexiVented mouse was rinsed in 1× PBS,
weighed, and homogenized in 3 mL of cold 2:1 (v/v) methanol:water using a Tissuemizer probe.
Fifty µL of 1% (w/v) triphenylphosphine (Sigma, St. Louis, MO, USA) dissolved in methanol
was added to the samples to prevent auto-oxidation of lipids. A mixture of deuterated internal
standards was then added to each homogenate: AA-d8, PGE2-d4, and 2-AG-d8 (13.3 pmol each)
and PEA-d4, OEA-d4, and AEA-d8 (100 pmol each). After vortexing, the samples were chilled
for an hour at −80 °C. The samples were then centrifuged for 20 min at 3000× g at 4 °C. The
supernatants were mixed with 2 mL of 1:1 (v/v) hexane:ethyl acetate (containing 0.1% acetic
acid) and 1 mL of high-performance liquid chromatography (HPLC) water, while the resulting
pellets were dissolved overnight at 50 °C in 3 mL of 0.1 M NaOH for protein determination.
After vigorous vortexing, the samples were centrifuged at room temperature at 800× g for 5 min
to separate the two layers. The top organic layer was transferred into a clean glass tube and the
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bottom aqueous layer was subjected to another round of organic solvent extraction. The pooled
organic fractions were dried under nitrogen gas. One-hundred µL of methanol was used to
reconstitute the samples, which were then transferred to HPLC vials for analysis by LC-MS/MS
as previously described (Wang, Borazjani et al. 2013). The chromatographic peak area of each
lipid mediator was divided by the peak area of its linked internal standard, followed by
subsequent normalization to the protein content of each lung sample. The quantities of each lipid
mediator in the control lungs (no VG/PG, no vanilla exposure) were set to 1.0.
Lung mRNA Extraction and Gene Expression Analysis by Quantitative RT-PCR
Total RNA was isolated from the right superior lung lobe of each non-flexiVented mouse
according to directions from the manufacturer, using the RNeasy Plus Mini Kit (Qiagen;
Germantown, MD, USA). Quantification was performed using a NanoDrop ND-1000
spectrophotometer (Thermo Scientific; Wilmington, DE, USA). A RevertAid First Strand cDNA
synthesis kit (Thermo Scientific) was used to synthesize cDNA, following the manufacturer’s
protocol. Real-time PCR was performed with SYBR Green PCR Master Mix (Qiagen) on a
Stratagene Mx3005P thermocycler following the manufacturer’s program recommendations. The
comparative cycle threshold (ΔΔCT) was used to determine relative gene expression, with
GAPDH as the reference gene. Results are reported as fold change in test samples compared to
control [(2−ΔΔCT)].
RT2 Profiler PCR Array
The lungs of the non-flexiVented mice were analyzed for the expression of 84 genes
related to immunotoxicity (PAMM-179Z) on an RT2 PCR array (Qiagen), per the manufacturer’s
instructions. As previously described (Noel, Hansen et al. 2020), total RNA (0.5 μg) was reverse163

transcribed with the RT2 First Strand Kit (Qiagen 330401), and the cDNA was diluted with
RNase-free water. The cDNA sample was mixed with RT2 SYBR Green qPCR Master mix
(Qiagen 330503). A total of 25 μL of aliquots were added to the wells of the PCR Array plate
containing the pre-dispensed gene-specific primer sets. We performed the PCR per the cycling
conditions of the Applied Biosystems model 7300 real-time cyclers. Gene expression and fold
change was calculated using the ΔΔCt method, with the web-based PCR Array data analysis
software. ΔCt data were calculated using the average geometric mean of the following genes:
Hsp90ab1, Gusb, Actb, and B2m, as the normalization factor (n = 4 per group).
Immunoglobulin Level Determination by ELISA
IgG1 was measured in serum (1:100,000 v/v) and bronchoalveolar lavage fluid (BALF;
1:100 v/v) from the flexiVented mice following previously described procedures (Szafran, Lee et
al. 2018) with an anti-mouse IgG1 and biotinylated anti-mouse IgG1 antibody (Biolegend).
Samples were normalized using an IgG1 standard (Thermo Fisher). IgG2b was measured in
serum (1:10,000 v/v) and BALF (1:100 v/v) following the manufacturer’s protocol, using a
mouse IgG2b ELISA kit (Thermo Fisher).
Protein Analysis for ELISA and Lipid Mediator Extraction Standardization
Serum samples were diluted 1:50 v/v in deionized water, while BALF samples and
dissolved lung pellets remained undiluted (25 µL total volume) for protein quantification
following the manufacturer’s instructions using a PierceTM BCA Protein Assay Kit (Thermo
Fisher, Waltham, MA, USA).
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Ingenuity Pathway Analysis (IPA)
As previously described (Wang, Borazjani et al. 2013, Noël, Xiao et al. 2016), RT-PCR
and RT2 Profiler gene expression data were analyzed through the use of Ingenuity Pathway
Analysis (Qiagen, Ingenuity Systems, Redwood City, CA, USA) (Kramer, Green et al. 2014).
The Diseases and Functions Analysis identified the biological functions and/or diseases that were
most significant from the data set. Molecules from the dataset that met the > +/−1.5 fold-change
cutoff and were associated with biological functions and/or diseases in the Ingenuity Knowledge
Base were considered for the analysis.
Statistical Methods
A two-way or one-way analysis of variance was used to evaluate differences using
GraphPad Prism Software (Version 7, San Diego, CA, USA) or SigmaPlot Software (Version
11.0, San Jose, CA, USA). Grubb’s outlier test was performed to identify outliers in treatment
groups. Gene expression results are considered significant with a fold-change > +/−1.5 compared
to respective air control group. Significance was considered using a p-value of p < 0.05. Data
from flow cytometry were analyzed after log-transformation.
Results
VG/PG Plus Vanilla Impaired Lung Functional Parameters
Results of whole-body plethysmography and flexiVent lung function testing with
methacholine challenge did not differ between air controls and VG/PG (Figure 6.1). At
methacholine doses greater than 25 mg/mL, the VG/PG plus vanilla group demonstrated greater
tidal and minute volumes than the air control group (p < 0.05) (Figure 6.1 A,B). Tissue damping
(Figure 6.1 C), measured via the flexiVent, was also significantly greater in the VG/PG plus
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vanilla group at 25 mg/mL methacholine (p < 0.05) compared to the VG/PG and the air control
groups. The other lung function parameters measured via the flexiVent system were not
significantly changed (data not shown).
VG/PG and VG/PG Plus Vanilla Did not Alter Lung Macrophage Counts
Macrophage counts on hematoxylin and eosin (H&E) stained lung slides from mice
treated with VG/PG and VG/PG plus vanilla were not significantly different from the air control
values (Figure 6.2). Counts were normalized to the number of alveoli per image due to
differences in inflation of the lungs. In addition, globally the lung tissue from the air controls and
the two exposure groups of mice appeared normal, with no significant changes in lung
histopathology. Rarely, eosinophils were observed in the lung tissue of VG/PG− and VG/PG
plus vanilla-exposed mice. The histology of the nasal passages of all mice was also
unremarkable.
VG/PG Altered Lung Cell Immunophenotype
The gating strategy for identifying lung innate and adaptive immune cells is shown in
Figure 6.3 A,B. The VG/PG and VG/PG plus vanilla samples did not produce any significantly
different results compared to air controls for alveolar macrophages (F4/80+, CD11c+, CD11b−),
interstitial macrophages (F4/80+, CD11b+, Gr1−), or neutrophils (CD11b+, CD11c−, Gr1+)
(Figure 6.3 C). VG/PG alone did not significantly alter the percentage NK cells, but there was a
slight significant increase in VG/PG plus vanilla compared to air controls (p = 0.0214). Both
VG/PG and VG/PG plus vanilla groups displayed significantly increased dendritic cell
populations (CD11b+, CD11c+) versus air controls (p = 0.0161 & p = 0.0142, respectively).
Regarding the adaptive immune cell responses, VG/PG and VG/PG plus vanilla did not alter
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cytotoxic T cell populations (CD8+), but compared to controls, VG/PG significantly increased
both T helper cell (CD4+, p = 0.0280 & p = 0.0077, respectively) and B cell populations
(CD19+, p = 0.0003 & p = 0.0001, respectively), regardless of whether vanilla flavoring was
present (Figure 6.3 D).
VG/PG Increased Levels of Lipid Mediators
We assessed the levels of lipid mediators that have immunomodulatory effects, either
through their pro- or anti-inflammatory properties. Exposures to VG/PG and VG/PG plus vanilla
significantly increased the pulmonary levels of the endocannabinoid 2-AG (p < 0.001) by
approximately four-fold over air controls (Figure 6.4 A). Neither of those exposures, however,
altered the pulmonary levels of OEA (Figure 6.4 B) or PEA (Figure 6.4 C). AEA levels were not
quantifiable by our method. Additionally, VG/PG and VG/PG plus vanilla significantly
increased levels of 12-hydroxyeicosatetraenoic acid (12-HETE), approximately two-fold over air
controls (Figure 6.4 F, p = 0.043 & p = 0.019, respectively). Although the values did not reach
statistical significance, there was an increased trend in PGE2 (Figure 6.4 D), PGD2 (Figure 6.4
E), and AA (Figure 6.4 G) levels in the VG/PG and VG/PG plus vanilla groups over the air
control group.
Alteration of Gene Expression by VG/PG and VG/PG plus Vanilla
Several genes were dysregulated in response to VG/PG or VG/PG plus vanilla (Figure
6.5). One gene, Il-6, was upregulated and seven genes, Aldh8a1, Btnl10, F2, Gypa, Myh3, Snca,
and Trim10, were downregulated in response to VG/PG alone. Two genes, Ak4 and Hpx, were
upregulated, and one gene, Apof, was downregulated in response to VG/PG plus vanilla. The
PG/VG e-cig aerosol dysregulated genes related to biotransformation (Aldh8a1), transcription
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factors expressed in pulmonary surfactant (F2) (Kong, Li et al. 2016), synuclein-alpha (Snca),
which interacts with phospholipids and proteins, as well as Il-6, a multifunctional cytokine,
whose enhanced expression was correlated with reduced production of pulmonary surfactant
protein A (SPA) (Doumanov, Jordanova et al. 2012). The VG/PG plus vanilla e-cig aerosol
increased the expression of Hpx, which protects against oxidative damage and affects the antiinflammatory properties of high-density lipoprotein (HDL) (Watanabe, Grijalva et al. 2009).
Ingenuity Pathway Analysis (Figure 6.5 B) revealed that the gene networks that are dysregulated
by the PG/VG e-cig aerosol we used are associated with metabolism of cellular proteins and with
control of lipid levels.
Immunoglobulin Levels Were Altered by VG/PG plus Vanilla
Based on the increases in T helper cells and B cell populations, we investigated whether
there were corresponding increases in IgG1 and IgG2b antibody production by ELISA in serum
and BALF (Figure 6.6). The levels of IgG1 and IgG2b were not altered in serum or BALF from
animals exposed to VG/PG, but there was a significant increase in IgG1 levels in the BALF of
animals exposed to VG/PG plus vanilla over air controls (p = 0.0431).
Discussion
PG and/or VG are key constituents of e-liquid formulations and are used in virtually all
ENDS devices (Itoh, Aoshiba et al. 2018). These delivery vehicles are heated through an e-cig
device at 200 °C or greater (Canistro, Vivarelli et al. 2017). The thermal degradation of VG plus
the interaction with the other e-liquid constituents produce emissions of aldehydes, including
formaldehyde and acetaldehyde, known to be potent threats to human health (Geiss, Bianchi et
al. 2016, Sleiman, Logue et al. 2016). PG and VG are biologically relevant molecules with
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emulsifying properties, which in the form of an e-cig aerosol, can interact with cells of the
respiratory tract and potentially impair lipid homeostasis in the lungs (Itoh, Aoshiba et al. 2018).
In this study, we examined the effects of a 70/30% VG/PG e-cig aerosol, with or without French
vanilla flavoring, on mouse lung function and inflammation. We identified increases in markers
associated with lung immunotoxicity (gene expression), alterations in lung cell
immunophenotyping, and immunosuppression (lipid-based immune mediators) due to VG/PG
exposure.
We used two complementary methods to evaluate lung function in mice, non-invasive
whole-body plethysmography, and invasive forced oscillation technique (FOT), enabling us to
provide descriptive measures of phenotypic characteristics of lungs that have been exposed subacutely to e-cig aerosols. While whole-body plethysmography provides estimates for lung
volumes, the FOT allows for accurate measurements of lung mechanics (Irvin and Bates 2003).
The most profound effect of adding the vanilla flavoring was on lung function. At a
methacholine challenge dose of 25 mg/mL, whole-body plethysmography revealed increased
estimates of lung tidal (Figure 6.1 A) and minute (Figure 6.1 B) volumes in mice exposed to the
70%/30% VG/PG plus vanilla e-cig aerosol. This same aerosol also increased G, the maximum
tissue damping (Figure 6.1 C), an indicator of lung tissue resistance. It is important to note that
they were no significant baseline tissue damping changes (<5 cm H2O/mL) for either e-cig group
(Figure 6.1 C). Following bronchoconstriction induced by aerosolized methacholine (25
mg/mL), however, the mice exposed to the e-cig aerosol containing vanilla exhibited increased
lung tissue resistance (G) (Figure 6.1 C). Thus, in a context of transient bronchoconstriction,
only the mice from the VG/PG plus vanilla group showed a heightened response. Unique
responses from this particular group also were manifested in other outcomes, including an
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increased population of lung NK cells (Figure 6.3), increased lung gene expression of Ak4 and
Hpx (Figure 6.5), and increased levels of IgG1 in BALF (Figure 6.6). It was previously reported
that increased lung tissue resistance is a multi-factorial event that can include alterations in tissue
compliance, viscosity, and cellular infiltration (Bachofen and Scherrer 1967). In addition to the
increased percentages of DC, CD4, and CD19 immune lung cells caused by e-cig aerosol
exposures, we found an increased NK cell population solely in the VG/PG plus vanilla group
(Figure 4.3). This may be a contributing factor to the impaired lung function observed for this
particular group. Indeed, augmented levels of NK cells also are present in BALF from chronic
obstructive pulmonary disease (COPD) patients (Eriksson Ström, Pourazar et al. 2018). Further,
in mouse cigarette smoke exposure studies, NK cells were linked to chronic airway inflammation
(Hansen, Chan et al. 2014), as well as being in an enhanced primed and activated state (Motz,
Eppert et al. 2010). It is well-known that the COPD phenotype is characterized by decline in lung
function (Motz, Eppert et al. 2010, Hansen, Chan et al. 2014, Eriksson Ström, Pourazar et al.
2018). Overall, these results suggest that changes in immune lung cells, including NK cells, may
be related to lung function impairment in a context of exposures to inhaled pollutants.
Additionally, the chemical profile of the inhaled pollutants may have an impact on lung function.
Ethyl vanillin and vanillin are MAO enzyme inhibitors (Truman, Stanfill et al. 2019). Lung
MAO functions include the degradation of circulating catecholamines, such as serotonin and
norepinephrine (Fowler, Logan et al. 2005). Thus, reduced lung MAO activity can result in an
increased concentration of these vasoactive substances, further leading to sympathetic activation
(Fowler, Logan et al. 2005, Andreas, Haarmann et al. 2014, Joho, Ushijima et al. 2017), which
has been associated with both obstructive, as well as restrictive, lung diseases (Andreas,
Haarmann et al. 2014, Joho, Ushijima et al. 2017). This suggests that the specific chemical
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profile of vanilla flavoring may also play a role in the VG/PG plus vanilla group altered lung
function.
Lung tissue resistance or damping (G) is a measure that represents tissue physical
properties or local heterogeneity in the lungs. G also reflects energy dissipation, which is
required for expansion of the lung tissue (Collins, Ikegami et al. 2003, Irvin and Bates 2003,
Manali, Moschos et al. 2011). Since we did not observe any significant changes in respiratory
system resistance (Rrs) (data not shown), but found an increase in tissue damping (G) at 25
mg/mL of mechacholine (Figure 6.1 C), this suggests that the VG/PG plus vanilla e-cig aerosol
exposure caused changes in peripheral lung function rather than in the central airways (Irvin and
Bates 2003). This increase in G may be representative of alterations in the peripheral lung, in
terms of either inhomogeneity of airflow or increased airway resistance (Manali, Moschos et al.
2011), which may be caused by the increased lung cell infiltration (NK, DC, CD4, and CD19)
that was observed in the VG/PG plus vanilla group. This pulmonary mechanics phenotype can
translate into mice having to spend more energy to expand their lungs (Darrah, Mitchell et al.
2016). Lung tissue damping (G) is known to increase with increasing lung volumes (McGovern,
Robichaud et al. 2013). This is supported by the estimated increased in tidal and minute volumes
in the VG/PG plus vanilla group (Figure 6.1 A,B). It is unknown, however, whether the
estimated lung volumes that we measured by whole-body plethysmography are reflective of
increased physiological lung volumes, which are associated with obstructive lung diseases and
hyperinflation (Ferguson 2006, Gagnon, Guenette et al. 2014, Soffler, Hayes et al. 2017).
Overall, here, in our murine model, we identified an effect of vanilla flavoring on lung function
that was not present in the VG/PG alone group. Our results can be compared to the study by
Glynos et al. (Glynos, Bibli et al. 2018) which did not find a difference in murine lung function
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after a 4 week exposure to PG/VG without flavoring or nicotine. Interestingly, they did see a
difference initially after 3 days of exposure with vehicle alone, but no difference with the
flavoring (tobacco blend) either at 3 days or 4 weeks (Glynos, Bibli et al. 2018). The key here
seems to be the flavoring differences. Vanilla flavor affects lung function while tobacco flavor
does not. Moreover, in an asthma mouse model, exposures to various unflavored (PG/VG only)
and flavored e-cig aerosols, including banana pudding and black licorice, without nicotine,
increased the baseline measurements of lung function, including tissue damping (G), following
house-dust mite treatment (Chapman, Casey et al. 2019). Impaired lung function was also
observed in mice following an 8 week exposure to e-cig aerosol composed of tobacco flavor plus
100% VG or PG, with and without nicotine (Larcombe, Janka et al. 2017). This study
specifically showed that VG-based e-cig aerosols amplified alterations in lung function,
including effects on tissue damping, when compared to PG-based e-cig aerosols (Larcombe,
Janka et al. 2017). Studies in human patients have identified immediate differences in lung
function parameters from short-term ENDS exposure, but long-term effects have not been
evaluated (Vardavas, Anagnostopoulos et al. 2012). One possibility suggested by these results is
that the impact of e-cig aerosol exposure on lung function may be time-dependent and flavor
specific.
French vanilla e-liquid contains three main flavoring chemicals: ethyl vanillin (at a
concentration of 8.4 mg/mL), vanillin (at a concentration of 6.1 mg/mL), and maltol (at a
concentration of 4.1 mg/mL) (Tierney, Karpinski et al. 2016, Eddingsaas, Pagano et al. 2018).
This results in a high e-liquid cumulative total flavoring chemical concentration of 18.6 mg/mL.
While maltol is an alcohol, ethyl vanillin and vanillin are aldehydes, a chemical family that has
respiratory tract irritation properties (Tierney, Karpinski et al. 2016). It was previously
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demonstrated that the cytotoxicity of ethyl vanillin, vanillin, and maltol is dose-dependent in
human bronchial epithelial cells (BEAS-2B) and in mouse neural stem cells, and that these
flavoring chemicals are often found at cytotoxic concentrations (>1 mg/mL) in e-liquid
formulations (Hua, Omaiye et al. 2019). Moreover, flavoring chemicals in e-liquids transfer
readily to e-cig aerosols (Behar, Wang et al. 2018). There also may be additional toxicity from
the flavoring chemicals when they interact with the e-liquid humectants, PG and VG, as the
chemical reactions that occur when they are heated and aerosolized through an e-cig device, can
lead to the potential formation of aldehydes and acetals (Erythropel, Davis et al. 2019, Hua,
Omaiye et al. 2019). As mentioned previously, vanillin PG acetal is more pro-inflammatory than
vanillin (Erythropel, Davis et al. 2019, Erythropel, Jabba et al. 2019). In our study, we would
expect to have higher levels of vanillin VG acetals than vanilla PG acetals due to the VG/PG
ratio that we used (70/30). Furthermore, the inhalation toxicity of vanillin is well established, as
evidenced by the National Institute of Occupational Safety and Health (NIOSH) 8 h occupational
exposure limit for vanillin by inhalation, which is 10 mg/m3 (Tierney, Karpinski et al. 2016,
Erythropel, Davis et al. 2019). The average e-liquid daily consumption rate is about 3–5 mL for
e-cig users (Tierney, Karpinski et al. 2016, Hua, Omaiye et al. 2019). Thus, the elevated
cumulative ethyl vanillin and vanillin concentrations found in e-liquids, plus the daily quantity of
e-liquid used, in relation to the vanillin inhalation exposure limit, fuel concerns related to the
potential respiratory effects of prolonged vanilla-flavored e-cig use. In addition, the median
lethal concentration (LC50) of vanillin by route of inhalation in mice is 41.7 mg/kg (ChemIDplus.
A Toxnet Database). In our study, which used a representative e-cig user vaping topography
profile, the mice were exposed to 240 puffs per day. We observed that the 6 week exposure to
the vanilla-flavored e-cig aerosol produced distinctive effects in terms of decline lung function,
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increased percentage of NK cells, as well as BALF IgG1 levels (Figure 6.1, Figure 6.3, and
Figure 6.6), when compared to the baseline e-cig aerosol composed solely of VG/PG. Overall,
the well documented inhalation toxicity of vanilla and that of its base chemical flavoring
constituents (ethyl vanillin, vanillin, and maltol), support our data that indicate an enhanced
toxicity of the VG/PG plus vanilla e-cig aerosol compared to that of the VG/PG e-cig aerosol.
In terms of lung immune cells, alveolar macrophage numbers were evaluated by counting
macrophages on H&E stained lung slides and by flow cytometry (Figure 6.2). Neither
assessment found a significant difference with VG/PG alone or VG/PG plus vanilla. The result
from H&E staining is consistent with a prior 3 day exposure study in which no differences were
noted in alveolar morphology when lungs from air-exposed and ENDS-exposed mice were
compared (Husari, Shihadeh et al. 2016). These results are also consistent with a study that found
no difference in the degree of macrophage infiltration in BALF from ENDS vehicle-treated mice
after 4-weeks of ENDS exposure (Glynos, Bibli et al. 2018). We did, however, identify an
increase in the percentage of natural killer cells in mice exposed to VG/PG plus vanilla (Figure
6.3 C). Studies exploring the effects of e-cig use on NK cells are limited, but one study found a
decrease in NK cell function with cinnamaldehyde exposure in vitro (Clapp, Pawlak et al. 2017).
Further studies are needed to determine whether vanilla flavoring impairs NK cell function as
well. While not specifically linked to e-cigarette use, NK cells have been demonstrated to play a
role in the development of allergic airway inflammation and asthma (Culley 2009, Mathias,
Guernsey et al. 2014). We also identified increases in the percentage of lung cells identified as
dendritic cells, CD4+ T cells, and CD19+ B cells, suggesting that a skewed VG/PG ratio can
induce a humoral immune response (Figure 6.3 D). Due to this finding, we decided to further
explore a possible induction of the humoral immune response by measuring serum and BALF
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immunoglobulin levels by ELISA. IgG1 and IgG2b were chosen due to their ability to reduce
airway inflammation (Ishikawa, Kobayashi et al. 2011, Vidarsson, Dekkers et al. 2014). A
previous study involving traditional cigarettes identified IgG1 increases and IgG2 decreases in
the serum and BALF from smokers as compared to non-smokers (Reynolds 1988). In the present
study, VG/PG alone did not significantly increase IgG2b levels in either serum or BALF (Figure
6.6 C–D), but there was an increased trend in IgG1 levels (Figure 6.6 A,B). The addition of
vanilla flavoring significantly increased IgG1 levels above those of the air controls. Interestingly,
there was a decreased trend in IgG2b with vanilla flavoring that almost coincides with the
decrease in lung function. In the literature, IgG2b levels have been positively associated with
lung function and negatively with asthma (Reynolds 1988).
Contrary to the results by Madison et al. (Madison, Landers et al. 2019), we did not see a
difference in gene expression of Sfpa, Sfpb, Sfpc, or Sfpd in the lungs of mice exposed to ENDS
vehicles (Figure 6.5). This may be explained by the different durations of e-cig aerosol
exposures: 6 weeks in our study versus 16 weeks in Madison et al. (Madison, Landers et al.
2019). Furthermore, our analysis was performed on lung tissue samples and not in BALF, and
their study utilized a greater PG/VG ratio (Madison, Landers et al. 2019). We also evaluated
several genes related to immunotoxicity. We found that the e-cig aerosol composed solely of
VG/PG dysregulated more genes than did the e-cig aerosol containing vanilla flavoring, 8 genes
versus 3, respectively (Figure 6.5 A). The majority of the genes altered by the exposure to the
VG/PG e-cig aerosol were down-regulated (Figure 6.5 A) and were related to metabolism of
cellular protein, as well as to levels of both phospholipids and lipids (Il-6, F2, Snca, and
Aldh8a1) as per Ingenuity Pathway Analysis (Figure 6.5 B). These results could suggest a
possible mechanism for the lungs to control an aberrant lipid profile. Moreover, cytokine gene
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expression identified an increase in I-l6 from VG/PG e-cig aerosol exposures (Figure 6.5 A). It
was previously demonstrated in vitro that Il-6 expression correlated with reduced production of
pulmonary surfactant protein A (SPA) (Doumanov, Jordanova et al. 2012). This result is also
consistent with other studies (Lerner, Sundar et al. 2015, Husari, Shihadeh et al. 2016, Glynos,
Bibli et al. 2018) but is in contrast to Madison et al. (Madison, Landers et al. 2019). This could
be attributed to differences between studies in the e-liquid constituents and the VG/PG ratios
used, as this ratio affects aldehydes formation in the aerosol and very few studies use the same
source of e-liquid. It is worth noting that there are no e-liquid or ENDS device standards for
ENDS-related health research. In the limited number of genes that we investigated, while the
VG/PG e-cig aerosol did not dysregulate genes associated with oxidative stress, the VG/PG plus
vanilla aerosol up-regulated the expression of Hpx, a biomarker of oxidative damage (Figure 6.5
A). In addition, there was no overlap in the genes that were dysregulated by the two e-cig
aerosols (Figure 6.5 A), suggesting that flavor may contribute to the induction of molecular
changes via distinct mechanisms. In our study, the flavor-specific toxicity of e-cig aerosol,
without nicotine, is supported by the distinct molecular changes (Figure 6.5 A), impaired lung
function (Figure 6.1), increased in NK immune cells (Figure 6.3), and the IgG1 levels found in
the BALF (Figure 6.6) of VG/PG plus vanilla exposed-mice compared to mice exposed solely to
the VG/PG e-cig aerosols. Overall, our data suggest that when heated and aerosolized through an
e-cig device, PG and VG may induce molecular changes related to lipid metabolism in the lungs.
Endocannabinoids, such as 2-AG, are derived from the phospholipid membrane (Rodríguez de
Fonseca, Del Arco et al. 2005). These lipid-based immune mediators are believed to be primarily
anti-inflammatory, due to engagement with the cannabinoid receptor-1 or cannabinoid receptor-2
(Panikashvili, Shein et al. 2006, Lourbopoulos, Grigoriadis et al. 2011, Krishnan and Chatterjee
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2012, Lu, Peng et al. 2014, Cabral, Ferreira et al. 2015). Alternatively, 2-AG may be
metabolized by COX-2 into other anti-or pro-inflammatory eicosanoids (Rockwell, Snider et al.
2006, Rockwell, Raman et al. 2008, Raman, Kaplan et al. 2012). To our knowledge, no other
ENDS study has evaluated the levels of endocannabinoids following exposure to ENDS or
ENDS vehicle. Here, we demonstrated an increase in 2-AG levels following exposure to VG/PG,
independent of vanilla (Figure 6.4 A). Furthermore, we identified an increase in 12-HETE
(Figure 6.4 F) and an increased trend in PGE2 (Figure 6.4 D), PGD2 (Figure 6.4 E), and AA
(Figure 6.4 G), all eicosanoids, or in the case of AA, a polyunsaturated omega-6 fatty acid
derived from 2-AG metabolism which have been shown to elicit both pro-inflammatory (Park,
Pillinger et al. 2006, Nazarewicz, Zenebe et al. 2007, Mabalirajan, Rehman et al. 2013,
Nakanishi and Rosenberg 2013) and anti-inflammatory effects (Joshi, Zhou et al. 2001, Yakar,
Melamed et al. 2003, Scher and Pillinger 2009, Sun, Xu et al. 2015). While it is unclear what
role these compounds play in immune responses following ENDS exposure, we have identified
an additional mechanism in which ENDS can disrupt lung lipid homeostasis.
Overall, our study shows that 6 week of inhalation exposure to VG-rich e-cig aerosols
(70%/30% VG/PG), without nicotine or flavoring, increases the populations of immune lung
cells, as evidenced by the percentage of DC, CD4 and CD19 cells (Figure 6.3), as well as the
extracted amounts of endocannabinoid (2AG) and eicosanoid (12-HETE) in the lungs of mice
(Figure 6.3). This e-cig aerosol exposure also dysregulated the expression of eight genes related
to immunotoxicity, with functional networks associated with metabolism of cellular protein and
lipid homeostasis (Figure 6.5). In contrast, the 70%/30% VG/PG plus vanilla e-cig aerosol
exposure affects lung function (Figure 6.1), increases the percentage of NK, DC, CD4 and CD19
immune lung cells (Figure 6.3), as well as the amount of 2AG and 12-HETE in the lungs of mice
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(Figure 6.4). This exposure also dysregulated the expression of 3 genes, including up-regulation
of Hpx, which is associated with oxidative stress (Figure 6.5). The BALF levels of IgG1 also
were significantly elevated in this exposure group (Figure 6.6). Taken together, our results
suggest that exposures to only e-cig delivery vehicles VG/PG, without nicotine, affect the lungs,
and that addition of vanilla flavoring may enhance the lung responses.
In conclusion, this study provides more evidence that ENDS use is not benign. It is
unknown what role the changes seen in this study play in pulmonary immune responses to a
pathogen or to the development of chronic lung diseases, including asthma and emphysema. Our
findings, however, demonstrate that ENDS delivery vehicles alone can influence markers of lung
inflammation, lipid-based immune mediators, and the lung immunophenotype. Our study
focused on a 70/30% mixture of VG/PG and one flavoring, French vanilla, and this is only one
of thousands of possible ENDS mixtures. Overall, our study suggests that while PG and VG are
GRAS food additives and may be harmless when ingested, they pose hazards to the lungs when
inhaled from an ENDS device. With the increased trend in youth and non-smokers using ENDS,
it is imperative that further research is conducted to tease out the complexities in the effects of
ENDS on human pulmonary health.
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Table 6.1

Characterization of e-cig aerosol exposures
HEPA-Filtered Air

70% VG/30%
PG

70% VG/30% PG
+ Vanilla

25.5 ± 1.2

26.4 ± 4.3

24.6 ± 1.6

Relative humidity
(%RH) (± SD) †

69.7 ± 9.3

68.0 ± 3.1

73.1 ± 4.2

Total particulate matter
(TPM) concentration
(mg/puff) (± SD)

---

0.041 ± 0.031

0.035 ± 0.028

Temperature (°C) (± SD)
†

†

The temperature and relative humidity were measured inside the exposure chambers using a
small hydrometer.
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Figure 6.1

Inhalation of e-cig aerosol composed of 70%/30% VG/PG plus vanilla flavor
impairs lung function

Whole-body plethysmography with methacholine challenge was used to determine tidal volume
(A), and minute volume (B) (n = 8 per group), while the flexiVent® system was used to assess
the maximum tissue damping (C) (n = 6 per group). Data are expressed as mean ± standard error
of the mean (SEM). Differences were analyzed by a two-way ANOVA. * p < 0.05.
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Figure 6.2

Inhalation of e-cig aerosol composed of 70/30% VG/PG alone or with vanilla
flavor does not impact lung tissue macrophages

H&E stained lung slides from mice treated with air (n = 5), VG/PG (n = 6), and VG/PG plus
vanilla (n = 6) were evaluated for the number of macrophages in 5 representative images at 40x.
(A) Counts were normalized to the number of alveoli per image to account for differences in
lung section inflation. (B) Representative images of H&E stained slides of mouse lungs at 400×
magnification.
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Figure 6.3

Inhalation of e-cig aerosols composed of 70%/30% VG/PG alone or with vanilla
flavor increases lung immune cells

(A,B) Gating Strategy for Identifying Lung Innate and Adaptive Immune Cells. (A) NK cells
were identified as CD49+/CDllb−, AMs as F4/80+/CD11c+/CD11b−, IMs as
F4/80+/CD11b+/Gr1−, DCs as CD11b+/CD11c+, and Neutrophils as CD11b+/CD11c−/Gr1+.
(B) T helper cells were identified as CD4+, cytotoxic T cells as CD8+, and B cells as CD19+.
Extracellular staining for innate (C) and adaptive (D) immune cells in the lungs of mice treated
with air (n = 5), VG/PG (n = 6), or VG/PG (n = 6) with vanilla. * p < 0.05. Cells were identified
as natural killer cells (NK, CD49+, CDllb−), alveolar macrophages (AM, F4/80+, CD11c+,
CDllb−), interstitial macrophages (IM, F4/80+, CDllb+, Gr1−), dendritic cells (DC, CDllb+,
CDllc+), neutrophils (NEU, CD11b+, CDllc−, Gr1+), cytotoxic T cells (CD8+), T helper cells
(CD4+), or B cells (CD19+). Error bars are SEM. Differences were analyzed by one-way
ANOVA, and a Grubb’s outlier test was utilized to identify outliers in each treatment group.
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Figure 6.4

Inhalation of e-cig aerosols composed of 70%/30% VG/PG alone or with vanilla
flavor affects the extracted amount of endocannabinoid and prostaglandins in the
lungs

The right middle lung lobe was extracted for lipid mediators and quantified by LC-MS/MS using
deuterated standards for mice exposed to air (n = 5), VG/PG (n = 6), and VG/PG (n = 6) plus
vanilla. 2-AG (A), OEA (B), PEA (C), PGE2 (D), PGD2 (E), 12-HETE (F), and AA (G) levels
are pictured. AEA levels were too low to quantify. Data are expressed as mean ± SEM.
Differences were analyzed by a one-way ANOVA (* p < 0.05, *** p < 0.001).
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Figure 6.5

Inhalation of e-cig aerosols composed of 70%/30% VG/PG alone or with vanilla
flavor dysregulates lung gene expression

(A) Heatmap demonstrating the expression of immunotoxicity related genes in lungs of mice.
Black color denotes no difference in fold-change compared to air controls. (B) Ingenuity
Pathway Analysis (IPA) gene networks associated canonical pathways and function. Data are
expressed in fold-changes compared to air control group (n = 4–6 mice per group). A greater
than ±1.5-fold change is considered significant.

184

Figure 6.6

Inhalation of e-cig aerosols composed of 70%/30%VG/PG plus vanilla flavor
alters IgG1 levels in bronchoalveolar lavage fluid (BALF)

IgG1 and IgG2b levels measured by ELISA (A,C) in serum and BALF (B,D) (n = 6 in all groups
except the air control where n = 5). Values are normalized on protein. * p < 0.05. Error bars are
SEM, and differences were analyzed by one-way ANOVA.
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CHAPTER VII
CONCLUSIONS AND FUTURE DIRECTIONS
Conclusions
Since its discovery in the early 1990s, there has been a plethora of research on the eCB
system and its components. Although it is clear the system has an important role in immunity,
the scientific community has barely scratched its surface. More work is needed to fully
understand the mechanisms that underlie the ability of the eCB system to regulate inflammation.
Although initial studies have shown promise regarding the pharmacological perturbation of the
system, we still have not fully elucidated the physiological effects of altering the eCB system.
Studies have shown eCBs to be anti- or pro-inflammatory depending on the tissue context and
the disease process, indicating that the role of the eCB system in immunity is complex and not
easily studied (Gallily, Breuer et al. 2000, Facchinetti, Del Giudice et al. 2003, Mach and
Steffens 2008, Alhouayek, Lambert et al. 2011, Mimura, Oka et al. 2012, Rettori, De Laurentiis
et al. 2012). Additionally, the ability of toxicants to disrupt eCB metabolism adds another layer
of complexity in the quest to understand this important system. Further investigations into this
area will improve our knowledge on this topic while also simultaneously identifying targets for
pharmacological intervention to control inflammation.
The goal of the research in this dissertation was to explore the relationship between
eCBs, their metabolizing enzymes, and immune homeostasis, with an emphasis on the effects of
CPF in the murine lung. Ces is one of several bona fide endocannabinoid metabolizing enzymes
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and they are highly abundant in the murine lung. This dissertation first explored the idea that
inhibition of eCB metabolism might activate a negative feedback mechanism that controls LPSinduced inflammation. The major finding from this work (Chapter 2) suggested that the
endocannabinoid system could be activated in spleen due to the suppression of a 2-AG catabolic
enzyme, Ces2g, in response to inflammation (Figure 7.1). This might be one mechanism to limit
inflammation. Results from Chapter 5 further confirmed a role for Ces2g during inflammation,
this time its expression was suppressed during LPS-mediated inflammation in lung. The
mechanism and physiological purpose behind the LPS-mediated decrease in Ces2g expression
has yet to be explored, although our results suggest it may be part of a negative feedback
mechanism to control inflammation.
In contrast to the murine studies in Chapter 2 that focused on biochemical and immune
effects in the spleen, Chapter 3 focused on the same inflammation control mechanisms in human
PBMCs. The major findings from this chapter are that: i) we identified MAGL as the primary
PBMC 2-AG hydrolytic enzyme (Figure 7.1), and ii) we determined that both MAGL and CES1
were abundantly expressed in human monocytes and, to a lesser extent, in lymphocytes. The
significance of these results is that MAGL, and not CES1, would be the more appropriate
therapeutic target to increase 2-AG levels in circulating immune cells. In addition, the presence
of MAGL and CES1 in various human immune cells suggests a broader role for these enzymes
in immune cell activation and function.
CPF is still a widely used agricultural pesticide (Grube, Donaldson et al. 2011), despite
its associated neurotoxic effects in laboratory animals (Rauh, Garfinkel et al. 2006, Rauh,
Arunajadai et al. 2011, Rauh, Perera et al. 2012, Carr, Adams et al. 2013, Carr, Graves et al.
2014, Carr, Armstrong et al. 2017) and epidemiological studies linking it to respiratory illness
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(Hernandez, Parron et al. 2011, Ye, Beach et al. 2013, Doust, Ayres et al. 2014, Mamane,
Raherison et al. 2015, Shaffo, Grodzki et al. 2018). Chapters 4 and 5 focused on the ability of
CPF to alter immune responses through inhibition of eCB metabolizing enzymes in the murine
lung. Although only minor alterations were identified in the immune endpoints, quite a few
significant discoveries were made: 1) Ces1d, Ces1c, and Ces2g are expressed at reasonably high
levels in murine lung, 2) Ces1d is expressed in murine alveolar macrophages, 3) eCB
metabolizing enzymes – Ces1d, Ces1c, and Ces1b – in murine lung of different ages were
specifically inactivated following oral CPF exposures, 4) Ces1c, and to a lesser extent Ces1d,
appear to have a protective role that protect the lung from the toxic effects of CPF (Figure 7.2),
and 5) Magl is the primary 2-AG hydrolytic enzyme in the murine lung (Figure 7.1). A central
hypothesis in this dissertation was that low-dose CPF would inhibit eCB metabolizing enzymes
leading to a subsequent increase in eCB levels that could alter lung immunity (Figure 1.3).
Given that i) Magl, but not Ces, was able to hydrolyze 2-AG in murine lung, and ii) Magl was
not inhibited by low-dose CPF exposure, this hypothesis was not supported. Instead, the results
of this dissertation suggest that Ces enzymes play a protective role against the toxic effects of
CPF in lung and Ces inhibition by CPF is unrelated to the eCB system. However, this
dissertation does not rule out the possibility that higher CPF doses could alter the lung’s immune
response to LPS. In support of this idea, pharmacological inhibition of Magl in the murine lung
reduced the extent of LPS-induced pro-inflammatory cytokine expression (Figure 7.3), and this
enzyme can be inhibited by CPO under certain conditions (such as in the brain). Overall, further
investigations are needed to determine whether Ces enzymes in lung have roles beyond being
mere bioscavengers of oxon metabolites and if these results can translate to humans.
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The identification of Ces1d in murine alveolar macrophages suggests that in vivo studies
in mice and ex vivo studies of these cells may be an appropriate model for exploring the role of
CES1 in human macrophages. It is important to note that not all mouse macrophages express
Ces enzymes [e.g., mouse resident and thioglycolate-elicited peritoneal macrophages do not
express Ces1d to any extent (Imamura, Schiller et al. 1983)]. These findings suggest that the
microenvironment where macrophages develop and mature (lung vs peritoneal cavity) is
important for establishing Ces1d expression. Thus, not all types of murine macrophages will
make appropriate models for human macrophage studies.
Finally, this dissertation explored the safety of e-cigarette vehicle (Chapter 6). Subchronic exposure to e-cig vehicle in a murine model greatly induced the lung 2-AG levels
compared to air controls, which correlated with alterations in immune endpoints (Figure 7.4).
Many of the same assays used in chapters 2-5 were employed in the context of e-cig vehicle in
chapter 6, including determining the levels of lipid mediators, pro-inflammatory cytokine
expression, and lung immunophenotype in murine lung. Although the main significance of these
results suggest that e-cigarettes are not benign and can disrupt normal immune homeostasis,
these results also demonstrated that xenobiotics other than pesticides can alter the eCB system.
In fact, CPF, LPS, and e-cig vehicle could all disrupt some aspect of the eCB system, sparking
many more questions than answers and hinting at a broader role for the eCB system in
physiological homeostasis.
Future Directions
The e-cig study had a limited focus on the eCB system other than the quantification of
endocannabinoids and their metabolites after e-cigarette vehicle exposure. Future studies on this
topic would benefit by assessing the activities of the eCB metabolizing enzymes. A more
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thorough investigation of the e-cigarette vehicle on eCB metabolizing enzyme activity, including
ABPP-MS profiling of lung serine hydrolases, and eCB metabolizing enzyme gene expression
would provide further information towards identifying the mechanism by which e-cigarette
vehicle increases lung 2-AG levels. Adding an immune stimulant following e-cigarette vehicle
exposure would: i) provide further evidence that e-cigarette vehicles can disrupt lung immune
homeostasis, ii) provide additional evidence for a role of 2-AG in immunity, and iii) help educate
the public regarding e-cigarette safety, allowing public health officials, lawmakers, and
individuals to make more informed decisions on e-cigarette use.
To further explore the mechanistic aspect of Ces2g suppression caused by LPS, future
studies should focus on linking Ces2g inhibition to the downregulation in expression of other
genes linked to LPS stimulation, such as those regulated by the stimulus-activated transcription
factor Nf-B. Additionally, while the present studies have shown that Ces2g has the capacity to
hydrolyze 2-AG, the ability of Ces2g to metabolize other lipid mediators has not been
determined. The development of a method to rescue Ces2g gene expression following treatment
with LPS would allow for the identification of physiological effects that result from Ces2g
inhibition. Studies in a Ces2g-/- strain of mice would also provide further evidence for the effects
that are caused by Ces2g downregulation. A more complete understanding of the role of Ces2g
in LPS-induced inflammation may enable the development of CES2 inhibitors to control
inflammation.
A future study that replicates the WT mouse cohorts of Chapters 4 and 5 in a rat model
could be undertaken to examine species differences with respect to serine hydrolase sensitivity to
CPF. In Buntyn et al. 2017, CPF doses at 1 mg/kg and/or lower altered spleen and liver 2-AG
and AEA hydrolysis activity in juvenile rats (Buntyn, Alugubelly et al. 2017). However, dosages
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of 2.5 mg/kg in mice did not have the same effects (Chapter 4). If rat lung eCB metabolizing
enzymes are more sensitive to CPF treatment, exploring the eCBs levels, eCB metabolism, and
immune effects of CPF in rat lungs would provide a more complete picture of CPF as a potential
lung immunotoxicant. Additionally, exploring the mouse model with longer CPF-dosing
regimens, higher doses of CPF, or alternative immune stimulants (such as a virus) would provide
the opportunity to identify alterations in the lung immune system that where not apparent in the
study design from Chapters 4 and 5.
The current studies did not tease out the exact significance of Ces1c and Ces1d inhibition
by CPF; however, they did suggest that Ces1c may be the principal lung detoxification enzyme
of the reactive oxon in adults. Further studies, specifically in Ces1c-/- mice, would be warranted
to confirm this hypothesis, and additional studies would be needed to determine if this enzyme
provides mouse-specific protection from pesticides such as CPF. Alternatively, CPF could be
administered with Ces inhibitors. Mouse and rat plasma, unlike humans, have high levels of Ces
activity (due to Ces1c in mouse) (Li, Sedlacek et al. 2005). A combined CPF/Ces inhibitor
dosing regimen in rodents could be explored as an alternative model for CPF toxicity studies
rather than CPF alone.
Because inhibition of both enzymes altered pro-inflammatory cytokines in the lung,
Ces1d and Magl have therapeutic potential. For example, JZL184, a Magl inhibitor, could be
explored as a drug to limit inflammation. More studies will be needed to fully understand the
immune effects of Ces1d. In the context of Ces1d expression in murine alveolar macrophages
and their potential use as a model for human macrophage studies, future investigations could
compare various immune endpoints following treatments of human THP1 cells (which express
high levels of CES1) and mouse alveolar macrophages (which express Ces1d). Because CES1 is
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being explored as a therapeutic target, if the two models are similar enough, murine alveolar
macrophages could have implications for pharmaceutical development and testing.
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Figure 7.1

Overview of 2-AG hydrolytic enzymes identified in this dissertation

MAGL/Magl is the primary 2-AG hydrolytic enzyme in human PBMCs and mouse lungs.
Ces2g in the murine spleen was identified as a 2-AG hydrolytic enzyme. Inhibiting 2-AG
hydrolysis causes a subsequent increase in 2-AG levels. LPS inhibits Ces2g in the murine spleen
and lung.
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Figure 7.2

Overview of the biochemical and immune effects of CPF on the murine lung

This figure provides an overall summary of chapters 4 and 5 investigating the effects of CPF on
lung serine hydrolases and LPS-induced inflammation. Immune effects were only identified in
adult female mice. Overall, Ces1c may play a protective role against immunotoxic effects of
CPF.
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Figure 7.3

Overview of the effects of Ces1c, Ces1d, and Magl Inhibition on LPS-induced
cytokine levels

Ces1c inhibition in the adult female murine lungs has no effect on the LPS-induced proinflammatory cytokine levels. Ces1d inhibition exacerbated the expression of LPS-induced proinflammatory cytokines, and Magl inhibition attenuated the expression of LPS-induced proinflammatory cytokines in the female murine lung.
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Figure 7.4

Overview of the effects of e-cig vehicle on immune homeostasis

E cig vehicle induced both pro- and anti- inflammatory effects on the normal murine lung
immune homeostasis.
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suppresses carboxylesterase 2g activity and 2-arachidonoylglycerol hydrolysis: A
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This publication is the contents of Chapter 2. For this study, I assisted with the animal study,
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enzymes in human peripheral blood mononuclear cells under inflammatory conditions.
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This publication is the contents of Chapter 3. For this study, blood was shipped to Mississippi
State University from the University of Rochester. I cultured the resulting PBMCs, performed
most of the assays, ran statistics, prepared most of the figures, and wrote the first draft of the
paper for publication.
Chapter 6
Szafran, B. N., Pinkston, R., Perveen, Z., Ross, M. K., Morgan, T., Paulsen, D. B., . . . Noël, A.
(2020). Electronic-Cigarette Vehicles and Flavoring Affect Lung Function and Immune
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This publication is the contents of Chapter 6. For this study, the animal exposure and lung
function tests were performed by our collaborators at Louisiana State University. I performed
many of the assays (flow cytometry, lipid mediator extraction, qPCR, histopathology, and
ELISA), ran statistics on data from assays I performed (except the lipid mediator data), prepared
many of the figures, and wrote the first draft of the paper for publication.
Other
Scheaffer, H. L., Borazjani, A., Szafran, B. N., & Ross, M. K. (2020). Inactivation of CES1
Blocks Prostaglandin D2 Glyceryl Ester Catabolism in Monocytes/Macrophages and
Enhances Its Anti-inflammatory Effects, Whereas the Pro-inflammatory Effects of
Prostaglandin E2 Glyceryl Ester Are Attenuated. ACS Omega.
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For this manuscript, I performed the animal studies, contributed to the methods section of the
manuscript, and reviewed the manuscript before submission
Works in Progress
Chapters 4 and 5
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chlorpyrifos on serine hydrolase activities, lipid mediators, and immune responses in
lungs of neonatal and adult mice. Submitted.
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major aspects of this study and manuscript preparation. The only assay I did not perform is the
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acetylcholinesterase activity, and I did not perform statistics or prepare the figures for the
proteomics data. Cnr1-/- data from Chapter 4 is in preparation for a separate, smaller paper.
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